On this page
Quick Reference
Overview and Recommendations
Background
- •Recognize colorectal cancer (CRC) as a heterogeneous malignancy primarily manifesting as adenocarcinoma, originating from the glandular epithelium of the large intestine. It typically follows the adenoma-carcinoma sequence, driven by the accumulation of genetic mutations in the Wnt/β-catenin signaling pathway, or the serrated pathway characterized by BRAF mutations and CpG island methylator phenotype (CIMP).
- •Identify the three primary molecular pathways: Chromosomal Instability (CIN), which accounts for 85% of sporadic cases; Microsatellite Instability (MSI), resulting from deficient mismatch repair (dMMR) seen in or sporadic MLH1 silencing; and the CIMP pathway. These pathways dictate tumor behavior, prognosis, and sensitivity to modern immunotherapies.
- •Distinguish between anatomical subtypes, as right-sided (proximal) tumors often present with different molecular profiles and worse prognoses compared to left-sided (distal) tumors. Rectal cancer, defined as occurring within 15 cm of the anal verge, requires distinct management strategies due to the narrow pelvic anatomy and the necessity of preserving sphincter function.
- •Screen for high-risk populations, including those with (Ulcerative Colitis or Crohn’s), hereditary syndromes like (FAP), or a significant family history. Emerging risk factors include central obesity, maternal obesity (intergenerational risk), and specific microbial signatures such as Fusobacterium nucleatum and Clostridioides difficile.
- •Monitor the shifting epidemiology toward early-onset colorectal cancer (EOCRC). Patients diagnosed before age 50 often present with more advanced stages and distal lesions, necessitating a lower threshold for diagnostic workup in symptomatic young adults who might otherwise be misdiagnosed with benign conditions like .
Evaluation
- •Suspect colorectal cancer in any adult presenting with iron-deficiency anemia, unexplained weight loss, or persistent changes in bowel habits such as new-onset constipation or 'pencil-thin' stools. Right-sided lesions often present with occult bleeding and fatigue, while left-sided lesions are more likely to cause overt and obstructive symptoms.
- •Ask specifically about the duration of symptoms, as the clinical nadir typically occurs 2 to 4 months before presentation. Inquire about a family history of colorectal or endometrial cancers to screen for using the Amsterdam II or Bethesda criteria.
- •Examine the patient thoroughly, starting with a mandatory digital rectal examination (DRE) to assess for low-lying rectal masses, fixation to surrounding tissues, and sphincter tone. Perform abdominal palpation to check for masses, hepatomegaly (suggestive of liver metastases), or (suggestive of peritoneal carcinomatosis).
- •Order a high-quality as the gold standard for diagnosis. Utilize computer-aided detection (CADe) systems where available to maximize the adenoma detection rate (ADR). If colonoscopy is incomplete or contraindicated, consider Computed Tomographic Colonography (CTC) or colon capsule endoscopy.
- •Obtain a tissue biopsy for histopathological confirmation and universal molecular testing. Every new diagnosis must be tested for mismatch repair (MMR) proteins (MLH1, MSH2, MSH6, PMS2) via immunohistochemistry or for microsatellite instability (MSI) via PCR to guide immunotherapy and identify hereditary risks.
- •Perform systemic staging using contrast-enhanced CT of the chest, abdomen, and pelvis to identify distant metastases. For rectal cancer, obtain a high-resolution pelvic MRI to assess the circumferential resection margin (CRM), extramural venous invasion (EMVI), and the depth of invasion relative to the mesorectal fascia.
- •Measure baseline serum Carcinoembryonic Antigen (CEA) levels. While not useful for screening due to low sensitivity, an elevated baseline CEA is a prognostic marker and serves as a vital tool for monitoring recurrence following curative-intent treatment.
- •Evaluate nutritional and inflammatory status using indices like the Prognostic Nutritional Index (PNI) or the Systemic Immune-inflammation Index (SII). Low albumin and high neutrophil-to-lymphocyte ratios are independent predictors of poor surgical outcomes and reduced overall survival.
- •Rule out paraneoplastic syndromes in atypical cases. For example, Erythema gyratum repens (a 'wood-grain' skin rash) or the sudden appearance of multiple seborrheic keratoses (Leser-Trélat sign) may be the first clinical indication of an underlying colonic malignancy.
- •Consider genetic counseling and germline multigene panel testing (MGPT) for all patients diagnosed under age 50 or those with tumor testing suggestive of a hereditary syndrome, regardless of family history.
Management
- •Initiate a multimodal prehabilitation program 2–4 weeks prior to elective surgery. This should include structured aerobic and resistance exercise, nutritional optimization, and psychological support to improve physiological reserve and reduce postoperative complications.
- •Perform surgical resection as the primary curative modality for localized disease. For colon cancer, execute a (CME) with central vascular ligation. For rectal cancer, (TME) is the gold standard to ensure the removal of the intact mesorectal envelope.
- •Utilize minimally invasive platforms, such as robotic-assisted surgery, particularly for complex rectal dissections. Robotic surgery is associated with lower conversion rates to open surgery and better visualization in the narrow male pelvis compared to conventional laparoscopy.
- •Administer adjuvant chemotherapy for Stage III colon cancer to eradicate micrometastases. The standard regimen is mFOLFOX6 (Oxaliplatin 85 mg/m², Leucovorin 400 mg/m², and 5-FU 2400 mg/m² infusion) for 3 to 6 months depending on risk stratification (IDEA trial criteria).
- •Optimize the timing of adjuvant therapy, especially in patients with lymph-vascular invasion (LVI). Initiating chemotherapy within 3.2 weeks of surgical resection is associated with significantly improved overall survival.
- •Implement Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer. This involves delivering both chemotherapy (e.g., FOLFOX) and chemoradiotherapy (50.4 Gy with concurrent capecitabine) prior to surgery to increase pathological complete response (pCR) rates and facilitate organ preservation.
- •Prescribe Pembrolizumab 200 mg IV every 3 weeks as the first-line standard of care for patients with microsatellite instability-high (MSI-H) or dMMR metastatic colorectal cancer, as established by the KEYNOTE-177 trial.
- •Select targeted agents for metastatic disease based on RAS and BRAF status. For RAS wild-type, left-sided tumors, use anti-EGFR therapy (Cetuximab or Panitumumab). For RAS-mutated or right-sided tumors, combine chemotherapy with anti-VEGF therapy (Bevacizumab 5 mg/kg).
- •Treat BRAF V600E-mutated metastatic disease with the combination of Encorafenib 300 mg daily plus Cetuximab, which has shown superior survival outcomes in the second-line setting compared to standard chemotherapy.
- •Monitor for treatment-related toxicities, such as oxaliplatin-induced . Consider duloxetine 30–60 mg daily for established neuropathy or non-invasive magnetic field therapy for persistent pain.
- •Manage high-output stomas (HOS) aggressively in the early postoperative period to prevent dehydration and electrolyte imbalances. Monitor stoma output daily; outputs exceeding 1500 mL/day require medical intervention with antimotility agents and oral rehydration solutions.
- •Refer patients with colorectal peritoneal metastases for evaluation of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with Mitomycin C 30 mg/m² at specialized centers.
- •Follow a rigorous surveillance protocol post-resection: CEA testing every 3–6 months, annual CT scans of the chest/abdomen/pelvis, and colonoscopy at 1 year, then every 3–5 years based on findings.
- •Incorporate liquid biopsy (ctDNA) monitoring where available to detect molecular residual disease (MRD). Post-surgical ctDNA positivity is a highly specific predictor of recurrence and may guide the intensification of adjuvant therapy.
- •Avoid routine follow-up colonoscopy immediately after uncomplicated unless 'alarm' symptoms (anemia, weight loss) are present or the patient is over age 50 and overdue for screening.
- •Refer all patients with suspected hereditary syndromes to a specialized genetics clinic for cascade testing of biological relatives to prevent future cancers in the family.
Board Review — High Yield
- •Apple core lesion — Classic radiographic appearance of a constricting colorectal carcinoma on barium enema.
- •Streptococcus gallolyticus (bovis) — Bacteremia or endocarditis with this organism is highly associated with underlying colorectal neoplasia; mandatory colonoscopy required.
- •Lynch Syndrome — Autosomal dominant germline mutation in MMR genes (MLH1, MSH2, MSH6, PMS2); associated with proximal colon cancer and endometrial cancer.
- •FAP (Familial Adenomatous Polyposis) — APC gene mutation on chromosome 5q; results in thousands of polyps and 100% cancer risk by age 40 if untreated.
- •CEA (Carcinoembryonic Antigen) — Tumor marker used for monitoring recurrence, not for screening; high preoperative levels correlate with poor prognosis.
- •Turcot Syndrome — Association of hereditary polyposis with CNS tumors (medulloblastoma or glioblastoma).
- •Gardner Syndrome — FAP variant with extra-colonic manifestations including osteomas, desmoid tumors, and sebaceous cysts.
- •Microsatellite Instability (MSI-H) — Predicts excellent response to PD-1 inhibitors (Pembrolizumab) but poor response to 5-FU monotherapy in Stage II.
Deep Dive — Evidence Details
Colorectal Cancer: Definition, Synonyms, and Classification
- ▸Colorectal cancer is defined as an epithelial malignancy of the colon or rectum, with Early-Onset CRC (EOCRC) specifically defined by a diagnosis before age 50 [6, 15].
- ▸The AJCC 9th edition proposal introduces Tumor Deposits (TDs) as an independent staging parameter to resolve survival outcome non-hierarchies found in the 8th edition [13].
- ▸Histological classification requires >50% extracellular mucin to define the Mucinous Adenocarcinoma (MAC) subtype [11].
Colorectal cancer (CRC) is a malignant neoplastic disease arising from the epithelial lining of the colon or rectum, most commonly manifesting as adenocarcinoma [15]D. It remains a leading cause of cancer-related morbidity and mortality globally, with specific subtypes like stage III disease carrying a substantial risk of recurrence even after curative resection [4][18]D.
Synonyms and Alternate Names
Also Called: Colon cancer, Rectal cancer, Colorectal adenocarcinoma, Bowel cancer, and Large intestine cancer.
Clinical Phases and Definitions
To standardize the clinical course and of CRC, the following phases and terms are defined:
- Prodromal/Pre-malignant: The asymptomatic period or the phase of non-specific symptoms (e.g., occult bleeding, change in bowel habits) prior to definitive diagnosis. This often involves the adenoma-carcinoma sequence or the development of carcinoma in situ (Tis) [7]D.
- Progressive: The phase characterized by active tumor growth and local invasion through the bowel wall layers (T1–T4) or lymphatic/systemic spread [5][13]D.
- Nadir: In the oncological context, this refers to the point of maximal reduction in tumor burden or tumor markers (e.g., CEA) following neoadjuvant therapy or surgical resection.
- Plateau: A period of stable disease during surveillance where no evidence of progression or recurrence is detected via imaging or biomarkers [8]D.
- Recovery: The post-therapeutic phase focused on surgical healing, restoration of bowel function, and monitoring for long-term complications like frailty, often assessed via the Skeletal Muscle Index (SMI) [4].
Anatomical and Histological Classification
CRC is primarily classified by its anatomical location and histological features, which significantly influence prognosis and treatment response [11].
Anatomical Location
Tumors are categorized based on their position relative to the splenic flexure:
- Right-sided (Proximal) Colon: Includes the cecum, ascending colon, and transverse colon. These often present with different molecular profiles compared to distal tumors [11].
- Left-sided (Distal) Colon: Includes the descending colon and sigmoid colon [11].
- Rectum: Defined as the terminal portion of the large intestine, approximately 15 cm from the anal verge. Accurate locoregional staging in rectal cancer (especially T1) requires high-resolution MRI or endoscopic ultrasound (EUS) [5].
Histological Variants
| Variant Name | Key Distinguishing Feature | Associated Markers/Biology |
|---|---|---|
| Adenocarcinoma (NOS) | Most common type; originates from glandular epithelium. | Standard driver mutations (APC, KRAS, TP53) [6]D. |
| Mucinous Adenocarcinoma (MAC) | Characterized by >50% extracellular mucin component [11]. | Associated with distinct recurrence patterns depending on location [11]. |
| Signet Ring Cell Carcinoma | Cells contain large amounts of mucin that push the nucleus to the periphery. | Highly aggressive with poor prognosis. |
| Early-Onset CRC (EOCRC) | Diagnosis before age 50 [6]D[15]D. | Increased chromosomal instability; MYC, RAD21, GNAS, and MAPK1 amplifications [6]D. |
| Globo-H High CRC | High expression of the Globo-H glycan target [18]D. | Associated with DUSP14 overactivation [18]D. |
TNM Staging and the AJCC 9th Edition Proposals
The American Joint Committee on Cancer (AJCC) 8th edition is the current standard, though the 9th edition has proposed critical updates to address survival paradoxes [13]D. In the 8th edition, Stage IIIA patients often showed better survival than Stage II patients, a discrepancy the 9th edition seeks to rectify by rebalancing T and N stages and incorporating Tumor Deposits (TDs) as an independent parameter [13]D.
Invasion Depth (T-Stage) Protocol
Step 1 → Endoscopic Evaluation: Identification of the lesion and initial morphology assessment. Step 2 → Invasion Depth Prediction: Distinguishing between superficial (Tis/T1a) and deeply invasive (T1b) lesions. This is increasingly assisted by Artificial Intelligence (AI) to avoid unnecessary radical surgery for superficial lesions [7]D. Step 3 → Locoregional Staging: For rectal lesions, MRI and EUS are used to determine the depth of submucosal invasion and nodal involvement [5].
Molecular and Immune Stratification
Modern classification extends beyond histology to include the immune microenvironment and systemic inflammatory status. Multiplex immunohistochemistry (mIHC) is used to profile immune markers such as CD3, CD8, CD45RO, PD-1, LAG-3, and Tim-3 in the tumor center and invasive margin to predict outcomes [14]D.
Furthermore, systemic indices provide indirect measures of the host-tumor interaction:
- Prognostic Nutritional Index (PNI): Calculated from serum albumin and total lymphocyte count; lower scores correlate with poor overall survival (OS) [1].
- Systemic Immune-inflammation Index (SII): Integrates neutrophil, lymphocyte, and platelet counts to reflect the inflammatory state [2].
- Albumin/Neutrophil-to-Lymphocyte Ratio (ANLR): A combined metric used to stratify progression-free survival (PFS) [9][10].
Recent microbiome research has also reclassified key pathogens; for instance, the link between the Fusobacterium nucleatum group and CRC is now known to be driven specifically by Fusobacterium animalis [12]D.
| Biomarker | Threshold/Value | Clinical Significance |
|---|---|---|
| FIT (f-Hb) | ≥10 ug/g | Threshold for urgent cancer referral in symptomatic patients [17]D. |
| EOCRC Age | <50 years | Defines early-onset disease with distinct molecular biology [6]D[15]D. |
| Mucinous Component | >50% | Histological requirement for MAC classification [11]. |
| Skeletal Muscle Index (SMI) | Variable | Imaging-based surrogate for frailty and recurrence risk [4]. |
Epidemiology and Risk Factors
- ▸CRC incidence is rising in multiple regions, and no single risk factor explains most cases. [276] [280] [284]
- ▸Age-related risk increases are detectable even among adults aged 18–44 years, with the highest lesion detection reported at ages 40–44 years. [273]
- ▸Early-onset CRC is increasing worldwide; deficient mismatch repair is a distinct molecular feature in a Chinese early-onset cohort. [277]
- ▸NAFLD/MASLD, metabolic syndrome, and hypertension are associated with colorectal neoplasia or CRC in observational studies. [271] [272] [279] [281]
- ▸Lynch syndrome and previous non-CRC malignancy identify populations requiring consideration of tailored CRC surveillance. [274] [275]
- ▸Screening benefit depends on follow-up after a positive stool test; navigation and coordinated systems may reduce diagnostic delays. [266] [267]
Global and age-related epidemiology
Colorectal cancer (CRC) accounts for more than 10% of the global cancer burden, and its incidence is increasing in several regions, including sub-Saharan Africa and China. [276] [280] [284] The available evidence does not identify a single dominant cause; rather, CRC risk reflects the cumulative effects of metabolic, behavioral, hereditary, inflammatory, socioeconomic, and possibly environmental factors. [276] In Nigeria, more than half of patients reportedly die within 1 year of diagnosis, with late presentation and limited access to treatment contributing to the poor outcome. [284]
Age remains a major determinant of colorectal neoplasia. In a colonoscopy-based cohort of 3,959 adults aged 18–44 years, detection rates for polyps, adenomas, and serrated lesions increased significantly with age, with the highest rates in individuals aged 40–44 years. [273] These findings support attention to risk assessment before traditional screening ages, although the study was single-center and based on people undergoing colonoscopy rather than a general population sample. [273] Early-onset CRC, commonly defined as diagnosis before 50 years, is increasing worldwide and has also increased in China. [277] In a Chinese hospital cohort, deficient mismatch repair was identified as a distinct molecular feature of early-onset CRC, although the study did not establish that mismatch-repair deficiency was a population-level cause of the observed incidence increase. [277]
The population aged 65 years or older is projected in the United States to reach 82 million by 2050, representing approximately 23% of the population. [266] This demographic shift will increase the number of older adults requiring individualized decisions about screening and surveillance; the potential benefit of removing premalignant lesions must be balanced against comorbidity, life expectancy, procedural burden, and time to benefit. [266]
Metabolic and cardiometabolic risk factors
Metabolic dysfunction is consistently represented among the newer risk-factor studies. Nonalcoholic fatty liver disease (NAFLD) is associated with a higher prevalence of colorectal polyps, and a 2026 meta-analysis identified candidate risk factors for polyp development among people with NAFLD; these factors were subsequently used to construct and validate a prediction model. [271] Metabolic dysfunction-associated steatotic liver disease (MASLD) has likewise been associated with increased colorectal neoplasia risk. [281] In patients with MASLD who had undergone baseline and surveillance colonoscopy, longitudinal improvement in cardiometabolic risk factors was evaluated in relation to metachronous advanced colorectal neoplasia, supporting the clinical importance of dynamic metabolic health rather than a single baseline measurement. [281]
A UK Biobank cohort of 379,173 adults aged 40–69 years examined metabolic syndrome (MetS), its component abnormalities, and CRC incidence using age- and sex-stratified analyses. [279] The study specifically assessed whether associations differed by sex and by age below versus at least 60 years, indicating that the relationship between MetS and CRC may be heterogeneous rather than uniform across demographic groups. [279] In a large Japanese population study, hypertension was associated with CRC incidence in analyses comparing hypertensive and normotensive participants, including 85,399 hypertensive and 113,724 normotensive individuals who were not taking antihypertensive medication. [272] Because the Japanese study used observational claims and health-check data, the association should not be interpreted as proof that hypertension directly causes CRC. [272]
Behavioral, social, and geographic factors
A pooled Finnish analysis of 224,048 participants from seven cohorts, including 2,006 CRC cases, evaluated incidence trends according to education, cigarette smoking, alcohol consumption, physical inactivity, and body mass index. [276] The study underscores that CRC incidence varies across combinations of social and behavioral exposures, but no single factor accounts for most cases. [276] Regional applicability is important: a multicenter Nigerian case-control study evaluated whether 13 risk factors previously identified in high-income populations were associated with CRC in Nigerian adults, where clinicodemographic patterns and tumor characteristics may differ from those populations. [284]
Screening access and awareness are themselves important population-level determinants of CRC outcomes. In rural populations of northern China, awareness and participation in screening remained inadequate, particularly in communities representing a substantial proportion of the national population. [280] Stool-based screening is effective only when abnormal results are followed by diagnostic colonoscopy; patients with positive stool tests have increased CRC risk, yet follow-up colonoscopy rates remain suboptimal. [267] Patient navigation, digital reminders, coordinated systems, and open-access colonoscopy are proposed interventions to reduce this gap and potentially lower CRC incidence and mortality. [267]
Hereditary and acquired high-risk states
Lynch syndrome is caused by germline pathogenic variants in DNA mismatch-repair genes and confers increased CRC risk. [274] In an English National Health Service registry of 4,732 mismatch-repair carriers, surveillance adherence and age-specific CRC incidence and mortality were evaluated, reflecting the importance of regular colonoscopic surveillance in this high-risk group. [274] A history of cancer at another primary site may also identify increased subsequent CRC risk: a Canadian cohort of 172,928 non-CRC cancer survivors assessed standardized incidence ratios, incidence differences, and site-, sex-, age-, and survivorship-specific predictors of subsequent primary CRC. [275]
Interpretation of treatment-focused evidence
Several cited studies concern established CRC rather than risk of developing CRC. They address third-line treatment for metastatic CRC, vitamin D supplementation during metastatic-disease therapy, postoperative electroacupuncture, surgical outcomes in patients with heart failure, and management of chemotherapy-related gastrointestinal toxicity. [268] [269] [270] [278] [282] These studies should not be used to infer population incidence or etiologic risk factors. Similarly, preliminary microbiome-screening research in FIT-positive individuals primarily evaluates stool-collection feasibility and compliance, not validated causal risk. [283]C Experimental observations involving CD132 downregulation, γδ-T-cell loss, apoptosis, and microsporidia in adenomas and CRC may indicate biological changes during neoplastic progression, but the small study of 55 subjects cannot establish these findings as epidemiologic risk factors. [285]
| Risk domain | Evidence from the cited literature |
|---|---|
| Age | Polyp, adenoma, and serrated-lesion detection increased through ages 18–44; older-adult screening decisions should account for time to benefit. [266] [273] |
| Metabolic disease | NAFLD/MASLD, metabolic syndrome, and hypertension were associated with polyps, advanced neoplasia, or CRC in observational studies. [271] [272] [279] [281] |
| Behavioral and social factors | Smoking, alcohol, physical inactivity, BMI, education, screening awareness, and access were evaluated as determinants of incidence or prevention. [276] [280] |
| Hereditary susceptibility | Lynch syndrome caused by germline mismatch-repair variants confers increased CRC risk and requires enhanced surveillance. [274] |
| Previous cancer | Non-CRC cancer survivors may have elevated subsequent primary CRC risk, varying by primary cancer site and patient characteristics. [275] |
Etiology and Triggering Factors
- ▸Hereditary CRC syndromes account for approximately **5–10%** of CRC; LS and FAP are major syndromic causes [452].
- ▸LS is caused by pathogenic germline MMR-gene variants and accounts for approximately **4%** of CRC [447].
- ▸MMR deficiency produces MSI and promotes tumorigenesis through accumulation of insertion–deletion errors [443,453].
- ▸Chronic IBD-associated inflammation can produce multifocal colitis-associated cancer with persistent epithelial, immune, stromal, and microbial inflammatory memory [442].
- ▸Microbiome and metabolome changes are associated with premalignant and malignant CRC biology, but the supplied evidence does not establish a single causal microbial trigger [442,444,448,459].
- ▸Biallelic MSH3 or MLH3 alterations and possible heterozygous second-hit mechanisms broaden the spectrum of inherited MMR-related CRC risk [455].
- ▸Incomplete tumor screening and cascade testing mainly delay detection of inherited risk rather than directly causing CRC [441,447,452].
Colorectal cancer (CRC) is etiologically heterogeneous, arising through interactions among inherited susceptibility, acquired somatic alterations, chronic mucosal inflammation, immune and stromal responses, and environmental or microbial exposures. The references supplied support the following framework, although several are diagnostic, treatment, or translational studies rather than direct evaluations of causal risk.
Hereditary susceptibility
Hereditary colorectal cancer syndromes account for an estimated 5–10% of CRC, with Lynch syndrome (LS) and familial adenomatous polyposis (FAP) representing major entities [452]. The hereditary adenomatous polyposis syndromes are systemic, incurable cancer-predisposition disorders with variable inheritance patterns, age at onset, polyp burden, and cancer spectrum [440]. Their principal gastrointestinal risks include malignancies of the colon, rectum, duodenum, ampulla, and stomach [440]. FAP and related polyposis syndromes therefore promote CRC through constitutional defects in epithelial growth control and adenoma formation, whereas their clinical expression depends on the specific syndrome and gene involved [440].
LS results from pathogenic germline variants in DNA mismatch-repair (MMR) genes and is estimated to cause approximately 4% of CRC [447]C. Defective MMR permits accumulation of insertion–deletion errors and produces microsatellite instability (MSI), a molecular route to tumorigenesis that is also relevant to prognosis and immune-checkpoint treatment response [443][453]. Universal tumor screening by MMR immunohistochemistry or MSI testing is used to identify tumors that may reflect LS; abnormal results require appropriate tumor reflex testing and, when indicated, germline assessment [443][447]C. In one prospective Russian registry of 2,101 unselected patients with primary colorectal adenocarcinoma, MSI/MMR status was evaluated to characterize population-level prevalence and clinicopathological correlates [453].
Beyond canonical LS genes, biallelic pathogenic variants in noncanonical MMR genes such as MSH3 and MLH3 can cause adenomas or CRC through excess somatic deletion mutations and the mutational signature designated ID4 [455]D. The available evidence also supports a possible “second-hit” mechanism in which a heterozygous germline variant becomes pathogenic after loss or inactivation of the normal allele in tumor tissue [455]D. Tumor MSI, MMR immunohistochemistry, and quantitative mutational signatures may help refine the interpretation of uncertain germline MMR variants within Bayesian pathogenicity assessment [457]D.
Inflammation-associated carcinogenesis
Inflammatory bowel disease (IBD), particularly chronic colitis, creates a distinct pathway to colitis-associated cancer (CAC) [442]. CAC develops in chronically inflamed mucosa and differs from sporadic CRC by field effects, multifocality, and the sequence of molecular events leading to malignancy [442]. The initiating or sustaining trigger may be persistent mucosal inflammation, repeated epithelial injury and regeneration, immune dysregulation, and inflammation-associated mutation [442]. Experimental evidence further indicates that epithelial, immune, stromal, and microbial compartments can retain altered states after the original inflammatory stimulus has subsided; this phenomenon is described as inflammatory memory [442]. Such memory may involve persistent molecular, cellular, tissue, or microbial states that modify responses to later challenges, including epithelial epigenetic memory and trained innate immunity [442].
Microbiome and metabolic influences
Microbial communities may contribute to CRC initiation or progression by influencing inflammation, epithelial signaling, DNA damage, metabolism, and local immune responses, although the supplied studies do not establish a single causal organism or exposure [442][444][448][459]D. Colorectal laterally spreading tumors, which are premalignant lesions with clinically important malignant potential, have been associated with a coordinated microbial, metagenomic, and circulating-metabolite pattern termed a carcinogenic eco-metabolic shift [444]. This finding supports a relationship between altered microbial metabolism and high-risk premalignant biology, but does not prove that the shift initiates tumorigenesis [444].
In locally advanced rectal cancer, oral and fecal shotgun metagenomic profiles—including bacterial, archaeal, eukaryotic, and viral taxa—were examined in relation to response to neoadjuvant chemoradiotherapy [448]. These data primarily address treatment response rather than cancer causation, but they reinforce the potential relevance of oral–gut microbial interactions to CRC biology [448]. A multi-omics study of 3,026 CRC patients identified an insomnia-related molecular subtype associated with microbiome, immune, and therapy-relevant heterogeneity [459]D. Because that analysis was associative, insomnia-related inflammation, circadian disruption, and microbiome changes should be regarded as candidate modifiers rather than established independent causes of CRC [459]D.
Somatic evolution and tumor microenvironment
CRC progression also reflects clonal somatic evolution within a heterogeneous epithelial, immune, and stromal ecosystem [442][456]D. Multi-omics analyses identified a GPRC5A-positive malignant epithelial subpopulation associated with malignant features, and functional genomic, cellular, and xenograft experiments were used to investigate its contribution to tumor behavior [456]D. These findings support cellular-state diversity as a mechanism of progression, invasion, and treatment heterogeneity rather than a single initiating trigger [456]D.
Factors that identify inherited risk but are not themselves causes
A personal or family history of polyposis, early-onset CRC, multiple primary tumors, or LS-associated cancers should trigger hereditary risk assessment and germline testing because these features may reveal an inherited predisposition [440][443][447]C. Cascade genetic testing can identify at-risk relatives, but uptake is limited by structural and informational barriers, particularly in medically underserved populations [441]C. Real-world studies document incomplete MMR screening, genetics referral, and germline testing despite guideline recommendations [447]C[452]. These healthcare-access failures do not cause CRC directly, but they delay recognition of inherited risk and preventive management [441]C[447]C[452].
The supplied evidence does not establish aspirin, pharmacogenetic treatment markers, urothelial-cancer alterations, postoperative anastomotic microbiota, or immunotherapy response as primary causes of CRC [446][449]C[451]C[454]D[458]D. Aspirin has preventive evidence in LS, including fewer CRCs in the CAPP2 trial, but this represents risk modification after inherited susceptibility rather than an etiologic trigger [458]D.
| Pathway | Mechanism or association | Evidence |
|---|---|---|
| Polyposis syndromes | Germline predisposition to adenoma formation and gastrointestinal cancers | [440] |
| Lynch syndrome | Germline MMR defects, MSI, and accumulation of insertion–deletion errors | [443][447]C[453] |
| Noncanonical MMR defects | MSH3/MLH3 loss, deletion mutations, ID4 signature, and possible second hits | [455]D[457]D |
| Chronic colitis | Persistent inflammation, repeated injury, mutation, and inflammatory memory | [442] |
| Microbiome/metabolome | Eco-metabolic shifts and microbial associations with tumor biology | [442][444][448][459]D |
| Somatic evolution | Heterogeneous malignant epithelial populations and tumor-microenvironment interactions | [456]D |
Pathophysiology and Molecular Biology
- ▸dMMR/MSI-H and MMRp/MSS CRC represent biologically and therapeutically distinct groups, with greatest checkpoint-inhibitor sensitivity concentrated in dMMR/MSI-H disease [304][305][309][316].
- ▸Immune resistance may be intrinsic or adaptive and may present as single-organ or systemic progression [313].
- ▸TAM polarization, COX-2 signalling, VEGF-mediated vascular biology, antigen presentation, T-cell exhaustion, and myeloid suppression shape the CRC immune microenvironment [304][305][306][320].
- ▸Cell-cycle dysregulation involving Rb–E2F, NF-κB, JAK–STAT, Hippo–YAP, cyclins, CDKs, and CDK inhibitors is central to colitis-associated carcinogenesis [322].
- ▸CRC biology includes microbiome-derived virulence functions, molecular residual disease, rare actionable fusions such as ALK, and distinct early-onset and metastatic phenotypes [307][315][319][320][321].
Molecular heterogeneity and major biological subtypes
Colorectal cancer (CRC) is a molecularly heterogeneous disease in which genomic instability, epigenetic dysregulation, altered signalling, immune editing, stromal remodelling, and microbiome-derived effects interact to determine tumor initiation, progression, treatment response, and recurrence [307][320]D[321]D. A clinically central distinction is between mismatch-repair-proficient/microsatellite-stable (MMRp/MSS) tumors and mismatch-repair-deficient/microsatellite-instability-high (dMMR/MSI-H) tumors [304][305][309][312][316]. dMMR/MSI-H disease represents a biologically distinct subtype with increased susceptibility to immune checkpoint inhibition, whereas most MMRp/MSS tumors obtain little or no benefit from currently available immunotherapy regimens [304][316]. The prevalence and clinicopathological correlates of MSI-H/dMMR disease vary by population and clinical setting; a contemporary multicenter Japanese registry was established specifically to define these features in resectable Asian CRC [312].
Defective mismatch repair permits the accumulation of insertion–deletion errors and point mutations, producing a mutation-rich tumor and a broader repertoire of potential neoantigens. This biology provides a mechanistic basis for the activity of PD-1/PD-L1-directed treatment in MSI-H/dMMR CRC, although primary resistance and progression after an initial response remain clinically important [305][309][313][316]. In a retrospective cohort of 166 patients with advanced dMMR/MSI-H CRC treated with immunotherapy, progression was categorized as intrinsic, occurring at first restaging, or adaptive, occurring after initial disease control; progression was also classified as single-organ or systemic, illustrating that immune resistance is biologically heterogeneous rather than a single event [313].
Oncogenic and tumor-suppressor pathways
Established CRC biomarkers include MSI/MMR status, KRAS, and BRAF, while p53 and PTEN are being investigated as additional prognostic markers [311]. A retrospective cohort of 103 resected colorectal adenocarcinomas specifically assessed p53 expression and PTEN deficiency by immunohistochemistry, reflecting continued uncertainty about how these tumor-suppressor abnormalities should be integrated with routine molecular classification [311]. Cell-cycle disruption is a central feature of inflammation-associated carcinogenesis. Single-cell studies summarized in a recent review indicate that malignant CRC cells are predominantly enriched in the G2/M phase, whereas epithelial cells in inflammatory bowel disease may show G1 arrest or excessive proliferation, suggesting that cell-cycle abnormalities arise during chronic inflammation and may precede overt malignancy [322]D.
The Rb–E2F, NF-κB, JAK–STAT, and Hippo–YAP pathways form an interconnected regulatory network in colitis-associated carcinogenesis [322]D. Cyclins D1, A2, and B1; cyclin-dependent kinases; and the inhibitors p21, p27, and p57 collectively influence proliferation, checkpoint control, and malignant progression [322]D. These observations support a model in which chronic inflammatory signalling and defective cell-cycle control cooperate to select epithelial cells capable of sustained proliferation and transformation [322]D.
Rare actionable genomic events further expand CRC heterogeneity. ALK fusions are uncommon in CRC but have been associated with sensitivity to ALK inhibitors; genomic profiling of 56,206 advanced CRC tumors was used to define their prevalence, clinicogenomic context, and therapeutic implications [319]D. Alterations in phosphatidylinositol 4-kinase and phosphatidylinositol phosphate kinase family genes have also been explored as potential prognostic or therapeutic biomarkers, although the available analysis was pan-cancer and included CRC only within a broader 18-tumor-type dataset [317]C.
Tumor microenvironment and immune regulation
Tumor-associated macrophages (TAMs) are a major component of the CRC tumor microenvironment and exist along a continuous spectrum between pro-inflammatory M1-like and anti-inflammatory, immunosuppressive M2-like states [304]. Their polarization influences tumor growth, immune suppression, angiogenesis, and the effectiveness of immunotherapy, particularly in MMRp/MSS disease in which inadequate immune activation is a major therapeutic barrier [304]. This has prompted investigation of macrophage polarization as a treatment target and of strategies that reprogram or deplete immunosuppressive myeloid populations rather than focusing exclusively on tumor-cell-intrinsic targets [304].
The inflammatory microenvironment is also therapeutically modifiable. Preclinical rationale and a randomized phase 2 trial evaluated whether COX-2 inhibition with celecoxib could augment neoadjuvant PD-1 blockade with toripalimab in locally advanced dMMR/MSI-H CRC, supporting a model in which prostaglandin-mediated inflammation can influence antitumor immunity [306]. Similarly, the phase 3 COMMIT trial tested whether chemotherapy and VEGF inhibition could synergize with PD-L1 blockade in first-line dMMR/MSI-H metastatic CRC, reflecting the potential for vascular normalization, antigen release, and immune-cell recruitment to alter checkpoint sensitivity [305].
Microbiome, residual disease, and metastasis
CRC-associated microorganisms should not be interpreted solely by taxonomy. A revised driver–passenger model emphasizes virulence factors and microbial functions, because the same organism may have different effects at different stages and individual microbial pathways may produce multiple, even divergent, host responses [321]D. Thus, microbial participation may involve direct epithelial injury, inflammatory activation, immune modulation, and metabolic effects rather than simple presence or absence of a bacterial taxon [321]D.
Recurrence after curative-intent treatment is increasingly understood as a dynamic process involving molecular residual disease (MRD), immune editing, tumor-microenvironment remodelling, and therapy-resistant cellular states [320]D. Circulating tumor DNA is being used as an MRD biomarker to identify patients at increased relapse risk and refine adjuvant-treatment decisions, while immune determinants include MMR/MSI status, tumor mutational burden, antigen-presentation capacity, T-cell exhaustion, myeloid suppression, and spatial immune exclusion [320]D. These mechanisms are relevant to locally recurrent rectal cancer, for which biomarker-based prediction of postoperative recurrence may improve selection for salvage surgery and neoadjuvant treatment intensification [323]D.
Early-onset CRC, defined as disease occurring before age 50, is increasingly regarded as a biologically distinct entity rather than simply an earlier presentation of late-onset CRC; systematic evidence identifies differences in genomic, epigenetic, and transcriptomic profiles and in dysregulated signalling pathways [307]. Liver metastases likewise demonstrate substantial biological heterogeneity. Integrative genomic and clinical profiling of liver-only metastatic CRC has been used to develop biologically informed frameworks for personalized resection and highly selected transplantation, in recognition that recurrence after hepatic surgery remains frequent [315].
| Determinant | Biological implication | Evidence |
|---|---|---|
| dMMR/MSI-H | Mutation-rich phenotype, enhanced immunogenicity, and increased checkpoint sensitivity; resistance remains possible | [305][309][313][316] |
| MMRp/MSS | Predominant CRC group with limited benefit from current immunotherapy; immunosuppressive TME is a major barrier | [304] |
| TAM polarization | M1-like and M2-like states influence inflammation, immune suppression, angiogenesis, and therapy response | [304] |
| Cell-cycle disruption | Abnormal G2/M enrichment and dysregulated Rb–E2F, NF-κB, JAK–STAT, and Hippo–YAP signalling | [322]D |
| Microbial virulence functions | Functional effects may differ by stage and may not be predicted by taxonomy alone | [321]D |
| MRD and immune escape | ctDNA, immune editing, exhaustion, myeloid suppression, and spatial exclusion influence recurrence | [320]D |
| Rare genomic drivers | ALK fusions and PI4K/PIPK alterations may provide investigational or biomarker-directed opportunities | [317]C[319]D |
Clinical Features
- ▸Clinical presentation is primarily determined by tumor location, with right-sided lesions causing occult anemia and left-sided lesions causing obstruction.
- ▸High BMI (≥ 28 kg/m²) is a significant risk factor for early-onset colorectal cancer (age ≤ 50) and increases the technical difficulty of rectal cancer surgery.
- ▸Digital rectal examination and modern digital rectoscopy are essential for assessing rectal tumor characteristics and suitability for organ-preservation strategies.
The clinical presentation of (CRC) is highly heterogeneous, dictated primarily by the anatomical location of the primary tumor, the stage of disease at presentation, and patient-specific factors such as body mass index (BMI). While many patients are identified through screening while asymptomatic, those presenting clinically often exhibit a progression of symptoms over weeks to months. Understanding the physiological basis for these symptoms is essential for early detection and appropriate staging.
Presenting Symptoms
Patients typically present with a history of altered bowel habits, abdominal pain, or rectal bleeding. The timeline of progression is critical; symptoms often develop insidiously and reach a clinical nadir over 2 to 4 months before the patient seeks medical attention.
- Right-Sided (Proximal) Lesions: The ascending colon has a larger caliber and liquid fecal content. Consequently, tumors here often grow to a significant size before causing obstructive symptoms. Patients frequently present with symptoms of chronic occult blood loss, such as fatigue and dyspnea, leading to a diagnosis of iron-deficiency . Vague, dull abdominal pain may be the only localized symptom.
- Left-Sided (Distal) Lesions: The descending and sigmoid colon have a narrower lumen and more solid stool. Tumors in this region are more likely to cause obstructive symptoms, including a change in bowel habits (e.g., "pencil-thin" stools), colicky abdominal pain, and overt .
- Rectal Lesions: These often present with (a distressing sensation of incomplete evacuation), bright red blood per rectum, and occasionally mucus discharge.
Constitutional symptoms, particularly weight changes, are significant prognostic indicators. Significant weight loss is often observed in advanced stages, though preoperative weight loss interventions are sometimes utilized in patients with a BMI ≥ 28 kg/m² to reduce surgical morbidity [103]. Weight fluctuations are also common during adjuvant chemotherapy, where factors like age and chemotherapy regimen (e.g., oxaliplatin-containing) influence health-related quality of life [101].
Physical Examination Findings
A systematic physical examination is required to assess for local extension, metastatic spread, and the patient's physiological fitness for intervention.
- Abdominal Examination: Palpation may reveal a firm, non-tender mass, most commonly in the right lower quadrant (cecal cancer) or left lower quadrant (sigmoid cancer). The presence of hepatomegaly or a nodular liver edge suggests hepatic . may indicate peritoneal carcinomatosis.
- Rectal and Pelvic Examination: A digital rectal examination (DRE) is mandatory for any suspected CRC. It allows for the assessment of tumor distance from the anal verge, fixation to surrounding tissues, and the presence of palpable lymphadenopathy. In modern outpatient settings, digital rigid rectoscopy (e.g., LumenEye) provides high-resolution visualization and biopsy capability without the need for sedation, facilitating the "watch-and-wait" strategy for rectal organ preservation [110].
- Systemic and Autonomic Assessment: While not a primary feature of the cancer itself, autonomic and systemic stability must be assessed, particularly in older patients with . Intraoperative and postoperative blood pressure is critical; maintaining systolic blood pressure within ± 10% of baseline using agents like norepinephrine can reduce biomarkers of kidney injury during major abdominal resections [102]. Furthermore, patients receiving targeted therapies like must be monitored for treatment-induced hypertension (SBP/DBP ≥ 140/90 mmHg) and proteinuria [107].
Phenotypic Variants
The presentation of CRC varies significantly based on the patient's metabolic profile and the tumor's location. High BMI is a recognized risk factor, particularly for early-onset colorectal cancer (EOCRC), defined as diagnosis at age ≤ 50 years [106].
| Variant | Key Features | Frequency/Reasoning |
|---|---|---|
| Early-Onset CRC (EOCRC) | Occurs in patients ≤ 50 years; strongly associated with high BMI and often presents at more advanced stages [106]. | Increasing global incidence; requires high index of suspicion in younger symptomatic patients. |
| Right-Sided (Proximal) | Predominantly presents with occult bleeding, iron-deficiency anemia, and vague right-sided pain. | ~25-30% of cases; often diagnosed later due to subtle symptoms. |
| Left-Sided (Distal) | Presents with obstructive symptoms, changes in stool caliber, and overt hematochezia. | ~40-50% of cases; more likely to be detected early due to visible bleeding. |
| Low Rectal Cancer | Located within 5 cm of the dentate line; high surgical difficulty, especially in patients with BMI ≥ 28 kg/m² [109]. | ~15-20% of cases; requires specialized surgical approaches (e.g., LAR or APR). |
Red Flags
Certain clinical findings necessitate urgent diagnostic workup or surgical consultation to prevent catastrophic complications:
- Acute Bowel Obstruction: Characterized by obstipation, abdominal distension, and high-pitched or absent bowel sounds.
- Perforation: Sudden onset of severe, generalized abdominal pain with rebound tenderness and guarding.
- Severe Post-Procedural Pain: Following interventions like endoscopic submucosal dissection (ESD), moderate to severe pain occurs in 44.9-62.8% of patients [100]. Uncontrolled pain may indicate a complication or require advanced , such as bupivacaine liposome transversus abdominis plane (TAP) blocks [108] or lidocaine-based patient-controlled analgesia [104].
Atypical Presentations
Clinicians must remain vigilant for atypical presentations that may mimic other conditions. In younger patients, symptoms like rectal bleeding are frequently misattributed to , leading to delays in diagnosing EOCRC [106]. Additionally, long-term cancer survivors (surviving ≥ 5 years) may present with non-specific symptoms related to late-onset treatment effects or secondary malignancies, where lifestyle factors like smoking and physical activity levels significantly impact all-cause mortality [111][112].
| Variant | Key Features | Frequency/Reasoning |
|---|---|---|
| Early-Onset CRC | Age ≤ 50 years; associated with high BMI; often advanced at diagnosis [106]. | Increasing incidence; requires early investigation of symptoms. |
| Right-Sided | Occult bleeding, anemia, vague pain, larger mass at presentation. | ~30%; larger lumen allows for prolonged asymptomatic growth. |
| Left-Sided | Obstructive symptoms, pencil-thin stools, hematochezia. | ~45%; narrower lumen leads to earlier obstructive signs. |
| Low Rectal | Tenesmus, rectal bleeding; surgical difficulty increases with BMI ≥ 28 kg/m² [109]. | ~20%; proximity to anal sphincter complicates management. |
Diagnosis and Workup
- ▸Use personal and family history to identify possible hereditary adenomatous polyposis syndromes and refer appropriate patients for germline testing [440].
- ▸Australian guidance recommends **universal MMR or MSI screening in all colorectal cancer patients**, but real-world completion of screening, referral, and germline testing is variable [447].
- ▸AI-assisted colonoscopy is being evaluated for size-specific polyp detection, but cross-platform rankings are indirect and should not replace expert colonoscopy or pathology [461].
- ▸The FOCUS chromoendoscopic classification categorizes flat ulcerative-colitis-associated lesions from Type I to Type III and requires histopathologic correlation [470].
- ▸CT-derived quantitative metrics, AI body-composition measures, and CT texture models are investigational tools for response, prognosis, and nodal-risk prediction [473][477].
- ▸Cardiac metastasis is an exceedingly rare colorectal-cancer presentation supported mainly by case reports and case series [468].
Clinical suspicion and hereditary-risk assessment
Diagnostic workup should begin with a structured personal and family history, because hereditary adenomatous colorectal polyposis syndromes are systemic cancer-predisposition disorders with variable inheritance, age at onset, phenotype, and gastrointestinal cancer risk [440]. Relevant risks include malignancies of the colon, rectum, duodenum, ampulla, and stomach [440]. Individuals whose history or phenotype suggests an adenomatous polyposis syndrome should undergo formal risk assessment and germline genetic testing; identifying these syndromes can support timely endoscopic and surgical management and may reduce cancer incidence and mortality [440]. The available guideline abstract does not provide a single numerical threshold for referral, so testing decisions should follow the full guideline rather than an isolated polyp-count cutoff [440].
Tumor biomarker assessment and Lynch syndrome evaluation
Mismatch-repair (MMR) or microsatellite-instability (MSI) testing is central to hereditary-risk assessment in colorectal cancer. Australian guidance recommends universal MMR or MSI screening in all colorectal cancer patients, although real-world implementation is variable [447]C. In a retrospective review of colorectal multidisciplinary-team records from two South Australian public hospitals, 1,775 patients were reviewed and 1,129 colorectal cancer cases were identified for assessment of MMR/MSI screening, genetics referral, and germline-testing uptake [447]C. The study specifically examined the transition from deficient MMR or MSI-high findings to genetics referral and germline testing, highlighting that identification of a molecularly eligible patient does not ensure completion of inherited-risk evaluation [447]C.
A positive deficient-MMR or MSI-high result should therefore prompt review of personal and family history and consideration of germline testing for Lynch syndrome, while recognizing that the cited real-world study documented variable uptake rather than establishing a universal completion rate [447]C. Genetic counseling is particularly important when a pathogenic germline variant is suspected because adenomatous polyposis syndromes are incurable systemic disorders requiring ongoing gastrointestinal surveillance and management [440].
Endoscopic characterization and tissue diagnosis
Colonoscopy remains the principal setting in which colorectal lesions are directly visualized, sampled, and removed, but the supplied evidence focuses on methods that may improve lesion recognition and characterization rather than defining a complete colonoscopy protocol. A 2026 systematic review and network meta-analysis evaluated randomized trials of artificial-intelligence-assisted colonoscopy versus standard colonoscopy, with efficacy analyzed according to polyp size and exploratory rankings across AI platforms [461]. Because cross-platform comparisons were indirect, any apparent ranking should be interpreted cautiously [461]. The cited abstract describes the study objective and design but does not provide numerical pooled detection estimates; therefore, AI assistance should be regarded as an adjunct rather than a replacement for high-quality colonoscopy, endoscopist judgment, pathology, or complete examination [461].
For flat dysplasia in ulcerative-colitis-associated neoplasia, chromoendoscopic assessment may be structured using the FOCUS classification. In a single-center retrospective study, 33 lesions from 26 patients were evaluated across 230 biopsy sites [470]. FOCUS categories were Type I, suggestive of nondysplasia; Type II, suggestive of dysplasia with low confidence; and Type III, suggestive of dysplasia with high confidence [470]. The study compared prospectively recorded endoscopic classifications with histopathology and assessed diagnostic performance and reproducibility [470]. Histopathology remains the reference against which this classification was evaluated; the supplied abstract does not report the resulting sensitivity, specificity, or agreement estimates [470].
Cross-sectional imaging and preoperative risk modeling
In patients receiving neoadjuvant therapy, contrast-enhanced CT may provide quantitative information beyond conventional anatomic assessment. A retrospective study of patients treated with neoadjuvant therapy and surgery between 2016 and June 2025 evaluated CT-derived extracellular-volume fraction and arterial-enhancement fraction together with AI-assisted body-composition measures, including skeletal-muscle index, skeletal-muscle attenuation, and the visceral-to-subcutaneous adipose-tissue ratio [473]. Baseline values and changes after treatment were incorporated into models intended to predict treatment response and prognosis [473]. These variables remain investigational prognostic or response-assessment tools in the cited evidence because the abstract does not establish prospective clinical utility or a validated decision threshold [473].
CT texture features combined with clinical indicators have also been investigated for preoperative prediction of central lymph-node metastasis. In one retrospective two-hospital study, 1,187 patients were screened and 228 were included; postoperative pathology identified 76 patients with central lymph-node metastasis and 152 without it [477]. The resulting model was developed to assist preoperative assessment of nodal disease and surgical extent, but the supplied abstract does not report its discrimination, calibration, or external-validation performance [477]. Such models should therefore complement, not replace, multidisciplinary review and pathologic staging [477].
Unusual metastatic presentations
Cardiac metastasis from colorectal cancer is described as exceedingly rare [468]C. A systematic review searched PubMed, Scopus, and Web of Science through October 2025 for case reports and case series describing cardiac involvement, including clinical presentation, anatomy, imaging, management, and outcomes [468]C. New cardiac symptoms or imaging abnormalities in a patient with colorectal cancer should be interpreted in the context of this rare metastatic possibility, although the cited evidence consists primarily of case-based literature and does not establish a standardized diagnostic algorithm [468]C.
| Domain | Evidence-supported application | Important limitation |
|---|---|---|
| Hereditary-risk assessment | Personal/family history assessment and germline testing for suspected adenomatous polyposis syndromes [440] | No single referral cutoff is provided in the cited abstract [440] |
| MMR/MSI testing | Universal screening is recommended by Australian guidance for all colorectal cancer patients [447]C | Uptake and downstream germline testing remain variable in practice [447]C |
| Endoscopic enhancement | AI-assisted colonoscopy and FOCUS chromoendoscopic classification [461][470] | AI comparisons are indirect; FOCUS performance estimates are not provided in the abstract [461][470] |
| Imaging models | CT quantitative, body-composition, and texture features for response, prognosis, or nodal-risk modeling [473][477] | Retrospective evidence; reported abstracts do not establish routine-use thresholds [473][477] |
| Rare metastatic disease | Case-based evaluation of possible cardiac metastasis [468]C | No standardized diagnostic algorithm is established [468]C |
Differential Diagnosis
- ▸Diverticulitis is a major CRC mimic; CT is essential for confirmation, and post-diverticulitis colonoscopy is recommended after complicated disease or when alarm symptoms or incomplete screening are present. [342]
- ▸Crohn disease may resemble CRC clinically and radiologically, while inflammation can reduce the specificity of fecal immunochemical test–DNA testing. [345]
- ▸Colitis cystica profunda is a benign distal lesion that can mimic malignancy and commonly presents with rectal bleeding. [346]
- ▸Sessile serrated lesions and hyperplastic polyps remain difficult to distinguish histologically in some cases despite simplified diagnostic criteria. [351]
- ▸Iron-deficiency anemia has both malignant and nonmalignant gastrointestinal causes and warrants context-appropriate endoscopic assessment. [135][354]
- ▸Indeterminate lung nodules and lymph nodes in patients with CRC should not automatically be labeled metastatic on imaging alone. [349][479]
Overview
Colorectal cancer (CRC) may resemble inflammatory, infectious, diverticular, benign neoplastic, and structural colorectal disease. The differential is particularly important when symptoms are nonspecific—such as rectal bleeding, altered bowel habit, abdominal pain, diarrhea, mucus discharge, weight loss, or iron-deficiency anemia (IDA)—or when imaging demonstrates focal mural thickening, a mass, abscess, or perforation. Definitive distinction generally requires colonoscopy with biopsy, although cross-sectional imaging is important when diverticulitis, perforation, obstruction, or an extracolonic process is suspected. [342][343][135]
Diverticulitis and diverticular disease
Acute colonic diverticulitis is a major mimic of left-sided CRC because both may cause abdominal pain, altered bowel habits, systemic inflammation, bowel-wall thickening, and an apparent mass. Computed tomography (CT) is considered essential to confirm diverticulitis, particularly at the first presentation and in severe disease. [342] CT interpretation can remain difficult in perforated diverticulitis: a study from the SCANDIV trial specifically assessed whether preoperative CT could identify colonic malignancy and fecal contamination before operative treatment. [343]
The possibility of an underlying malignancy is clinically important after diverticulitis. Colonoscopy is recommended after complicated diverticulitis and is suggested after uncomplicated disease when alarm symptoms are present or CRC screening is not current. [342] Retrospective models developed in a tertiary-care cohort identified increasing age and male sex as predictors associated with higher CRC risk after diverticulitis; these models are exploratory and do not replace endoscopic assessment. [355][356]
Inflammatory bowel disease
Crohn disease and other inflammatory bowel disorders can produce abdominal pain, diarrhea, rectal bleeding, anemia, inflammatory imaging findings, and mucosal lesions that overlap with CRC. In patients with Crohn disease, inflammation-related mucosal turnover may cause false-positive fecal immunochemical test–DNA results, limiting unadjusted stool testing as a discriminator. An algorithm-enhanced system incorporating clinical variables, fecal KRAS mutation, methylation markers, and fecal calprotectin was developed specifically to improve differentiation between CRC and Crohn disease in high-risk symptomatic patients. [345]
Inflammatory bowel disease-associated neoplasia is itself part of the differential: a lesion may represent active inflammation, dysplasia, or invasive carcinoma. Endoscopic submucosal dissection has been systematically evaluated for colorectal neoplasia in patients with inflammatory bowel disease, reflecting the diagnostic and therapeutic difficulty created by chronic inflammation and fibrosis. [478]
Benign rectal and colorectal lesions
Colitis cystica profunda is an uncommon benign colorectal lesion that can closely mimic malignancy clinically, radiologically, and endoscopically. In a systematic review of histologically confirmed cases, the mean patient age was approximately 40 years, and common presentations included rectal bleeding (70%), mucus discharge (32%), diarrhea (24%), and abdominal or rectal pain (26%). Lesions were predominantly distal, with rectal involvement in 61% of reported cases. Histologic confirmation is therefore essential when a distal mass has atypical features or discordant biopsy and imaging findings. [346]
Serrated colorectal polyps, particularly sessile serrated lesions and hyperplastic polyps, may also enter the differential of a serrated or flat lesion. Despite simplified World Health Organization criteria requiring at least one unequivocally architecturally distorted serrated crypt for diagnosis of a sessile serrated lesion, interobserver and intraobserver variability persists among pathologists. [351] Pathology review may be required when endoscopic appearance and initial classification are uncertain.
Iron-deficiency anemia and occult gastrointestinal disease
IDA can be a presenting manifestation of CRC, but it is not specific for malignancy. A systematic review of adults with IDA evaluated the prevalence of normal findings, nonmalignant gastrointestinal disease, and gastrointestinal malignancy after endoscopic investigation, emphasizing that benign upper- or lower-gastrointestinal pathology remains an important alternative explanation. [135] Endoscopic evaluation is also clinically relevant in premenopausal women: a retrospective cohort of women aged 18–49 years with IDA assessed the diagnostic yield of upper and/or lower endoscopy, demonstrating that age and sex should not by themselves exclude gastrointestinal investigation. [354]
Imaging and histologic distinctions after a colorectal lesion is identified
Rectal tumors may differ in histologic phenotype without representing a separate disease from CRC. MRI-based clinical and imaging nomograms have been developed to distinguish mucinous from nonmucinous rectal adenocarcinoma, a distinction that may be difficult before surgery. [357] MRI cytometry has likewise been investigated for differentiating poorly differentiated from well- or moderately differentiated rectal tumors, but these approaches are exploratory and require pathologic correlation. [352]
Small pulmonary nodules in a patient with CRC should not automatically be classified as metastases; a multicenter deep-learning study addressed noninvasive differentiation of subcentimeter lung metastases from benign lung nodules. [479] Similarly, enlarged lymph nodes may be reactive rather than metastatic; dual-layer spectral CT parameters and morphologic features have been studied to distinguish metastatic from nonmetastatic nodes, but nodal imaging remains a staging aid rather than a substitute for histology. [349]
Practical diagnostic approach
A focal colorectal lesion, unexplained IDA, persistent alarm symptoms, or atypical recovery after diverticulitis should prompt complete diagnostic evaluation rather than attribution to a presumed benign disorder. CT is particularly important when diverticulitis or perforation is suspected, whereas colonoscopy with adequate biopsy remains central for distinguishing carcinoma from inflammatory disease, benign mimics, and serrated lesions. [342][343][346][351]
| Mimic | Features overlapping with CRC | Discriminating evaluation |
|---|---|---|
| Diverticulitis | Pain, bowel-wall thickening, inflammatory mass, perforation | CT; interval colonoscopy when complicated, symptomatic, or screening is incomplete [342][343] |
| Crohn disease/IBD | Diarrhea, bleeding, anemia, inflammatory mucosal and imaging findings | Colonoscopy with biopsy; interpret stool DNA testing cautiously in active inflammation [345][478] |
| Colitis cystica profunda | Distal rectal mass, bleeding, mucus, pain | Histology, especially when imaging and superficial biopsy are discordant [346] |
| Serrated polyps | Flat or serrated colorectal lesion; potential diagnostic overlap | Expert histopathologic review when sessile serrated lesion versus hyperplastic polyp is uncertain [351] |
| Benign gastrointestinal disease causing IDA | Occult blood loss or anemia without cancer | Upper and lower endoscopic evaluation guided by clinical context [135][354] |
Management: Surgical and Local Therapies
- ▸High-quality TME with complete or near-complete mesorectal excision and negative CRM and DRM remains the principal surgical quality target for mid- and low-rectal cancer. [324][361][363]
- ▸Randomized evidence directly addresses long-term oncological outcomes after laparoscopic versus open proctectomy, while robotic and transanal approaches require careful interpretation of pathology, function, expertise, and learning-curve data. [324][328][361][363][368]
- ▸CME for right-sided colon cancer is a proposed refinement rather than an unequivocally mandatory standard, and its routine adoption remains debated. [366]
- ▸Local excision followed by risk-adapted adjuvant chemoradiotherapy is being evaluated as an organ-preserving alternative to completion TME for high-risk pT1 and low-risk pT2 rectal cancer. [365]
- ▸Emergency presentation, locally invasive disease, uncommon histology, and complex pelvic anatomy require individualized surgery in experienced multidisciplinary centres. [372][373][376]
Principles of oncological resection
Surgery remains central to curative treatment of resectable colorectal cancer, with the operative plan determined by tumour site, stage, relationship to adjacent organs, sphincter function, patient fitness, and the preceding multidisciplinary treatment strategy. [324] For mid- and low-rectal adenocarcinoma, high-quality total mesorectal excision (TME), an intact or near-intact mesorectal envelope, and negative circumferential and distal resection margins are key pathological objectives. [324][361][363]
For right-sided colon cancer, standard high-quality right hemicolectomy and complete mesocolic excision (CME) are distinct but related concepts; CME seeks to improve specimen quality, lymph-node yield, and oncological outcomes, although its routine adoption remains controversial because the incremental oncological benefit, technical complexity, training requirements, and service implications remain uncertain. [366] CME and D3 lymphadenectomy require careful identification of the mesenteric dissection plane, and a propensity-score-matched cohort found that real-time indocyanine-green near-infrared fluorescence was studied as an aid to lymphatic visualization during laparoscopic dissection. [375]
Open, laparoscopic, transanal, and robotic approaches
A planned individual-patient-data meta-analysis of the ALaCaRT and ACOSOG Z6051 randomized trials evaluated long-term recurrence and survival after laparoscopic versus open proctectomy in patients with cT1–3 N0–2 M0 rectal adenocarcinoma. [324] The parent trials had not demonstrated non-inferiority of laparoscopy for a composite pathological-success endpoint, defined using TME completeness, circumferential margin clearance, and distal margin clearance, and neither trial was individually powered for long-term oncological outcomes. [324] The meta-analysis therefore provides the most relevant randomized evidence for counselling patients about the long-term oncological safety of laparoscopic proctectomy rather than relying solely on short-term pathology metrics. [324]
In early-onset low rectal cancer, defined in the LASRE post-hoc analysis as age <50 years, laparoscopic and open surgery were compared in 240 early-onset and 799 late-onset patients. [364] Because early-onset disease may have more aggressive clinical and biological characteristics, age-specific interpretation is appropriate; the study specifically examined whether those characteristics altered the oncological comparison between operative approaches. [364]
Robotic TME may improve technical dexterity in the confined pelvis, but oncological superiority over laparoscopy remains unproven. [361] A randomized-trial meta-analysis compared robotic with laparoscopic TME for mid- or low-rectal adenocarcinoma located ≤10 cm from the anal verge, focusing on CRM positivity, resection quality, and early oncological outcomes. [361] A broader pathological-quality meta-analysis likewise assessed TME completeness, CRM positivity, and distal resection-margin positivity, while recognizing that apparent differences may be influenced by patient selection and tumour anatomy. [363]
Robotic surgery has also been evaluated for systemic inflammatory response, with a meta-analysis comparing postoperative biochemical markers after robotic versus laparoscopic colorectal surgery and prespecified colorectal-cancer subgroup analysis. [362] The proposed clinical rationale is reduced tissue trauma and a lower inflammatory response, but biochemical differences should not be treated as proof of superior recurrence or survival outcomes. [362] Adoption should account for the learning curve: a systematic review of more than 3,500 procedures described an initial phase covering approximately cases 1–25, with longer operating times but reported conversion rates of 1.0%–3.2%, followed by technical stabilization by approximately case 35. [368] Other learning-curve studies used CUSUM analysis of operative time and separately examined right colon, sigmoid, and rectal procedures, including 21 robotic rectal cases in one specialized-centre cohort. [377]C
Transanal TME is a technically demanding alternative for selected mid- and low-rectal tumours. [328] The multicentre randomized Ta-LaTME study compared transanal with laparoscopic TME using long-term quality-of-life measures, EORTC QLQ-C30 and QLQ-CR29, and bowel function assessed by the Low Anterior Resection Syndrome score at baseline and at ≥12 months. [328] These patient-reported outcomes should be considered alongside oncological safety and the technical expertise of the treating unit. [328]
Anastomosis and organ preservation
After TME, anastomotic reconstruction may use immediate handsewn anastomosis, delayed Turnbull–Cutait anastomosis, double-stapling, or transanal techniques. [360] A systematic review and Bayesian network meta-analysis synthesized randomized and non-randomized comparative studies to evaluate these approaches simultaneously, reflecting the absence of a single universally preferred technique. [360] The choice should be individualized according to anastomotic height, tissue perfusion, tension, sphincter function, leak risk, and surgeon expertise. [360]
Local excision can preserve the rectum in carefully selected early cancers but requires pathological risk assessment and a defined salvage strategy. [365] The randomized phase 3 TESAR trial evaluated adjuvant chemoradiotherapy versus completion TME after local excision for high-risk pT1 and low-risk pT2 rectal cancer below the sigmoid takeoff, testing whether adjuvant treatment could provide an organ-preserving alternative to completion surgery. [365] This evidence is particularly relevant when completion TME is expected to cause substantial morbidity or impaired function, but local excision and organ preservation remain contingent on accurate staging, complete excision, and informed surveillance. [365]
Complex, emergency, and specialized situations
Pelvic exenteration or surgery beyond TME may be required for selected locally advanced sigmoid or rectal cancers involving adjacent structures, and perioperative inflammatory biomarkers have been investigated as predictors of postoperative complications in this setting. [373] Emergency colorectal cancer resection is associated with poorer perioperative and oncological outcomes than elective surgery, and age-stratified machine-learning analysis has examined clinical and sociodemographic predictors of emergency presentation. [376] These patients require individualized decisions regarding resection, diversion, staged reconstruction, and subsequent oncological treatment. [376]
Reduced-port robotic colorectal surgery has been assessed prospectively using a standardized 3+1-port configuration; among 60 patients, 40 underwent radical colorectal resection, including 23 rectal procedures, with a reported 100% non-conversion rate and a device-related safety endpoint based on Clavien–Dindo grade ≥III complications within 30 days. [371] A single-centre UK transition to a fully robotic colorectal practice was also reported as a feasibility and outcomes study, but its retrospective design limits causal comparisons with laparoscopy. [374]C Predictive modelling for robotic TME difficulty has additionally been developed and externally validated in prospective data, supporting selective case planning rather than replacing experienced surgical judgment. [369]
Radiotherapy remains an important local-treatment component for selected rectal cancers, particularly within neoadjuvant strategies. [367] The randomized phase II Neo-STAR trial evaluated short-course radiotherapy followed by CAPOX with tislelizumab versus short-course radiotherapy followed by CAPOX alone in locally advanced disease, including cT1–2N+M0 or cT3–4NanyM0 tumours. [367] Separately, a large real-world recurrence-mapping study assessed whether distal mesorectal irradiation is necessary during preoperative radiotherapy, providing evidence relevant to future target-volume optimization but not, by itself, a basis for changing established radiotherapy protocols. [370]
Rare histologies require different priorities: a systematic review of paediatric colorectal lymphoma described lymphoma as an uncommon colorectal malignancy and examined its diagnostic and surgical implications, underscoring that management should not simply follow adenocarcinoma pathways. [372]
| Situation | Evidence-informed considerations |
|---|---|
| Mid/low rectal adenocarcinoma | TME quality, CRM, DRM, and mesorectal integrity are central; laparoscopic versus open outcomes are addressed by individual-patient randomized-trial meta-analysis. [324][361][363] |
| Robotic TME | May offer technical advantages in the confined pelvis; comparative oncological superiority remains uncertain, and learning-curve effects are important. [361][362][363][368] |
| Transanal TME | Consider only in appropriately selected patients and experienced units; long-term QoL and LARS outcomes are key endpoints. [328] |
| Right-sided colon cancer | Standard high-quality right hemicolectomy remains foundational; routine CME requires careful consideration of evidence, complexity, and training. [366] |
| Early rectal cancer after local excision | High-risk pT1 and low-risk pT2 disease may be considered for adjuvant chemoradiotherapy versus completion TME within risk-adapted organ-preservation pathways. [365] |
| Locally advanced, emergency, or unusual disease | Consider exenterative or staged strategies, and avoid applying adenocarcinoma pathways uncritically to paediatric colorectal lymphoma. [372][373][376] |
Management: Systemic and Radiation Therapy
- ▸Response-adapted organ preservation after long-course chemoradiotherapy or short-course radiotherapy is being evaluated in early- and intermediate-stage rectal cancer; total mesorectal excision remains standard for many patients. [482]
- ▸Watch-and-wait after a clinical complete response is supported by selected retrospective evidence in immunotherapy-treated pMMR/MSS locally advanced rectal cancer, but requires careful selection and surveillance. [484]
- ▸ctDNA-selected cetuximab plus irinotecan rechallenge is an investigational strategy for RAS/BRAF wild-type metastatic colorectal cancer after prior cetuximab benefit. [481]
- ▸Later-line options include trifluridine/tipiracil, rechallenge chemotherapy, raltitrexed plus irinotecan-based regimens, and biomarker-directed therapies; most new comparative evidence is non-randomized. [485][486][493]
- ▸Radiation boost strategies for involved lateral pelvic lymph nodes and particle therapy for unresectable local recurrence remain areas of evidence uncertainty. [487][495]
- ▸Treatment planning should incorporate toxicity prevention and monitoring, including neutropenia, neuropathy, cognitive symptoms, symptom clusters, and potential leucovorin supply constraints. [483][485][488][496]
Treatment selection and multidisciplinary planning
Management of colorectal cancer should be individualized according to disease stage, resectability, tumour sidedness, molecular profile, metastatic distribution, performance status, prior treatment, and treatment goals; the updated evidence below is predominantly phase 2, retrospective, cohort, or systematic-review evidence and should complement—not replace—multidisciplinary decision-making. [481][482][487][490]
For locally advanced rectal cancer, total mesorectal excision remains a standard treatment, but neoadjuvant strategies are increasingly evaluated to improve organ preservation and reduce treatment-related morbidity. [482] In STAR-TREC, patients with early- or intermediate-stage rectal adenocarcinoma and ECOG performance status 0–1 were randomized to long-course chemoradiotherapy, short-course radiotherapy, or standard care, with response-adapted surgery or non-operative management; the trial was designed to assess organ preservation, oncological outcomes, toxicity, and quality of life. [482] Clinical complete response followed by watch-and-wait is also being studied after immunotherapy-containing neoadjuvant therapy in selected pMMR/MSS locally advanced rectal cancer, although the available multicentre evidence is retrospective and restricted to patients who achieved complete clinical response and had at least 12 months of follow-up. [484]C
Systemic therapy for metastatic disease
Molecular testing remains central to systemic treatment selection. In RAS/BRAF wild-type metastatic colorectal cancer, anti-EGFR therapy may be used in appropriate treatment lines, particularly when tumour shrinkage or conversion to resection is important. A retrospective study of 241 patients with liver-limited RAS wild-type disease compared first-line chemotherapy combined with panitumumab, cetuximab, or bevacizumab, evaluating depth of response, objective response, disease control, and conversion to resectability; these non-randomized data should be interpreted as comparative real-world evidence rather than proof of superiority. [491]
Cetuximab rechallenge is an emerging option for a molecularly selected subgroup. A non-randomized phase 2 trial evaluated cetuximab plus irinotecan in patients with RAS/BRAF wild-type metastatic disease who had previously benefited from cetuximab, subsequently progressed on or shortly after cetuximab, and received intervening therapy; eligibility was guided by circulating tumour DNA to identify potentially cleared resistance-associated RAS/BRAF alterations. [481] Rechallenge chemotherapy more broadly was assessed in a phase 2 study requiring prior progression-free survival of at least 4 months and a treatment-free interval of at least 4 months on the previously effective regimen; oxaliplatin-, irinotecan-, or raltitrexed-based regimens were administered with or without bevacizumab or cetuximab. [486]
In later-line disease, trifluridine/tipiracil remains a standard option for refractory metastatic colorectal cancer. The real-world ReTrITA analysis examined whether treatment-emergent grade 3–4 neutropenia was associated with progression-free and overall survival; any relationship between neutropenia and outcome is prognostic or treatment-associated and should not be used alone to escalate dosing. [485] Other refractory-disease evidence includes a prospective multicentre analysis of second-line raltitrexed plus irinotecan administered with bevacizumab, cetuximab, or no targeted agent; because treatment selection was non-randomized, comparisons are exploratory. [493] A retrospective study also compared immune checkpoint inhibitor regimens with trifluridine/tipiracil with or without bevacizumab, regorafenib, or fruquintinib in chemorefractory pMMR/MSS disease after propensity matching; its findings are hypothesis-generating because checkpoint inhibitors generally have limited activity in unselected pMMR/MSS tumours. [490]
Targeted treatment should be considered for actionable molecular subgroups. Real-world data describe HER2-positive metastatic colorectal cancer, including outcomes with trastuzumab plus pertuzumab and comparisons of anti-EGFR antibody versus bevacizumab in RAS wild-type disease. [489]C For previously treated KRAS G12C-mutated disease, a multicentre phase 1b/2 trial established a recommended combination dose of ifebemtinib 100 mg once daily plus garsorasib 600 mg twice daily; this regimen remains investigational pending disease-specific efficacy and safety interpretation. [494]C Experimental selenium nanoparticles targeting KRAS G13D through proposed GPX2-related mechanisms are preclinical or translational evidence and are not established clinical therapy. [492]
Radiation therapy and local recurrence
Radiation remains an important component of neoadjuvant and salvage management for rectal cancer. For clinically involved lateral pelvic lymph nodes, radiation dose escalation or boost during neoadjuvant chemoradiotherapy is being evaluated as a potential alternative or complement to lateral pelvic lymph-node dissection; a systematic review identified continuing uncertainty regarding safety, oncological benefit, and the appropriate relationship between boost strategies and surgery. [495]
For unresectable or inoperable locally recurrent rectal cancer, salvage surgery remains preferred when feasible, whereas photon radiotherapy, stereotactic body radiotherapy, and particle therapy may be considered in selected patients with curative intent. A systematic review emphasized that posterior and lateral recurrences may carry substantial surgical morbidity and that some recurrences remain unresectable after neoadjuvant treatment; evidence for particle therapy is therefore selective and heterogeneous rather than definitive. [487] Deep-learning-based automatic contouring may improve radiotherapy workflow and reduce contouring variability, but implementation requires quality assurance and ongoing updating of the system. [498]
Supportive care and treatment toxicity
Adjuvant chemotherapy can be associated with cognitive symptoms, depressive symptoms, and peripheral neuropathy; a prospective cohort of 127 patients with resected colon cancer compared patients receiving adjuvant chemotherapy with postoperative surveillance using cognitive, psychological, neuropathy, and neurotrophic-inflammatory assessments over 6 months. [483] Symptom burden during adjuvant chemotherapy may fluctuate over treatment stages, and prospective network analyses have examined the stability of symptom clusters to support stage-specific symptom management. [488] Leucovorin shortages have prompted observational comparison of standard-dose 400 mg/m² with reduced-dose 200 mg/m² administered on day 1 of each cycle in leucovorin-containing metastatic regimens; these data do not establish reduced dosing as equivalent, so regimen-specific clinical judgment is required. [496]
Colonic endoscopic submucosal dissection is a local treatment rather than systemic or radiation therapy, but a double-blind randomized trial evaluated submucosal 1% lidocaine with sodium alginate versus saline with sodium alginate to reduce colonic spasm and improve technical conditions during dissection. [480] Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy may be considered only in carefully selected patients with colorectal peritoneal metastases; contemporary institutional evidence assesses disease burden using the peritoneal cancer index and completeness of cytoreduction, but the role of HIPEC remains debated. [497]
| Clinical setting | Evidence-informed approach | Important limitation |
|---|---|---|
| Early/intermediate rectal cancer | Long-course chemoradiotherapy or short-course radiotherapy with response-adapted organ preservation | STAR-TREC results reported as 12-month phase 2/3 evidence; applicability depends on selection and response assessment. [482] |
| Locally advanced rectal cancer with clinical complete response | Consider structured watch-and-wait in selected patients | Evidence after immunotherapy-containing treatment in pMMR/MSS disease is retrospective. [484]C |
| RAS/BRAF wild-type metastatic disease | Anti-EGFR therapy, including selected ctDNA-guided cetuximab rechallenge | Rechallenge and biologic comparisons are mainly non-randomized. [481][491] |
| Refractory metastatic disease | Trifluridine/tipiracil, rechallenge regimens, raltitrexed/irinotecan-based therapy, or biomarker-directed treatment | Treatment choice requires prior exposure, molecular selection, toxicity assessment, and clinical context. [485][486][493][494]C |
| Locally recurrent rectal cancer | Salvage surgery when feasible; selected photon, SBRT, or particle therapy when unresectable/inoperable | Particle-therapy evidence is heterogeneous and based on systematic review of limited studies. [487] |
| Lateral pelvic lymph nodes | Investigational radiation boost strategies during neoadjuvant treatment | Benefit and safety relative to lymph-node dissection remain uncertain. [495] |
Supportive Care and Complication Management
- ▸Integrate nutrition, exercise, psychological support, and digital or virtual follow-up into individualized perioperative and survivorship care. [499][394]
- ▸Screen repeatedly for fatigue, cognitive symptoms, chemotherapy-related neuropathy, and evolving symptom clusters. [326][401][483][402][488]
- ▸Use validated QoL and bowel-function instruments after rectal surgery and monitor anastomotic leakage and incisional hernia for long-term consequences. [328][403][500]
- ▸Protective ileostomy closure should be individualized; randomized evidence found no significant overall advantage for early closure defined as ≤30 days versus late closure defined as ≥12 weeks across several major outcomes. [464]
- ▸Obstruction and metastatic disease require multidisciplinary treatment planning, with current evidence for stenting, delayed resection strategies, and immune-checkpoint inhibitors derived mainly from retrospective or comparative treatment studies. [406][504][309]
Principles of supportive care
Supportive care should be individualized across the perioperative, adjuvant-treatment, metastatic, and survivorship phases, with repeated assessment of nutrition, physical function, fatigue, psychological well-being, bowel function, neuropathy, cognition, and health-related quality of life (HRQoL). [499][326][394] Digital-health interventions have been evaluated in randomized controlled trials for nutritional status and QoL in patients with colorectal cancer; the 2026 systematic review and meta-analysis searched four databases through March 2026 and used random-effects models, although the supplied abstract does not report the pooled effect estimates. [499] Virtual multidisciplinary prehabilitation and rehabilitation models are being developed to coordinate exercise, nutritional, psychological, and clinical support before and after colorectal cancer surgery. [394]
Nutrition, exercise, and prehabilitation
Nutritional screening should be integrated with assessment of food access and treatment burden. Household food insecurity is a potentially bidirectional social determinant: cancer and its financial or functional consequences may increase food insecurity, while food insecurity may adversely affect cancer prevention, treatment, and survivorship outcomes. [501]C Patients with identified risk should receive dietetic assessment and linkage to practical food and financial-support services, while recognizing that the cited evidence is observational and not colorectal-cancer-specific. [501]C
Exercise-based prehabilitation is a reasonable component of perioperative care for appropriately selected patients. In PHYSSURG-C, patients were randomized to additional unsupervised moderate physical exercise before and after surgery versus standard care, with fatigue assessed at 4 weeks and 12 months; the analysis was a post hoc exploration of secondary outcomes, so conclusions about fatigue should remain cautious. [326] A single-center randomized interim analysis also evaluated trimodal prehabilitation combining exercise, nutritional support, and psychological counseling within an Enhanced Recovery After Surgery pathway; it included 45 patients and examined anxiety, depression, and HRQoL, but its preliminary evidence was limited by sample size and interim design. [397]C
Fatigue, cognition, and chemotherapy-related symptoms
Fatigue is common during and after treatment and should prompt evaluation for reversible contributors, including anemia, sleep disturbance, nutritional deficiency, depression, infection, medication effects, and deconditioning; the cited longitudinal CRC study specifically investigated inflammatory biomarkers and fatigue over as long as 3 years after surgery. [401] Because the study examined associations rather than treatment effects, inflammatory markers should not be used alone to direct fatigue therapy. [401]
Cognitive complaints should be assessed clinically, particularly after adjuvant chemotherapy. A prospective cohort of 127 patients with resected colon cancer compared patients receiving adjuvant chemotherapy with those under postoperative surveillance and assessed cognition, depressive symptoms, and peripheral neuropathy at baseline and 6 months, alongside serum brain-derived neurotrophic factor and inflammatory measures. [483] Persistent or functionally important cognitive symptoms warrant assessment of mood, sleep, medications, endocrine or metabolic abnormalities, and occupational or driving safety. [483]
Oxaliplatin-associated treatment-induced peripheral neuropathy should be monitored with patient-reported symptoms and functional interference. In 254 Chinese patients with colorectal cancer receiving oxaliplatin, the Treatment-induced Neuropathy Assessment Scale was evaluated for reliability and validity, with cutpoints anchored to walking impairment and clinician-reported toxicity grades. [402] These findings support structured symptom documentation, but the validated cutpoints are population- and instrument-specific. [402] Symptom clusters during adjuvant chemotherapy may change in prevalence and stability over treatment stages; a prospective longitudinal network study therefore supports repeated stage-specific symptom assessment rather than assuming a fixed symptom pattern. [488]
Surgical complications and bowel dysfunction
After anterior resection, anastomotic leakage remains an important postoperative complication requiring prompt clinical evaluation, imaging when indicated, source control, antibiotics, drainage, diversion, or reoperation according to severity. A population-based cohort found that the long-term HRQoL impact of leakage at 3 years was being specifically evaluated, with bowel dysfunction assessed using EORTC colorectal instruments; the supplied abstract characterizes the reported long-term impact as minimal, which does not eliminate the need for acute management or recognition of individual morbidity. [403]
Bowel dysfunction should be assessed systematically after rectal surgery using validated patient-reported tools, including the Low Anterior Resection Syndrome score and EORTC QLQ-CR29. The Ta-LaTME randomized trial compared transanal and laparoscopic total mesorectal excision in mid- and low-rectal cancer and evaluated long-term QoL, bowel function, and oncological outcomes at ≥12 months. [328] Patients with persistent urgency, clustering, incontinence, or obstructed defecation may require dietary modification, pelvic-floor rehabilitation, medication, irrigation, or specialist referral; the cited trial establishes the importance of measurement but does not compare these supportive treatments. [328]
For a protective ileostomy, early closure was defined as ≤30 days and late closure as ≥12 weeks in a systematic review and meta-analysis of nine randomized trials involving 387 patients. [464] The analysis found no significant differences in several reported outcomes, including blood loss, operating time, hospital stay, overall morbidity, major complications, anastomotic leakage, readmission, and perioperative mortality; closure timing should therefore be individualized according to recovery, anastomotic integrity, adjuvant-treatment plans, and patient factors. [464]
Incisional hernia should be assessed for pain, discomfort, functional limitation, and QoL, rather than treated as an imaging-only finding. In the Rein4CeTo1 cohort, CT surveillance at approximately 12 and 36 months and EQ-5D-5L and hernia-specific symptom questionnaires were used to evaluate its relationship with QoL after CRC surgery. [500]
Obstruction and metastatic disease support
Malignant large-bowel obstruction requires urgent multidisciplinary assessment, resuscitation, decompression, and planning of oncological and surgical treatment. Retrospective studies evaluated self-expandable metallic stents as a bridge to elective laparoscopic surgery versus emergency surgery, with reported outcomes including recovery, complications, oncological quality indicators, and survival. [504] In stage IV obstructive disease, a retrospective “quasi-bridge-to-surgery” strategy used successful stent placement as a biological selection tool before considering delayed primary-tumor resection; this remains nonrandomized evidence and should not replace individualized multidisciplinary decision-making. [406]C
For mismatch-repair-deficient or microsatellite-instability-high metastatic CRC, a systematic review and adjusted indirect comparison evaluated first-line immune-checkpoint inhibitors using phase III randomized trials and progression-free survival as the principal outcome. [309] Supportive care should accompany systemic treatment, including toxicity surveillance, symptom control, nutritional and psychosocial support, and early management of immune-related adverse events according to treatment protocols. [309]
Quality-of-life-focused follow-up
HRQoL should remain an explicit outcome after complex treatment. After hepatectomy for high-risk colorectal liver metastases, a prospective study followed QLQ-C30, liver-metastasis-specific QoL, and EQ-5D-5L measures from the preoperative period through 36 months, alongside disease status. [405] Surgical approach may also affect functional outcomes: the randomized Ta-LaTME study directly assessed QoL and bowel dysfunction after transanal versus laparoscopic TME. [328] These findings support survivorship reviews that combine recurrence surveillance with functional, psychological, nutritional, and symptom-based care. [405][328]
| Problem | Assessment focus | Evidence-informed management principle |
|---|---|---|
| Malnutrition or food insecurity | Weight, intake, functional decline, and access to food | Dietetic review, nutritional support, and social-resource linkage; evidence for food insecurity is observational. [501]C |
| Fatigue | Severity, trajectory, sleep, mood, anemia, nutrition, and deconditioning | Use repeated assessment and consider supervised or prescribed activity; exercise evidence includes a post hoc randomized analysis. [326][401] |
| Oxaliplatin neuropathy | Numbness, sensory symptoms, walking impairment, and treatment interference | Use structured patient-reported monitoring such as TNAS and reassess treatment burden. [402] |
| Low anterior resection syndrome | Urgency, frequency, clustering, incontinence, and obstructed evacuation | Measure with LARS and EORTC colorectal questionnaires and refer for pelvic-floor or bowel rehabilitation when persistent. [328] |
| Anastomotic leakage | Systemic illness, abdominal or pelvic symptoms, collections, and bowel dysfunction | Prompt diagnostic evaluation and graded source-control treatment; long-term QoL effects may be limited at population level but remain clinically variable. [403] |
| Incisional hernia | Bulge, pain, discomfort, activity limitation, and QoL | Clinical assessment with imaging when appropriate and surgical referral for symptomatic or complicated hernia. [500] |
| Obstructing colorectal cancer | Dehydration, electrolyte disturbance, sepsis, obstruction severity, and resectability | Urgent multidisciplinary decompression and individualized selection of stenting, elective surgery, diversion, or systemic treatment. [406]C[504] |
Prognosis and Long-term Outcomes
- ▸Three-year DFS was approximately 85% with either the KangDuo KD-SR-01 or da Vinci Xi robotic platform, with no significant difference between systems.[463]
- ▸Prognostic models for resectable colorectal liver metastases commonly lack external validation; only 33 of 293 reviewed studies reported external validation.[507]
- ▸Local recurrence after rectal cancer treatment occurs in approximately 2–10% of patients even after optimal treatment.[487]
- ▸ctDNA, perioperative immune recovery, HALP, and ctDNA RAS status are promising but incompletely validated prognostic or predictive tools in the evidence supplied.[508][510][513]
- ▸Guideline-concordant care and equitable access to recommended treatment are associated with the broader quality of CRC care and may influence survival outcomes.[469]
Overview
Long-term prognosis in colorectal cancer (CRC) depends on tumor stage, recurrence risk, treatment quality, molecular characteristics, comorbidity, nutritional and inflammatory status, and access to guideline-concordant care. Recent evidence also evaluates surgical technique, perioperative recovery, circulating tumor DNA (ctDNA), and management of recurrence or metastatic disease as potential determinants of long-term outcomes.[469][507][508]
Curative-intent surgery and surgical technique
In a multicenter randomized trial of 100 patients undergoing robot-assisted CRC resection, 3-year disease-free survival (DFS) was 85.3% with the KangDuo KD-SR-01 platform and 85.5% with the da Vinci Xi platform; the difference was not significant (log-rank P=0.995). Median follow-up was 37 months, indicating comparable medium-term oncologic outcomes between the two robotic systems.[463]
An updated meta-analysis comparing robotic with laparoscopic CRC surgery included 51 primary comparative studies, although quantitative synthesis was limited to studies reporting extractable abstract-level event counts. The analysis evaluated complications, anastomotic outcomes, oncologic outcomes, and other perioperative endpoints; interpretation should account for the predominance of nonrandomized evidence and heterogeneity among included studies.[467] A single-center cohort of stage I–III right-sided colon cancer similarly evaluated overall survival (OS) and relapse-free survival (RFS) after robotic versus laparoscopic right colectomy, but its median follow-up was only 22.6 months, limiting conclusions about long-term prognosis.[512]C
The optimal level of inferior mesenteric artery ligation remains uncertain. An individual-patient-data meta-analysis of randomized trials compared low ligation with high ligation after rectal or sigmoid cancer resection using 5-year OS and DFS as primary outcomes and restricted mean survival time differences as an effect measure. The study was specifically designed to determine whether ligation level influences long-term survival, but the supplied abstract does not provide the pooled estimates; therefore, no definitive survival advantage should be inferred from the available information.[460]
Recurrence risk and prognostic stratification
For resectable colorectal liver metastases, a systematic review identified 293 studies involving 85,150 patients in development cohorts and 5,549 in validation cohorts. Most prognostic models were intended for risk stratification rather than directly actionable prediction; Cox regression remained the dominant method, external validation was uncommon (33 of 293 studies), and reporting and methodological quality were heterogeneous. These limitations reduce confidence in using existing models to individualize recurrence estimates without clinical judgment.[507]
A prospective cohort study of 1,000 patients with stage II–III CRC undergoing curative-intent resection investigated perioperative immunocircadian recovery, ctDNA-based minimal residual disease, and long-term survival. The study addresses whether dynamic host recovery trajectories add prognostic information beyond conventional clinicopathologic factors and ctDNA, but quantitative outcome results are not included in the supplied abstract.[508]
Preoperative nutritional and immune status may also have prognostic value. A prospective cohort of patients with stage I–III gastric or colorectal cancer evaluated the hemoglobin–albumin–lymphocyte–platelet (HALP) score in relation to postoperative survival. Because the provided abstract does not report effect estimates or survival results, HALP should be regarded as an investigational risk marker rather than an established standalone prognostic tool.[513]
Adjuvant treatment, surveillance, and localized disease
After non-curative endoscopic submucosal dissection (ESD) for early CRC, a reconstructed individual-patient-data meta-analysis compared additional surgery with surveillance, using OS as the primary outcome and cancer-specific survival, overall recurrence, local recurrence, and distant recurrence as secondary outcomes. The supplied abstract confirms that these outcomes were evaluated but does not provide the comparative estimates; management should therefore continue to depend on histopathologic risk features, patient fitness, and multidisciplinary assessment rather than on this evidence alone.[505]
In localized appendiceal adenocarcinoma, a retrospective cohort with external validation examined relapse risk and the effectiveness of adjuvant chemotherapy in stage I–III disease. The study included a median follow-up of 62.6 months and assessed clinicopathologic and genomic predictors, but the supplied abstract does not report the resulting hazard ratios or chemotherapy effect estimates.[511]
A systematic review of disparities in adherence to CRC clinical practice guidelines synthesized real-world evidence concerning structural and systemic barriers, adherence to recommendations, and survival outcomes. The review supports guideline-concordant care as an important health-system component of prognosis, while emphasizing that inequities in access and implementation may contribute to outcome differences.[469]
Recurrence and metastatic disease
Local recurrence after rectal cancer treatment remains clinically important. A systematic review reported that approximately 2–10% of patients may develop local recurrence even after optimal treatment. Salvage surgery is generally considered the preferred potentially curative approach when feasible, whereas posterior or lateral recurrence may carry substantial morbidity and some recurrences remain unresectable despite neoadjuvant treatment. Particle therapy, photon radiotherapy, and stereotactic body radiotherapy were reviewed for selected unresectable or inoperable cases, but the evidence base remains limited and heterogeneous.[487]
For malignant large-bowel obstruction, a meta-analysis of 24 studies involving 3,449 patients compared self-expanding metal stents as a bridge to surgery with emergency surgery. The analysis included both perioperative and long-term oncologic endpoints, but the supplied abstract does not provide the pooled survival or recurrence estimates. Consequently, stenting should not be assumed to improve long-term cancer outcomes solely on the basis of its potential perioperative advantages.[465]
Cardiac metastasis from CRC is exceedingly rare. A systematic review of case reports and case series characterized clinical presentation, cardiac involvement, metastatic pathways, management, and outcomes; because the evidence consists primarily of highly selected reports, prognosis and treatment cannot be generalized reliably to the broader CRC population.[468]C In metastatic CRC treated with first-line chemotherapy plus anti-EGFR therapy, a systematic review evaluated whether ctDNA RAS status adds prognostic or predictive information among patients with tissue RAS-wild-type tumors. The abstract highlights inconsistent findings attributable to small samples, assay sensitivity, tumor heterogeneity, and methodological differences; ctDNA RAS status therefore requires standardized interpretation.[510]
Perioperative factors and survivorship
A meta-analysis of real-world studies assessed whether intraoperative dexmedetomidine use is associated with postoperative cancer survival. The biological rationale is that perioperative stress and immunosuppression may influence recurrence, but the supplied abstract does not provide CRC-specific quantitative estimates or establish causality.[506] Evidence on early versus late protective ileostomy closure after rectal cancer surgery also does not demonstrate a clear long-term advantage: nine randomized trials involving 387 patients found no significant differences in major postoperative outcomes, anastomotic leakage, readmission, perioperative mortality, or administration of adjuvant chemotherapy. The abstract does not report long-term DFS or OS differences.[464]
Practical interpretation
Prognosis should be estimated using validated stage-based and molecular assessment, while integrating recurrence pattern, resectability, treatment adherence, nutritional status, ctDNA where clinically available, and patient preferences. Emerging biomarkers and perioperative measures are promising but should not replace established multidisciplinary risk assessment until supported by externally validated, clinically actionable evidence.[469][507][508][510][513]
Landmark Trials and Key Evidence
- ▸The ALaCaRT and ACOSOG Z6051 individual-patient-data meta-analysis was designed to clarify long-term oncological outcomes after laparoscopic versus open rectal cancer surgery because the original trials were not individually powered for recurrence or survival. [324]
- ▸Robotic versus laparoscopic total mesorectal excision remains an area of uncertain oncological benefit despite potential technical advantages, particularly for tumours **≤10 cm from the anal verge**. [361]
- ▸Randomized evidence is evaluating PD-1 or other checkpoint-inhibitor integration with neoadjuvant therapy for pMMR rectal cancer and first-line combination strategies for dMMR/MSI-H metastatic disease. [176] [417] [305]
- ▸ICI regimens increase thyroid-related adverse events, with regimen-specific increases in hypothyroidism and hyperthyroidism. [413]
- ▸AI-assisted colonoscopy has been tested extensively in randomized trials using adenoma and sessile-serrated-lesion detection and miss rates as key endpoints. [416] [113] [424]
- ▸Survivorship, exercise, and psychosocial interventions broaden CRC evidence beyond tumour control to quality of life, treatment-related symptoms, and cancer-related fatigue. [415] [98] [222]
Surgical quality and rectal cancer outcomes
The planned individual-patient-data meta-analysis of the ALaCaRT and ACOSOG Z6051 randomized trials evaluated laparoscopic versus open proctectomy in patients with cT1–3 N0–2 M0 rectal adenocarcinoma. [324] Both parent trials had been unable to demonstrate non-inferiority of laparoscopy for a composite pathological endpoint comprising complete or near-complete total mesorectal excision and a clear circumferential resection margin, among other pathology criteria. [324] Because neither trial was individually powered for long-term recurrence or survival, the meta-analysis was designed to address these oncological outcomes using pooled individual patient data. [324]
A 2026 systematic review and meta-analysis restricted to randomized trials compared robotic with laparoscopic total mesorectal excision for mid- and low-rectal adenocarcinoma, defined as tumours ≤10 cm from the anal verge. [361] The review focused on resection quality and early oncological outcomes, including circumferential resection margin positivity and other measures of pathological adequacy; it concluded that the oncological benefit of robotic surgery remains uncertain despite possible technical advantages. [361]
Neoadjuvant therapy and immunotherapy
For previously untreated, non-metastatic rectal cancer with proficient mismatch repair (pMMR), a meta-analysis of phase II–III randomized trials compared standard neoadjuvant chemoradiotherapy with the same treatment plus a PD-1 inhibitor. [176] The rationale was that conventional chemoradiotherapy produces relatively low pathological and clinical complete-response rates in pMMR disease, while early randomized studies suggested that PD-1 blockade might improve tumour response. [176]
A separate network meta-analysis examined neoadjuvant short-course radiotherapy (SCRT)-based and long-course chemoradiotherapy (LCRT)-based platforms, with or without immune checkpoint inhibitors, for locally advanced pMMR rectal cancer. [417] The analysis addressed comparative efficacy and safety in the setting of limited direct evidence comparing SCRT and LCRT immunotherapy platforms. [417] Interpretation should therefore distinguish direct randomized comparisons from network-derived indirect comparisons. [417]
In dMMR/MSI-H metastatic colorectal cancer (mCRC), a randomized phase III COMMIT study compared first-line mFOLFOX6 plus bevacizumab, atezolizumab monotherapy, and the combination of mFOLFOX6, bevacizumab, and atezolizumab. [305] The study addressed the concern that, although first-line immunotherapy is effective, approximately half of patients receiving single-agent PD-1-directed treatment may progress within 12 months; the combination strategy was motivated by potential synergy among chemotherapy, VEGF inhibition, and PD-L1 blockade. [305]
A randomized-trial meta-analysis compared immune-checkpoint-inhibitor monotherapy with dual immunotherapy in dMMR/MSI-H mCRC, assessing objective response, progression-free survival, overall survival, duration of response, and safety. [423] A separate network meta-analysis evaluated endocrine toxicities across ICI regimens in CRC; six randomized trials were included, and ICI-based treatment generally increased thyroid-related toxicity compared with conventional therapy. [413] Pembrolizumab and ICI–tyrosine kinase inhibitor therapy significantly increased hypothyroidism risk, while hyperthyroidism was significantly increased with ICI–TKI therapy and ICI plus chemotherapy plus an anti-angiogenic antibody. [413]
Molecular and anatomical treatment selection
An individual-patient pooled analysis of 12 randomized trials in the ARCAD database assessed whether anti-EGFR efficacy varies across detailed anatomical tumour segments rather than only by the conventional right-versus-left classification. [419] Eligible patients had RAS-wild-type mCRC and received first-line doublet chemotherapy combined with either an anti-EGFR antibody or bevacizumab; overall survival was the primary endpoint, with progression-free survival and objective response as secondary endpoints. [419]
Endoscopic resection and prevention
An updated systematic review and meta-analysis of randomized trials compared traction-assisted with conventional endoscopic submucosal dissection (ESD) for superficial colorectal lesions. [414] The analysis examined whether traction improves efficiency, effectiveness, and safety, including the potential influence of endoscopist experience; conventional ESD was characterized as technically demanding, time intensive, and associated with clinically relevant adverse events. [414]
A separate randomized-trial meta-analysis assessed prophylactic clipping after colorectal ESD, comparing systematic defect closure with no clipping. [418] The principal safety outcomes were clinically significant delayed bleeding, postprocedural perforation, and post-electrocoagulation syndrome. [418] The evidence addresses prevention of post-ESD adverse events rather than oncological recurrence. [418]
Colonoscopy, artificial intelligence, and surveillance
A systematic review and meta-analysis of randomized controlled trials evaluated artificial-intelligence-assisted colonoscopy against conventional colonoscopy for adenoma detection. [416] Prespecified outcomes included adenoma detection rate, adenomas per colonoscopy, sessile serrated lesion detection rate, sessile serrated lesions per colonoscopy, adenoma miss rate, and sessile serrated lesion miss rate. [416]
A Bayesian network meta-analysis included 48 randomized trials and 38,986 patients to compare computer-aided detection systems and standard colonoscopy, with adenoma detection rate as the primary endpoint and sessile serrated lesion detection as a secondary endpoint. [113] An extended network meta-analysis specifically compared EndoAngel, EndoAID, CAD-EYE, GI Genius, and EndoScreener, assessing adenoma detection rate, adenomas per colonoscopy, withdrawal time, and additional detection outcomes. [424]
Supportive care and survivorship
A meta-analysis of 22 randomized trials involving 2,949 CRC survivors evaluated survivorship programmes intended to improve health-related quality of life. [415] The review used Cochrane risk-of-bias and GRADE methods to assess the certainty of evidence. [415] Exercise interventions delivered during adjuvant chemotherapy were synthesized across randomized, non-randomized, single-arm, and retrospective studies, with outcomes including exercise capacity, muscle strength, fatigue, pain, chemotherapy-induced peripheral neuropathy, psychological symptoms, and quality of life. [98] Psychosocial interventions for cancer-related fatigue were evaluated in randomized trials with short-term, medium-term, and long-term follow-up, and certainty was assessed using GRADE. [222]
Obstruction, peritoneal disease, and imaging standards
A Bayesian network meta-analysis compared immediate surgery with bridge-to-surgery strategies—including self-expandable metallic stents, decompression stomas, and transanal tubes—for potentially curable left-sided malignant colonic obstruction. [421] Outcomes included short- and long-term results, reflecting the continuing uncertainty over the optimal initial strategy. [421]
A systematic review examined reporting of MRI prognostic features in randomized neoadjuvant rectal-cancer trials, including mrT stage, extramural venous invasion, and tumour deposits. [422] The review focused on reporting frequency, consistency, and integration of these features over two decades. [422]
Finally, a systematic review and meta-analysis assessed prophylactic hyperthermic intraperitoneal chemotherapy added to radical surgery versus surgery alone in high-risk colorectal cancer with abdominal metastatic risk, including randomized and cohort evidence. [425] The target outcome was prevention of peritoneal recurrence from subclinical disease; the available evidence should be interpreted separately from established treatment strategies for overt peritoneal metastases. [425]
Methodological context
Covariate-adjusted log-rank testing can improve statistical power and precision in randomized oncology trials with time-to-event endpoints by incorporating prognostic baseline variables, while requiring preservation of type I error control. [420]
| Domain | Evidence evaluated | Key population or threshold |
|---|---|---|
| Rectal surgery | Laparoscopic versus open proctectomy; robotic versus laparoscopic TME | cT1–3 N0–2 M0 rectal cancer; robotic review limited to ≤10 cm from anal verge [324] [361] |
| Neoadjuvant treatment | Chemoradiotherapy with or without PD-1 inhibition; SCRT versus LCRT platforms with or without ICI | Untreated pMMR non-metastatic or locally advanced rectal cancer [176] [417] |
| Metastatic systemic therapy | ICI monotherapy, dual immunotherapy, and chemo–bevacizumab–atezolizumab strategies | dMMR/MSI-H mCRC [305] [423] |
| Detection and endoscopy | AI-assisted colonoscopy, traction-assisted ESD, and prophylactic clipping | Adenoma/SSL detection and post-ESD adverse events [414] [416] [418] [113] [424] |
| Supportive and preventive care | Survivorship, exercise, psychosocial programmes, obstruction strategies, and prophylactic HIPEC | CRC survivors, patients receiving adjuvant chemotherapy, malignant obstruction, and high-risk abdominal disease [98] [222] [415] [421] [425] |
Prevention and Screening
- ▸CRC screening is a continuum; every positive stool test requires organized, timely colonoscopy follow-up, supported by navigation, digital tracking, and coordinated access. [267]
- ▸FIT-based organized screening was associated with reduced CRC-specific mortality in a population program targeting adults aged **50–69 years**. [338]
- ▸Colonoscopy remains the therapeutic reference pathway, while capsule endoscopy and plasma cfDNA methylation assays are emerging alternatives whose roles are not established by the supplied evidence. [325,430]
- ▸Screening cessation in older adults should reflect life expectancy, comorbidity, procedural risk, and time to benefit rather than age alone. [266,432]
- ▸Equitable implementation requires mailed FIT, patient navigation, health-system partnerships, and tailored outreach for rural, Medicaid, HIV-positive, and other underserved populations. [280,330,335,429]
Screening strategy and completion
Colorectal cancer (CRC) screening should be organized as a complete pathway: offering an evidence-based test, communicating results, and ensuring timely diagnostic colonoscopy after an abnormal stool test. Positive stool-test results identify patients at increased risk of CRC, yet follow-up colonoscopy remains suboptimal; patient navigation, digital reminders and tracking tools, coordinated health-system workflows, and open-access colonoscopy are recommended approaches to reduce failure-to-follow-up and improve CRC outcomes. [267] Organized fecal immunochemical test (FIT) programs have also been associated with lower CRC-specific mortality in population-based evidence from the Basque Country, where screening targeted adults aged 50–69 years beginning in 2009. [338]
For asymptomatic average-risk adults, FIT and colonoscopy remain the principal evaluated strategies. A 2026 systematic review and meta-analysis specifically assessed the sensitivity and specificity of these tests using randomized and observational evidence, although the supplied abstract does not report pooled estimates. [426] Decision aids may support informed screening choices: a randomized trial enrolled 1,084 average-risk adults aged 50–75 years who were due for screening and compared standard screening information with information incorporating personalized risk of advanced colorectal neoplasia. [428]
Test selection and emerging alternatives
Colonoscopy permits direct examination, polyp removal, and biopsy, but it can be unpleasant and access may be limited by waiting times. [325] Colon capsule endoscopy using PillCam COLON 2 has therefore been evaluated as a noninvasive alternative for direct colonic visualization, including detection of colorectal polyps and CRC, with a systematic review and economic evaluation addressing clinical effectiveness, acceptability, and cost-effectiveness. [325] The supplied abstract does not establish that capsule endoscopy replaces colonoscopy; any positive or inadequately evaluated examination would still require a diagnostic and potentially therapeutic endoscopic pathway. [325]
Blood-based assays are investigational or emerging screening options rather than substitutes established by the supplied evidence. In a prospective high-risk cohort, 603 individuals were enrolled and 570 with successful colonoscopy were analyzed using a six-biomarker plasma cell-free DNA methylation model comprising Septin9 region 1, BCAT1, IKZF1, BCAN, VAV3, and Septin9 region 2. [430] The study evaluated risk stratification against colonoscopy, but the provided abstract does not report the model’s sensitivity, specificity, or clinical utility. [430]
Risk-adapted screening and surveillance
Risk assessment should incorporate age, comorbidity, family or hereditary risk, prior lesions, and relevant metabolic or immune conditions. In adults younger than 45 years, a single-center colonoscopy cohort of 3,959 people aged 18–44 years found that polyp, adenoma, and serrated-lesion detection increased with age; the study also evaluated metabolic risk factors among those aged 40–44 years. [273] These findings support attention to risk heterogeneity in younger adults but do not, by themselves, define a population screening interval. [273]
Patients with Lynch syndrome require enhanced colonoscopic surveillance because pathogenic mismatch-repair variants confer increased CRC susceptibility. [274] A national English NHS study linked registry and health-record data for 4,732 mismatch-repair carriers during 2010–2022 to examine surveillance adherence and the relationship between surveillance, CRC incidence, and mortality. [274] The supplied abstract does not provide the resulting effect estimates, so surveillance intensity should follow specialist hereditary-cancer guidance rather than this study alone. [274]
Older adults require individualized decisions about continuing or stopping screening and surveillance. The expanding population aged ≥65 years increases the importance of estimating life expectancy, comorbidity, procedural burden, and time to benefit; cessation becomes reasonable when limited life expectancy or substantial comorbidity makes eradication of premalignant lesions unlikely to provide meaningful benefit. [266] In a nationwide cohort of adults aged 75–85 years, propensity-matched colonoscopy and non-colonoscopy groups each included 19,005 people, and incident CRC occurred in 2.8% versus 3.7%, respectively; these observational findings inform but do not eliminate the need for individualized risk–benefit assessment. [432]C
Prevention and equity
Metabolic health may be a modifiable component of CRC prevention. Patients with nonalcoholic or metabolic dysfunction-associated steatotic liver disease have been studied because of increased colorectal neoplasia risk; prediction models have been developed for colorectal polyps in NAFLD, while a longitudinal cohort evaluated whether reducing cardiometabolic risk factors lowered metachronous advanced colorectal neoplasia in MASLD. [271][281] These studies support risk-factor optimization but do not establish a drug or specific metabolic target as CRC chemoprevention. [271][281]
Screening delivery must address rural and underserved populations. Rural Medicaid interventions have combined mailed FIT with patient navigation for follow-up colonoscopy, while health-plan–clinic partnerships and practice facilitation were studied to overcome implementation barriers. [335] A randomized rural screening trial used remotely delivered navigation to increase colonoscopy completion, and its recruitment experience emphasized partnerships with primary-care organizations and rural communities. [330] In people living with HIV, a systematic review and meta-analysis evaluated routine screening uptake and lesion detection compared with HIV-negative controls as this population ages and its absolute CRC burden rises. [429] A rural cross-sectional study in northern China assessed CRC awareness and participation determinants, underscoring the need for locally targeted education and access strategies. [280]
Quality and diagnostic safeguards
High-quality colonoscopy is essential after a positive stool test and during surveillance. Real-world propensity-matched evidence evaluated water-exchange versus conventional air-insufflation colonoscopy for adenoma detection, bowel preparation, advanced adenoma detection, sessile-serrated lesion detection, and procedure efficiency. [431] In acute left-sided obstructive CRC, the proximal colon may be inaccessible before surgery; a retrospective two-center study evaluated preoperative FDG-PET/CT for synchronous neoplasms, using postoperative clearing colonoscopy within 6 months as the reference standard. [433]C This imaging approach concerns staging and completion assessment in established obstructive cancer, not routine screening. [433]C
| Population or situation | Evidence-informed consideration |
|---|---|
| Average-risk adults | FIT and colonoscopy are the principal evaluated tests; shared decision-making can incorporate personalized advanced-neoplasia risk information. [426][428] |
| Positive stool test | Arrange timely diagnostic colonoscopy; navigation, digital tools, tracking, and open-access pathways can improve completion. [267] |
| Adults aged ≥65 years | Reassess benefit against life expectancy, comorbidity, procedural burden, and time to benefit; consider cessation when benefit is unlikely. [266] |
| Adults aged 75–85 years | Observational data showed CRC in 2.8% after colonoscopy versus 3.7% without colonoscopy in matched cohorts; individualize decisions. [432]C |
| Lynch syndrome | Use enhanced specialist colonoscopic surveillance; national data evaluated adherence and CRC outcomes in 4,732 mismatch-repair carriers. [274] |
| Rural or underserved populations | Combine mailed FIT with patient navigation and health-plan–clinic or primary-care partnerships. [330][335] |
Guidelines and Resources
- ▸Average-risk CRC screening begins at age 45 years under the ACS framework, with newer stool RNA, stool DNA, and blood-based assays evaluated in the 2026 update. [434]
- ▸Positive stool tests require timely colonoscopy; navigation, digital tools, open-access pathways, and coordinated systems can improve completion. [267]
- ▸Older-adult surveillance should be individualized according to life expectancy, comorbidity, competing risks, and time to benefit. [266]
- ▸Hereditary CRC evaluation should integrate personal and family history, germline testing, and syndrome-specific surveillance and treatment. [440, 254]
- ▸MSI/MMR testing has hereditary, prognostic, predictive, and immunotherapy implications and should follow standardized laboratory reporting practice. [260]
- ▸Rectal cancer care relies on pelvic MRI, appropriate distant-disease imaging, and multidisciplinary treatment planning. [251, 255, 252]
- ▸Treatment resources include updated JSCCR CRC guidance, taTME recommendations, neoadjuvant evidence syntheses, metastatic anti-EGFR rechallenge data, and UGT1A1 pharmacogenomic guidance. [257, 253, 438, 439, 437, 515]
Screening and follow-up
The American Cancer Society (ACS) 2026 update continues to address colorectal cancer (CRC) screening in average-risk adults in the context of increasing CRC incidence among adults younger than 65 years. The ACS lowered the recommended screening-initiation age to 45 years in 2018 and reassessed newer molecular-based tests, including a multitarget stool RNA test, next-generation multitarget stool DNA testing, and a blood-based cell-free DNA assay, using diagnostic-performance data and modeling studies evaluating potential effects on CRC incidence and mortality. [434]
A positive stool-based screening test requires timely diagnostic colonoscopy because positive results are associated with increased CRC risk. Follow-up remains suboptimal; evidence-informed approaches include patient navigation, digital reminders and coordination, open-access colonoscopy, and health-system and policy interventions designed to reduce delays and improve CRC outcomes. [267]
Surveillance decisions in older adults should incorporate life expectancy, comorbidity, functional status, competing risks, patient preferences, and the time required to benefit from removal of premalignant lesions. The AGA expert review emphasizes that the expanding population aged ≥65 years will increase the need for individualized decisions about continuing or stopping CRC surveillance when age or comorbidity limits its likely value. [266]
After recovery from diverticulitis, colonoscopy is recommended for complicated disease and suggested after uncomplicated disease when alarm symptoms are present or the patient is not current with CRC screening. CT is essential for confirming diverticulitis, particularly at the first presentation and in severe cases; post-diverticulitis colonoscopy may help exclude an underlying malignancy. [342]
Hereditary and molecular risk assessment
Hereditary adenomatous polyposis syndromes are systemic, incurable cancer-predisposition disorders with variable inheritance, age at onset, phenotype, and cancer risk. Major associated gastrointestinal cancer sites include the colon, rectum, duodenum, ampulla, and stomach. The 2026 ACG guideline supports personal- and family-history risk assessment, germline testing when indicated, and coordinated surgical and endoscopic management to reduce cancer incidence and mortality. [440]
The JSCCR hereditary CRC guideline describes hereditary CRC as accounting for approximately 5% of all CRCs and highlights early onset, synchronous or metachronous CRC, and malignancies in other organs as characteristic clues. Accurate diagnosis enables syndrome-specific surveillance and risk-reduction strategies; advances in genetics have expanded the recognized causative genes for polyposis and non-polyposis syndromes. [254]
Microsatellite instability (MSI) testing is clinically important because high MSI reflects mismatch-repair deficiency, is associated with chemotherapy resistance and response to immune-checkpoint blockade, and may identify Lynch syndrome. EMQN best-practice guidance provides 15 recommendations for MSI analysis and reporting in solid tumors, reflecting advances in testing methods and clinical interpretation. [260]
Imaging, staging, and radiotherapy
For colon and appendiceal cancer, ACR guidance emphasizes imaging of the chest, abdomen, and pelvis for initial staging and post-treatment restaging or surveillance, particularly to detect distant metastases. Appendiceal cancers are distinct from colon cancer and require separate consideration, although staging and surveillance also focus mainly on distant disease, especially intra-abdominal and pelvic spread. [256]
Rectal cancer requires high-resolution pelvic assessment for local tumor extension, complemented by evaluation of distant disease in the chest, abdomen, and pelvis. ACR appropriateness criteria address staging and disease monitoring through an evidence-based, multidisciplinary process that is reviewed annually. [255]
IMRT and IGRT are integral components of contemporary rectal cancer radiotherapy. The ESTRO technical guideline provides implementation guidance for these technologies, using literature review and expert consensus where evidence is limited. [251]
For stage I–III rectal neuroendocrine tumors, NANETS guidance addresses persistent variation in surveillance, staging, high-risk features, and indications for surgery. Modern staging incorporates pelvic MRI and somatostatin-receptor PET/CT using 68Ga- or 64Cu-DOTATATE, alongside advances in endoscopic mucosal management. [252]
Treatment guidance and evidence updates
The JSCCR 2024 treatment guideline revised all aspects of CRC management to incorporate evidence accumulated since earlier editions. Its objectives include standardizing treatment, reducing institutional variation, avoiding both undertreatment and unnecessary treatment, and improving communication with patients and the public. [257]
For low- and mid-rectal cancer, the updated EAES, ESCP, and ESGAR guideline evaluates transanal total mesorectal excision (taTME) against laparoscopic or robotic TME using randomized and matched nonrandomized evidence. Recommendations were developed with GRADE methodology and multidisciplinary and patient-partner input. [253]
Evidence syntheses inform neoadjuvant treatment selection. A network meta-analysis compared neoadjuvant chemoradiotherapy strategies in MSS locally advanced rectal cancer, defined as T3–4/N+ without distant metastases, using 18 articles involving 11,658 patients. [439] A separate meta-analysis evaluated neoadjuvant therapy combined with immunotherapy in pMMR/MSS nonmetastatic rectal cancer, reporting outcomes including pathologic and clinical complete response, major pathologic response, R0 resection, anal preservation, and adverse events. [438]
In chemorefractory metastatic CRC, anti-EGFR rechallenge is being evaluated for patients whose circulating tumor DNA remains RAS/BRAF wild type. A systematic review and meta-analysis compared this strategy with standard care in randomized trials, assessing disease-control rate, objective response rate, and survival outcomes. [437]
Irinotecan prescribing may be informed by UGT1A1 pharmacogenomics. Irinotecan is converted to SN-38, which is predominantly inactivated by UGT1A1; allele frequencies vary among populations. The UK CERSI-PGx guideline addresses UGT1A1 genotype testing for non-pegylated irinotecan, licensed in advanced CRC, and notes use of irinotecan in other gastrointestinal and rare malignancies. [515]
Related gastrointestinal malignancies
Consensus guidance for appendiceal tumors with peritoneal involvement addresses a heterogeneous disease group for which high-quality, disease-specific evidence is limited and treatment has often been extrapolated from CRC or pooled studies. The 2025 update used a modified Delphi process to standardize practice where management remains controversial. [435][264]
Australian guidance for people living with HIV recommends primary high-risk HPV testing with cytology triage for high-resolution anoscopy in anal-cancer screening. Screening is offered from 35 years for gay, bisexual, and other men who have sex with men and trans women living with HIV; recommendations also address cisgender women, trans men, and other cisgender men. [258]
| Clinical area | Resource focus | Key evidence or threshold |
|---|---|---|
| Screening | ACS 2026 | Screening initiation at 45 years; newer molecular tests evaluated [434] |
| Abnormal stool test | AGA/ASGE practice update | Timely colonoscopy; navigation and digital coordination [267] |
| Older adults | AGA expert review | Consider cessation when time to benefit is limited [266] |
| Hereditary CRC | ACG and JSCCR | Germline assessment; hereditary component approximately 5% of CRC [440][254] |
| Rectal cancer staging | ACR and ESTRO | Pelvic MRI, chest/abdomen/pelvis imaging, IMRT/IGRT [251][255] |
| Rectal neuroendocrine tumors | NANETS | MRI and 68Ga/64Cu-DOTATATE PET/CT [252] |
| Anal cancer in HIV | Australian guideline | Primary high-risk HPV testing with cytology triage; selected screening from 35 years [258] |
References
- [1]
Xu YB, Huang YS, Huang XX et al.. “Prognostic value of the prognostic nutritional index in colorectal cancer: a systematic review and meta-analysis.” BMC gastroenterology (2026). PMID: 41731387 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [2]
Wang P, Jiang H. “Prognostic value of systemic immune-inflammation index for colorectal cancer: a systematic review and meta-analysis.” Frontiers in oncology (2026). PMID: 41727644 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [3]
Wang Z, Zou J, Li Y et al.. “Prognostic and clinicopathological significance of heat shock proteins in colorectal cancer patients: a meta-analysis.” World journal of surgical oncology (2026). PMID: 41792786 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [4]
Manz NB, Reed J, Kanner CD et al.. “Temporal change in skeletal muscle index as a predictor of recurrence for patients with locally advanced colorectal malignancy: a retrospective cohort study.” Cancer imaging : the official publication of the International Cancer Imaging Society (2026). PMID: 41947259 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes - [5]
Daca-Alvarez M, Manzotti C, Zaffalon D et al.. “Accuracy and variability of locoregional staging in T1 rectal cancer: nationwide multicentre cohort study.” BJS open (2025). PMID: 41914767 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification, Diagnosis and Workup, Prognosis and Long-term Outcomes, Prevention and Screening - [6]
Tsokkou S, Konstantinidis I, Chatzikomnitsa P et al.. “The Molecular Signature of Early-Onset Colorectal Cancer Liver Metastases: Distinct Biology and Clinical Challenges.” International journal of molecular sciences (2026). PMID: 41977468 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification, Pathophysiology and Molecular Biology - [7]
Nemoto D, Togashi K, Zhu X et al.. “Artificial Intelligence-Based Prediction of Invasion Depth in Colorectal Cancer via Endoscopic Imaging (With Video): A Narrative Review.” Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society (2026). PMID: 41859770 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [8]
Cabitza VS, Capponi PC, Brusa I et al.. “Colorectal Cancer: A Landscape of New Potential Radiopharmaceuticals.” Molecular diagnosis & therapy (2026). PMID: 41807884 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [9]
Xie H, Xu N, Wei L et al.. “The prognostic value of the albumin/neutrophil-to-lymphocyte ratio in colorectal cancer patients: a retrospective cohort study.” Frontiers in oncology (2026). PMID: 41971429 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [10]
Shi X, Tian G, Zhou C et al.. “Albumin and neutrophil combined prognostic grade for predicting overall survival in colorectal cancer: a retrospective cohort study.” Frontiers in oncology (2026). PMID: 41907620 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [11]
Liu B, He H, Guan X et al.. “Clinicopathological characteristics and prognosis of patients with mucinous adenocarcinoma originating from the left colon, right colon, or rectum: a nationwide retrospective study in China.” Journal of gastrointestinal oncology (2026). PMID: 41816592 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [12]
Rosenbaum W, Rubio Garcia M, Löfgren-Burström A et al.. “Full-length 16S rRNA nanopore sequencing enables species resolution of Fusobacterium associated with colorectal cancer.” Gut microbes (2026). PMID: 41963777 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [13]
Pan AY, Kakavand H, Sioson L et al.. “A Critical Examination of the Changes Proposed by the AJCCCCEP for the AJCC 9th Edition Colorectal Cancer Staging System.” The American journal of surgical pathology (2026). PMID: 41957954 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [14]
Yin Y, Sun Z, Deng X et al.. “Integration of deep learning and radiomic features from multiplex immunohistochemistry images for reproducible Multi-Outcome prediction in a Multi-Center study of colorectal cancer.” International journal of medical informatics (2026). PMID: 41955913 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes - [15]
Fournier E, Schaffar R, Staehelin K et al.. “Rising early-onset colorectal cancer in Switzerland despite declining incidence in older adults: A nationwide population-based study, 1980-2021.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 41946179 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [16]
Ögren JÅ, Ekström J, Rameika N et al.. “Composite proteomic and metabolomic plasma biomarkers for detection of colorectal, lung and ovarian cancers.” Molecular cancer (2026). PMID: 41943016 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [17]
McSorley ST, Burton P, Chantler D et al.. “Faecal haemoglobin-based referral and investigation prioritisation is associated with colorectal cancer-specific survival in symptomatic patients: a retrospective observational study.” British journal of cancer (2026). PMID: 41927996 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [18]
Zohar K, Strecker M, Wartmann T et al.. “Globo-H diagnostic stratification and identification of DUSP14 as a candidate target in colorectal cancer.” International journal of cancer (2026). PMID: 41922912 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [19]
Lv Y, Wang F, Shen Y et al.. “Redefining the role of carbon nanoparticles in colorectal cancer surgery: From lymph node yield to diagnostic paradox.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41921381 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [20]
Nnene K, Nagar B, Boutall A et al.. “Treatment cost of colon cancer at a South African tertiary academic hospital.” Journal of cancer policy (2026). PMID: 41903647 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [21]
Chen X, Liu C, Liao H. “Risk of high-grade infections in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a meta-analysis of randomized controlled trials.” Frontiers in oncology (2026). PMID: 41959919 ↗
L1aSR_MA_RCTCited in: Epidemiology and Risk Factors, Management: Systemic and Radiation Therapy - [22]
Li G, Zhang W, Wang J et al.. “Prognostic role of statins in colorectal cancer: a systematic review and meta-analysis.” Frontiers in oncology (2026). PMID: 41930205 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [23]
Zhou Y, Sang S, Yuan M et al.. “Effects of transcutaneous auricular vagus nerve stimulation on perioperative anxiety in patients undergoing laparoscopic colorectal cancer surgery: a study protocol for a double-blind, prospective, single-centre, randomised controlled trial.” BMJ open (2026). PMID: 41942155 ↗
L2bTRIAL_NONRANDOMCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Landmark Trials and Key Evidence - [24]
Cairat M, Olivier E, Neau J et al.. “Systemic glucocorticoid use and risk of site-specific cancers: a methodological systematic review of observational studies.” Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2026). PMID: 41931525 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [25]
Liu X, Shuai J, Wang D et al.. “Incidence, risk factors, and a predictive nomogram for stoma-site incisional hernia after ileostomy reversal: A retrospective study.” Hernia : the journal of hernias and abdominal wall surgery (2026). PMID: 41995917 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Prognosis and Long-term Outcomes - [26]
Charalambidi M, Hukkinen T, Kaprio T et al.. “Demographic and Clinical Characteristics of Early-Onset Colorectal Cancer in Sweden and Finland: A Multicentre Retrospective Cohort Study Over Three Decades.” Journal of surgical oncology (2026). PMID: 41928416 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [27]
Khan AA, Hasan F, Marsool MDM et al.. “Enhanced adenoma detection with Endocuff Vision: a GRADE assessed systematic review and meta-analysis.” Clinical endoscopy (2026). PMID: 41956736 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Prevention and Screening - [28]
Zhang X, Wang P, Yu M et al.. “[Effect of electroacupuncture on intestinal function after laparoscopic colorectal cancer surgery].” Zhongguo zhen jiu = Chinese acupuncture & moxibustion (2026). PMID: 41987441 ↗
L1bRCTCited in: Epidemiology and Risk Factors, Diagnosis and Workup - [29]
Jiang Y, Pu Y, Huang Z et al.. “Clonal tracing of rare anal metastasis in esophageal squamous cell carcinoma: a case report with whole-exome sequencing and multimodal therapy.” Frontiers in immunology (2026). PMID: 41972165 ↗
L4CASE_REPORTCited in: Epidemiology and Risk Factors - [30]
Wang J, Yang Y, Yang X et al.. “The effectiveness of innovative educational techniques based on the Transtheoretical Model on the self-care ability of patients with colorectal cancer undergoing ostomy: A randomized controlled trial.” International journal of nursing sciences (2026). PMID: 41938003 ↗
L1bRCTCited in: Epidemiology and Risk Factors - [31]
Lal A, Mudford E, Merga BT et al.. “Long-Term Health and Economic Impacts of COVID-19 Disruptions on Bowel Cancer Inequalities in Victoria, Australia: A Modelling Study.” Cancer medicine (2026). PMID: 41992350 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Prevention and Screening - [32]
Moeckli B, Rocha M, Wassmer CH et al.. “Maternal obesity and the intergenerational risk of cancer: Epidemiologic evidence and mechanistic insights.” Cancer epidemiology (2026). PMID: 41990710 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Etiology and Triggering Factors - [33]
Alatise O, Doyle A, Mohammed T et al.. “A Pilot Randomized Cross-Over Trial Focused on Colonoscopy Skill Acquisition Using High Fidelity Versus Low Fidelity Simulators in Nigeria.” Journal of surgical education (2026). PMID: 41990515 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Prevention and Screening - [34]
Guimarães ACS, Rodrigues LLS, Campos LB et al.. “Beyond Human Papillomavirus (HPV): Detection of EBV and Polyomaviruses in Cervical and Anal Samples.” Journal of medical virology (2026). PMID: 41989205 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup - [35]
Zhang D, Tao P, Li J et al.. “Targeting PKM2-dependent glycolysis reprogrammes monocytes into Cadm1+ macrophages to promote mucosal repair and attenuate colitis progression.” Gut (2026). PMID: 41986135 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [36]
Leja M, Ražuka-Ebela D, Tepes B et al.. “Overview of Gastric Cancer Prevention Initiatives in Europe.” Helicobacter (2026). PMID: 41981861 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Diagnosis and Workup, Prevention and Screening - [37]
Rifkin S, Anderson SM, Chen X et al.. “Association between Clostridioides difficile Test Positivity and Colorectal Cancer Incidence in a Multisite Hospital-Based Retrospective Cohort Analysis.” Cancer research communications (2026). PMID: 41975657 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [38]
Shin JK, Kim HC, Lee WY et al.. “Calibrated Absolute Risk of Lymph-Node-Metastasis After Non-curative Endoscopic Resection of pT1 Colorectal Cancer.” Annals of surgical oncology (2026). PMID: 41973291 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [39]
Hüneburg R, Gieffers-Löwen J, Aretz S et al.. “Longitudinal Surveillance of Gastric Polyposis in Familial Adenomatous Polyposis: Incidence, Progression, and Endoscopic Outcomes.” United European gastroenterology journal (2026). PMID: 41972342 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup - [40]
Zhang B, Zhao Z, Yin P et al.. “Benchmarking progress in cause-specific cancers in China: a nationwide analysis of premature mortality from 1990 to 2023.” The Lancet regional health. Western Pacific (2026). PMID: 41970458 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [41]
Anderson SM, Cing Z, Drewes JL et al.. “Clostridioides difficile Detection in a Human CRC Cohort.” Open forum infectious diseases (2026). PMID: 41969757 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [42]
Wullaert L, van Leeuwen L, de Weerd V et al.. “Presurgical levels of circulating tumour DNA in patients with resectable chemotherapy-naïve colorectal liver metastases: association with multiorgan recurrence and survival in the MIRACLE cohort.” The British journal of surgery (2026). PMID: 41967049 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes - [43]
Zhang HX, Xu WJ, Jiang YX et al.. “Pyroptosis as a double-edged sword in colorectal cancer: Molecular mechanisms and therapeutic opportunities.” Apoptosis : an international journal on programmed cell death (2026). PMID: 41966661 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [44]
Piovani D, Figlioli G, Nikolopoulos GK et al.. “Global, regional, and national burden of colorectal cancer attributable to central obesity: a population attributable fraction analysis.” BMC medicine (2026). PMID: 41963940 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [45]
Schootman M, Li C, Peng C et al.. “Poverty and Mortality Risk in Patients With Colorectal Cancer.” JAMA network open (2026). PMID: 41961497 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [46]
Seum T, Mandic M, Safizadeh F et al.. “At what age should people with obesity start colorectal cancer screening?” International journal of cancer (2026). PMID: 41957948 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [47]
Gupta S, Liu L, Demb J et al.. “Colorectal Cancer and Mortality Risk Among Older Adults With vs Without Adenoma on Prior Colonoscopy.” JAMA (2026). PMID: 41954928 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Prevention and Screening - [48]
Seitz E, Tsai YY, Sanz-Pamplona R et al.. “Sex differences in the colorectal tumor-associated T cell responses.” Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2026). PMID: 41949638 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [49]
Corli O, Caldirola L, Galli F et al.. “Analgesic efficacy in women and men with cancer pain, treated with strong opioids: are there differences?” BMJ oncology (2026). PMID: 41948194 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [50]
van Roermund NS, Angerilli V, Nagtegaal ID et al.. “Prevalence and characteristics of sessile serrated lesions with dysplasia in Dutch fecal immunochemical test-positive screenees.” Endoscopy (2026). PMID: 41946470 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Prevention and Screening - [51]
Santos I, Liberal J, Teixeira P et al.. “The Role of the Gut Microbiome in Clinical Outcomes of Colorectal Cancer: A Systematic Review (2020-2025).” Oncology research (2026). PMID: 41799504 ↗
L2aSR_OBSCited in: Etiology and Triggering Factors - [52]
Tustumi F, Park A, Nakamura ET et al.. “Safety and efficacy of chemoprevention for familial adenomatous polyposis: a systematic review and meta-analysis.” Annals of coloproctology (2026). PMID: 41802305 ↗
L2aSR_OBSCited in: Etiology and Triggering Factors - [53]
Chen Y, Wang YT, Hu JY et al.. “Modulating the gut microbiota to enhance immune checkpoint inhibitor efficacy in colorectal cancer: mechanisms, therapeutic strategies, and clinical perspectives.” Gut microbes (2026). PMID: 41981741 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology and Molecular Biology, Management: Systemic and Radiation Therapy - [54]
Engin ED, Engin AB, Engin A. “Immune Evasion of Helicobacter pylori and Extra-Gastric Cancer Risk.” Journal of gastroenterology and hepatology (2026). PMID: 41972361 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [55]
Wuyi W, Tao P. “Microbe-driven immune suppression in colorectal cancer: the Fusobacterium nucleatum playbook.” Frontiers in immunology (2026). PMID: 41958661 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Management: Systemic and Radiation Therapy - [56]
Cummings LC, Freedman SD. “Increased gastrointestinal cancer risk in cystic fibrosis: Screening, prevention, and future directions.” Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society (2026). PMID: 41927358 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Prevention and Screening - [57]
Neufert C, Neurath MF. “Pathophysiology of colitis-associated colorectal cancer.” Nature reviews. Gastroenterology & hepatology (2026). PMID: 41922722 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [58]
Loaiza-Bonilla A, Leyfman Y, Cortiana V et al.. “Defining a Multi-Omic, AI-Enabled Stool Screening Paradigm for Colorectal Cancer: A Consensus Framework for Clinical Translation.” Cancers (2026). PMID: 41899514 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [59]
Li SWL, Au OTH, Lau EYT et al.. “Interplay Between Gut Microbiota and Cholesterol Metabolism in Colorectal Cancer.” International journal of molecular sciences (2026). PMID: 41898417 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [60]
Žukauskaitė K, Rauduvytė K, Baušys A et al.. “Surgery and the Gastrointestinal Microbiome in Cancer: Bidirectional Impacts and Therapeutic Opportunities - a Narrative Review.” Surgical oncology (2026). PMID: 41895157 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [61]
Khalil M, Baffy G, JohnBritto JS et al.. “Potential far-reaching metabolic consequences of cholecystectomy.” European journal of clinical investigation (2026). PMID: 41888988 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [62]
Sun S, Long F, Su B et al.. “The gut microbiome in colorectal anastomotic leakage: from mechanisms to precision.” Frontiers in medicine (2026). PMID: 41877779 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [63]
Dalamaga M, Rozani S, Petropoulou D. “Why Is Colorectal Cancer Occurring Earlier? Metabolic Dysfunction, Underrecognized Carcinogens, and Emerging Controversies.” Current obesity reports (2026). PMID: 41857189 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology and Molecular Biology - [64]
Fujiyoshi K, Sudo T, Shimamura S et al.. “A paradigm shift in genetic predisposition to colorectal cancer: the impact of germline multigene panel testing on diagnosis and management.” International journal of clinical oncology (2026). PMID: 41840140 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [65]
Li X, Wang Q, Yuan Q et al.. “The intratumoral microbiome in colorectal cancer: origins, microenvironmental interactions, and new horizons in precision medicine.” Frontiers in immunology (2026). PMID: 41836398 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [66]
Salazar-Ulbrich N, Haro-Solis D, Aguayo F et al.. “Genotoxic Bacteria and Oncogenic Viruses in Colorectal Cancer: Evidence, Gaps, and a Proposed Interaction Model.” International journal of molecular sciences (2026). PMID: 41828495 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology and Molecular Biology - [67]
Cataldi C, Karaoğlan BB, Liotta E et al.. “Decoding Immunotherapy Response in Colorectal Cancer: Translational Insights Beyond MSI.” Cancers (2026). PMID: 41827785 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology and Molecular Biology - [68]
Houlston RS, Dunlop MG. “Colonoscopy surveillance in Lynch syndrome: what it prevents and what it does not.” Journal of medical genetics (2026). PMID: 41825943 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [69]
Huo T, Huang X, Liao J et al.. “The bidirectional effects and mechanisms of the oral and gut microbiomes: a narrative review.” Frontiers in immunology (2026). PMID: 41808841 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [70]
Campos FG, Martinez CAR, Moura RN et al.. “Pouch cancer in familial adenomatous polyposis. Incidence, risk factors and literature review: a propos of three rare cases.” Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery (2026). PMID: 41983869 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, Supportive Care and Complication Management - [71]
Hashimoto H, Koda H, Nakajima K et al.. “Appendiceal Goblet Cell Adenocarcinoma With Mismatch Repair Deficiency and Microsatellite Instability-High Status: A Novel Molecular Signature Guiding Immuno-Oncology Strategy.” Pathology international (2026). PMID: 41872678 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, Pathophysiology and Molecular Biology - [72]
Chelluri R, Kovell S, Montanaro F et al.. “Upper tract urothelial carcinoma associated with Lynch syndrome.” Current opinion in oncology (2026). PMID: 41920568 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology and Molecular Biology - [73]
Han JY, Kim MJ, Park JW et al.. “Gut microbiome in colorectal cancer: recent advances and clinical implications.” Annals of coloproctology (2026). PMID: 41802308 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [74]
Wang X, Wei M, Yi Y et al.. “Elephant-derived Bacillus licheniformis modulates immune cells shedding light on cancer resistance.” Frontiers in microbiology (2026). PMID: 41994282 ↗
L5OTHERCited in: Etiology and Triggering Factors - [75]
Park SB, Koo HS, Kim DS et al.. “A Clinicopathologic, Molecular, and Prognostic Comparison Between Early- and Late-Onset Colorectal Cancer in Korea: A Single-Center Retrospective Cohort Study.” Journal of clinical medicine (2026). PMID: 41827154 ↗
L2bCOHORTCited in: Pathophysiology and Molecular Biology - [76]
Nikolouzakis TK, Souglakos J, Kantidakis EE et al.. “Metastatic Odyssey: Decoding the Genomic Journey from Primary Colorectal Cancer to Disseminated Disease.” Cancers (2026). PMID: 41976285 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Molecular Biology, Prognosis and Long-term Outcomes - [77]
Kendsersky ND, Erlick MR, Chen EY et al.. “The Evolving Role for Repeat Molecular Testing in Metastatic Colorectal Cancer.” Cancers (2026). PMID: 41899608 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Molecular Biology - [78]
Aktar S, Masoudi M, Moti D et al.. “Genetic Alterations Involved in Immune Escape Mechanisms of Circulating Tumour Cells in Colorectal Carcinogenesis.” Cancer medicine (2026). PMID: 41834250 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Molecular Biology - [79]
Zhao Y, Sui JF, Wu DN et al.. “Immuno-neural mechanisms in gastrointestinal tumorigenesis: bridging inflammation, neural regulation, and therapeutic innovation.” Frontiers in immunology (2025). PMID: 41799687 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Molecular Biology - [80]
Abbas H, Ahmed H, Shuja H et al.. “Comparative efficacy and safety of nivolumab-based combination therapies (with ipilimumab or binimetinib) in patients with microsatellite-stable and microsatellite-instability-high metastatic colorectal cancer: a systematic review and meta-analysis.” Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2026). PMID: 41934582 ↗
L2aSR_OBSCited in: Pathophysiology and Molecular Biology - [81]
Gu F, Chen Z, Lim X et al.. “Chinese Herbal Medicine in Ulcerative Colitis-Associated Carcinogenesis Treatment: Mechanisms, Progress, and Future Directions.” Drug design, development and therapy (2026). PMID: 41908932 ↗
L2aSR_OBSCited in: Pathophysiology and Molecular Biology - [82]
Xiong C, Wang W, Cha X et al.. “Pathological complete response following immunotherapy in dMMR/MSI-H ascending colon primary squamous cell carcinoma: a case report.” Frontiers in immunology (2026). PMID: 41958654 ↗
L4CASE_REPORTCited in: Pathophysiology and Molecular Biology, Diagnosis and Workup, Management: Systemic and Radiation Therapy, Prognosis and Long-term Outcomes - [83]
Bai L, Yan X, Wang Z et al.. “The Dual Role of DNA Hypermethylation and Hypomethylation in Colorectal and Gastric Tumorigenesis: Mechanisms and Non-Invasive Biomarker.” Frontiers in bioscience (Landmark edition) (2026). PMID: 41914278 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Molecular Biology - [84]
Whitmer R, Sepulveda J, Gandhi J et al.. “Biomarkers in Colorectal Cancer: Clinically Relevant Diagnostic and Prognostic Molecular Features, and the Future of Precision Medicine.” Journal of personalized medicine (2026). PMID: 41893000 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Molecular Biology - [85]
Kim SY. “Immunotherapy for microsatellite-stable colorectal cancer: overcoming resistance and exploring novel therapeutic strategies.” Annals of coloproctology (2026). PMID: 41802306 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Molecular Biology - [86]
Iglesias Coma M, Badia-Ramentol J, Martinez-Ciarpaglini C et al.. “Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy.” Gut (2026). PMID: 41980760 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology - [87]
Nasca V, Ambrosini M, Taieb J et al.. “Mucinous histology and resistance to immune checkpoint blockade in patients with microsatellite instability-high metastatic colorectal cancer.” The oncologist (2026). PMID: 41978558 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology - [88]
Xu T, Xie X, Gu X et al.. “Combined RAS and SMAD4 Mutations and Microsatellite Instability Predict Outcomes in Colorectal Lung Metastases Treated with Image-Guided Thermal Ablation.” Annals of surgical oncology (2026). PMID: 41975044 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology, Diagnosis and Workup - [89]
Li X, Xie M, Kang JX et al.. “Bifidobacterium catenulatum boosts anti-PD-1 efficacy in microsatellite stable colorectal cancer via activating CD8+ T cells.” Gut (2026). PMID: 41956809 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology - [90]
Ma M, Wang M, Yang Y et al.. “PVT1-104aa derived from the 8q24 gene desert promotes colorectal cancer tumorigenesis.” Clinical and translational medicine (2026). PMID: 41952439 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology - [91]
Ambrosini M, Gallois C, Gandini A et al.. “From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancer.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 41950572 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology - [92]
Han K, Zhu C, Xu Z et al.. “A CT-based model integrating deep learning features radiomics and body composition for preoperative prediction of microsatellite instability in colorectal cancer: a multicenter study.” European journal of radiology (2026). PMID: 41935453 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology - [93]
Walden D, Batalini F, Eslinger C et al.. “Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal Cancer.” JCO precision oncology (2026). PMID: 41931743 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology, Management: Systemic and Radiation Therapy - [94]
Yang X, Zhang T, Sun H et al.. “Hsa-miR-99a deficiency contributes to MSI-H colorectal cancer progression by activating the mTOR pathway and inducing Th1/Th2 imbalance.” Frontiers in immunology (2026). PMID: 41924263 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology - [95]
Hong ZG, Xiao B, Zheng M et al.. “Risk and Management of Bowel Obstruction in Colorectal Cancer Patients Undergoing Immunotherapy: A Cross-Sectional Multicenter Study.” ImmunoTargets and therapy (2026). PMID: 41924184 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology - [96]
Zhan Q, Zhang S, Cao B et al.. “Single-Cell Multi-Tissue T Cell Clonal Dynamics Reveal Distinct Immune Coercion Landscapes in MSI and MSS Colorectal Cancer.” International journal of molecular sciences (2026). PMID: 41898550 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology, Management: Systemic and Radiation Therapy - [97]
Petäinen L, Väyrynen JP, Böhm J et al.. “dMMR prediction from colorectal cancer histopathology: Leveraging non-tumor and low-magnification regions.” Computer methods and programs in biomedicine (2026). PMID: 41875848 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology - [98]
Yanagisawa T, Okamoto T, Hayashi K. “Effectiveness of exercise interventions in patients with colorectal cancer during adjuvant chemotherapy: a systematic review and meta-analysis.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41860634 ↗
L2aSR_OBSCited in: History and Physical Examination, Management: Systemic and Radiation Therapy, Supportive Care and Complication Management - [99]
Batrakoulis A, Perivoliotis K, Courneya KS et al.. “Comparative Efficacy of Various Exercise Types on Psychophysiological Outcomes in Colorectal Cancer Survivors: A Network Meta-Analysis.” Medicine and science in sports and exercise (2026). PMID: 41289064 ↗
L2aSR_OBSCited in: History and Physical Examination - [100]
Ortega-Macías AG, Toro AV, Ghosh N et al.. “Addition of dexmedetomidine to anesthesia regimen reduces pain level after endoscopic submucosal dissection: A systematic review and meta analysis.” Journal of clinical anesthesia (2026). PMID: 41260073 ↗
L2aSR_OBSCited in: History and Physical Examination - [101]
Varghese TS, Faithfull S, Frampton A et al.. “Association of patient factors and health-related quality of life with weight changes during chemotherapy for colorectal cancer: secondary analysis of the SCOT trial.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41711962 ↗
L1bRCTCited in: History and Physical Examination - [102]
Li J, Jiang H, Song QL et al.. “Individualized intraoperative blood pressure control with norepinephrine reduces kidney injury biomarkers but not creatinine-defined acute kidney injury in older patients with hypertension undergoing major abdominal surgery: a single-center randomized controlled trial.” BMC anesthesiology (2026). PMID: 41491434 ↗
L1bRCTCited in: History and Physical Examination - [103]
Koutoukidis DA, Jebb SA, Reynolds S et al.. “Preoperative Weight Loss in Patients With Excess Weight and Colorectal Cancer: The CARE Feasibility Randomized Clinical Trial.” JAMA network open (2025). PMID: 41359334 ↗
L1bRCTCited in: History and Physical Examination - [104]
Wu Y, Tian B, Li L et al.. “Efficacy and safety of lidocaine versus sufentanil in patient-controlled intravenous analgesia after laparoscopic colorectal cancer surgery: a prospective, randomized, double-blind clinical trial.” BMC anesthesiology (2025). PMID: 41318377 ↗
L1bRCTCited in: History and Physical Examination - [105]
Zhu X, Zhao S, Tang R et al.. “Effectiveness of Orem's self-care model nursing combined with nutritional intervention in postoperative patients with colorectal cancer.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2025). PMID: 41014371 ↗
L1bRCTCited in: History and Physical Examination - [106]
Wang H, Wu C, Zhou S et al.. “Body mass index and early-onset colorectal cancer risk: a systematic review and cohort-based meta-analysis.” Scandinavian journal of gastroenterology (2026). PMID: 41603036 ↗
L2aSR_OBSCited in: History and Physical Examination - [107]
Nihei S, Ujiie H, Saito K et al.. “A Prospective Comparison of Azilsartan and Amlodipine for Bevacizumab-induced Hypertension and Proteinuria in Colorectal Cancer.” In vivo (Athens, Greece) (2026). PMID: 41482380 ↗
L1bRCTCited in: History and Physical Examination - [108]
Li M, Wang W, Yang Y et al.. “Efficacy of bupivacaine liposome transversus abdominis plane block in enhancing postoperative recovery following laparoscopic colorectal cancer resection.” Langenbeck's archives of surgery (2025). PMID: 41042339 ↗
L1bRCTCited in: History and Physical Examination - [109]
Sun Y, Xu Z, Tang Y et al.. “Unveiling the impact of body mass index on surgical difficulty and oncological prognosis in low rectal cancer: post-hoc analysis of the LASRE trial.” International journal of colorectal disease (2025). PMID: 40844625 ↗
L1bRCTCited in: History and Physical Examination - [110]
Beni R, Sekhon Inderjit Singh HK, Harper H et al.. “Evaluating the clinical use and safety of LumenEye in an outpatient colorectal clinic: a single-centre retrospective cohort study.” Techniques in coloproctology (2026). PMID: 41796404 ↗
L2bCOHORTCited in: History and Physical Examination - [111]
Zhu C, Thong MSY, Doege D et al.. “Lifestyle factors and all-cause mortality in long-term cancer survivors: a population-based prospective cohort study.” European journal of epidemiology (2026). PMID: 41579289 ↗
L2bCOHORTCited in: History and Physical Examination - [112]
Hjorth CF, Olsen MH, Ulrichsen SP et al.. “Body mass index and colorectal cancer recurrence and mortality: A nationwide cohort study in Denmark.” International journal of cancer (2026). PMID: 41273020 ↗
L2bCOHORTCited in: History and Physical Examination - [113]
Shinozaki S, Watanabe J, Kanno T et al.. “Comparative Performance of Artificial Intelligence-Based Computer-Aided Detection Systems for Colorectal Polyps: A Systematic Review and Network Meta-Analysis.” Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society (2026). PMID: 41906553 ↗
L2aSR_OBSCited in: Diagnosis and Workup, Prevention and Screening - [114]
Hsu WF, Kuo CY, Yen HH et al.. “Computer-Assisted Colonoscopy in High-Adenoma Detection Rate Settings in a High-Risk Population: A Randomized Clinical Trial.” JAMA network open (2026). PMID: 41984482 ↗
L1bRCTCited in: Diagnosis and Workup, Prevention and Screening - [115]
Gerritse SL, van Meerten E, Duits AJ et al.. “The Keynote-177 Randomized Controlled Trial of First-line PD-1 Blockade for Microsatellite-High or Mismatch Repair-Deficient Advanced Colorectal Cancer: Potential Consequences of the Cross-Over Trial Design and Related Issues.” Cancer medicine (2026). PMID: 41980913 ↗
L1bRCTCited in: Diagnosis and Workup, Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence - [116]
Majano Díaz L, Rodríguez de Santiago E, Núñez Rodríguez H et al.. “Temporary interruption versus maintenance of anticoagulation in polypectomy of colorectal lesions: study protocol for a multicentre randomised non-inferiority clinical trial POLYPHEM.” BMJ open (2026). PMID: 41916623 ↗
L2bTRIAL_NONRANDOMCited in: Diagnosis and Workup, Landmark Trials and Key Evidence, Prevention and Screening - [117]
Marinho B, Velho G, Santos MD. “Cutaneous Manifestations as a Sentinel of Colorectal Cancer: A Case Report.” Journal of clinical medicine (2026). PMID: 41977089 ↗
L4CASE_REPORTCited in: Diagnosis and Workup, Prevention and Screening - [118]
Günaltili M, Guliyev M, Birsin Z et al.. “Prognostic value of the pretreatment CA19-9/Albumin ratio in de novo metastatic colorectal cancer: A retrospective cohort study.” Medicine (2026). PMID: 41961685 ↗
L2bCOHORTCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes - [119]
Li ZF, Guo J, Sun C et al.. “Support vector machine-based MRI radiomics predict response to neoadjuvant therapy and progression-free-survival of Colorectal Liver Metastases patients.” Medical physics (2026). PMID: 41988745 ↗
L5OTHERCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes - [120]
Habibzadeh P, Sorkin J, Hsu D. “Association Between Red Blood Cell Distribution Width-To-Albumin Ratio and Breast, Colorectal, Lung, and Prostate Cancers.” Cancer medicine (2026). PMID: 41981727 ↗
L5OTHERCited in: Diagnosis and Workup - [121]
Gurayah AA, An A, Kuchakulla M et al.. “Barriers to Health Care and Cancer Screening.” JAMA network open (2026). PMID: 41979877 ↗
L5OTHERCited in: Diagnosis and Workup, Prevention and Screening - [122]
Xinmo F, Minghua B, Xu Q et al.. “Integrative Multiomics and Single-Cell Analyses Identify FKBP10 as a Predictor of Radiotherapy Outcome in Colorectal Cancer.” Human mutation (2026). PMID: 41969611 ↗
L5OTHERCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes - [123]
Ewing AP, Tounkara F, Lawrence WR et al.. “Colorectal Cancer Screening and Health-Related Social Needs in a National Sample of US Adults.” JAMA network open (2026). PMID: 41954935 ↗
L5OTHERCited in: Diagnosis and Workup, Prevention and Screening - [124]
Nakajo S, Uemura M, Kusafuka H et al.. “Hypoxic CAF studies unveil PTHrP‑vitamin D‑RAS axis as pivotal in the CAF.” Oncology reports (2026). PMID: 41952490 ↗
L5OTHERCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes - [125]
Ferrera L, Martínez-Riveros H, Saña M et al.. “Concordance and Acceptability of Self- Vs. Clinician-Collected Anorectal Swabs for HPV Genotyping in Gay, Bisexual and Other Men Who Have Sex With Men in Metropolitan Barcelona.” Journal of medical virology (2026). PMID: 41949383 ↗
L5OTHERCited in: Diagnosis and Workup, Prevention and Screening - [126]
Klausch T, Lissenberg-Witte BI, Coupé VMH. “A Bayesian Prevalence-Incidence Mixture Model for Screening Outcomes With Misclassification.” Statistics in medicine (2026). PMID: 41943977 ↗
L5OTHERCited in: Diagnosis and Workup, Prevention and Screening - [127]
Townsend JS, Puckett MC, Coleman King SM et al.. “Knowledge, Symptom Awareness, and Referral Practices of Primary Care Providers in Early-Onset Colorectal Cancer.” Population health management (2026). PMID: 41943394 ↗
L5OTHERCited in: Diagnosis and Workup, Prevention and Screening - [128]
Huang CY, Qiu XS, Lu SW et al.. “Lymph-vascular invasion affects the selection of time interval between surgery and postoperative chemotherapy in colon cancer.” Current problems in surgery (2026). PMID: 41942244 ↗
L5OTHERCited in: Diagnosis and Workup, Management: Surgical and Local Therapies, Management: Systemic and Radiation Therapy, Prognosis and Long-term Outcomes - [129]
Yue Y, Sun Y, Huang Y et al.. “Safety and feasibility of combined transanal total mesorectal excision with delayed coloanal anastomosis in high-risk patients with low rectal cancer.” Techniques in coloproctology (2026). PMID: 41940995 ↗
L5OTHERCited in: Diagnosis and Workup, Management: Surgical and Local Therapies, Prognosis and Long-term Outcomes - [130]
Grießhammer E, Bogovic N, Geissler EK et al.. “Compartment-specific GLUT1 patterns in colorectal liver metastases: invasive-margin GLUT1 associates with outcome in solitary disease.” Cancer immunology, immunotherapy : CII (2026). PMID: 41940986 ↗
L5OTHERCited in: Diagnosis and Workup - [131]
Yu H, Reider L, Asenbaum U et al.. “Simultaneous microwave ablation and liver resection in patients with colorectal liver metastases.” HPB : the official journal of the International Hepato Pancreato Biliary Association (2026). PMID: 41934995 ↗
L5OTHERCited in: Diagnosis and Workup - [132]
Dhar E, Kabir MA, Nadar DR et al.. “Exploring Machine Learning Approaches for Decision Support in Neoadjuvant Therapy of Locally Advanced Rectal Cancer.” Oncology research (2026). PMID: 41930174 ↗
L5OTHERCited in: Diagnosis and Workup, Management: Systemic and Radiation Therapy - [133]
Gergő D, Tóth-Mészáros A, Schulze Wenning A et al.. “Efficacy and Safety of L-Menthol During Gastrointestinal Endoscopy-A Systematic Review and Meta-Analysis of Randomized Clinical Trials.” Journal of clinical medicine (2025). PMID: 40566063 ↗
L2aSR_OBSCited in: Differential Diagnosis - [134]
Thorndal C, Schelde-Olesen B, Kaalby L et al.. “Colon capsule endoscopy compared with conventional colonoscopy in patients with colonic diverticulitis: a randomized controlled superiority trial on patient-reported outcomes.” Endoscopy (2026). PMID: 40907531 ↗
L1bRCTCited in: Differential Diagnosis - [135]
De Silva R, Thomas JP, Murali N et al.. “The prevalence of nonmalignant gastrointestinal disease in patients with iron deficiency anemia: a systematic review and meta-analysis.” European journal of gastroenterology & hepatology (2026). PMID: 41784434 ↗
L2aSR_OBSCited in: Differential Diagnosis - [136]
Shinagawa T, Okada S, Shiratori H et al.. “Statistics and epidemiology of inflammatory bowel disease-associated colorectal neoplasia.” International journal of clinical oncology (2026). PMID: 41721152 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [137]
Neurath MF. “New insights into Th9 cells in inflammatory bowel diseases.” Seminars in immunology (2026). PMID: 41406701 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [138]
Marafini I, Frascatani R, Colella M et al.. “Bromodomain-containing 4 as a therapeutic target in inflammatory bowel diseases and colorectal cancer.” Frontiers in pharmacology (2025). PMID: 41311847 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [139]
Lopetuso LR, Murgiano M, Mantuano E et al.. “The Molecular Landscape of Inflammation in Inflammatory Bowel Disease (IBD): Targets for Precision Medicine.” Biomedicines (2025). PMID: 41301831 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [140]
Wang Q, Meng Q, Chen Y et al.. “Interaction between gut microbiota and immunity in health and intestinal disease.” Frontiers in immunology (2025). PMID: 41293162 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [141]
Quagliariello V, Forte P, Ciappina G et al.. “Fusobacteriumnucleatum: Pathophysiological and Clinical Involvement in Inflammatory Bowel Diseases, Colorectal Cancer and Cardiovascular Diseases.” Cancers (2025). PMID: 41154402 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [142]
Triantaphyllopoulos KA, Ragia ND, Panagiotopoulou ME et al.. “Integrating Inflammatory and Epigenetic Signatures in IBD-Associated Colorectal Carcinogenesis: Models, Mechanisms, and Clinical Implications.” International journal of molecular sciences (2025). PMID: 41096771 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [143]
Martinelli M, Cascelli N, Bartolo O et al.. “The Molecular Landscape of Colorectal Laterally Spreading Tumors: From Endoscopic Subtypes to Molecular Targets.” International journal of molecular sciences (2025). PMID: 40943367 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [144]
Mariani L, Colombo F, Meuli S et al.. “The role of CT Colonography in the assessment of inflammatory bowel Diseases patients.” European journal of radiology (2025). PMID: 40913942 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [145]
Siyam K, Elessi K, Al-Dahdouh M et al.. “Characteristics and outcomes of patients undergoing colonoscopy in Gaza Strip hospitals: a retrospective study.” BMC gastroenterology (2026). PMID: 41652363 ↗
L2bCOHORTCited in: Differential Diagnosis - [146]
Tran NT, Van Thai N, Khuyen NT et al.. “Aberrant TTF-1 expression in metastatic colorectal adenocarcinoma mimicking primary lung cancer: a case report and review of diagnostic pitfalls.” Diagnostic pathology (2025). PMID: 41310725 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [147]
Suárez M, Martínez R, Torres AM et al.. “Utility of Colonoscopy After Acute Colonic Diverticulitis.” Diagnostics (Basel, Switzerland) (2026). PMID: 41975762 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [148]
Tuynman JB, Yao H, Moolenaar LR et al.. “Transanal total mesorectal excision versus laparoscopic total mesorectal excision for mid and low rectal cancer (COLOR III): short-term outcomes of an international, multicentre, phase 3, randomised, controlled, non-inferiority trial.” The lancet. Gastroenterology & hepatology (2026). PMID: 41887239 ↗
L1bRCTCited in: Management: Surgical and Local Therapies - [149]
Sinicrope FA, Ou FS, Arnold D et al.. “Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.” The New England journal of medicine (2026). PMID: 41880612 ↗
L1bRCTCited in: Management: Surgical and Local Therapies, Management: Systemic and Radiation Therapy - [150]
Kitaguchi D, Forgione A, Innocenzi C et al.. “The role of complete mesocolic excision with central vascular ligation in colon cancer surgery: A systematic review and meta-analysis of prospective trials.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41774976 ↗
L2aSR_OBSCited in: Management: Surgical and Local Therapies - [151]
Reali C, Borra P, Francis NK. “Quality assurance of surgical techniques for right colon cancer: Systematic review.” Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2026). PMID: 41891400 ↗
L2aSR_OBSCited in: Management: Surgical and Local Therapies - [152]
Matsuda T, Nagatani Y, Funakoshi Y et al.. “Neoadjuvant FOLFOXIRI plus bevacizumab without radiotherapy for high-risk rectal cancer: multicentre phase II trial.” BJS open (2025). PMID: 41661200 ↗
L2bTRIAL_NONRANDOMCited in: Management: Surgical and Local Therapies - [153]
Mohammed KB, Kahin M, Okasha AA et al.. “Comparative Efficacy of Robotic-Assisted Versus Laparoscopic Resection for Colorectal Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Cureus (2026). PMID: 41732636 ↗
L1aSR_MA_RCTCited in: Management: Surgical and Local Therapies - [154]
Scardino A, Wolthuis A, Taffurelli G et al.. “Readmission rates and predictive factors in older patients undergoing colorectal cancer surgery: A multicenter European retrospective study.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41795429 ↗
L2bCOHORTCited in: Management: Surgical and Local Therapies - [155]
Zaman O, Zaman S, Ebraheem M et al.. “Trans-anal minimally invasive surgery (TAMIS): Case series on short-term outcomes and systematic review of the literature.” The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland (2026). PMID: 41916806 ↗
L2aSR_OBSCited in: Management: Surgical and Local Therapies, Prognosis and Long-term Outcomes - [156]
Al-Ihribat AR, Moqbel I, Oun A et al.. “Perioperative outcomes of robotic-assisted vs. conventional laparoscopy for colorectal cancer resection: a systematic review and meta-analysis.” Frontiers in surgery (2026). PMID: 41822113 ↗
L2aSR_OBSCited in: Management: Surgical and Local Therapies - [157]
Liang J, Chen W, Yang J et al.. “Laparoscopic-assisted vs open surgery for synchronous colorectal cancer: a retrospective cohort study of short-term and long-term outcomes.” BMC gastroenterology (2026). PMID: 41851844 ↗
L2bCOHORTCited in: Management: Surgical and Local Therapies - [158]
Butnari V, Mansuri A, Hanson M et al.. “Robotic sigmoid colectomy with intracorporeal anastomosis: IMV first approach-a video vignette.” Techniques in coloproctology (2026). PMID: 41896493 ↗
L4CASE_REPORTCited in: Management: Surgical and Local Therapies - [159]
Johns J, Lekamalage B, Cribb B et al.. “Anastomotic leak rates between powered and non-powered circular staplers in left-sided colorectal resection; a retrospective cohort study.” The New Zealand medical journal (2026). PMID: 41610291 ↗
L2bCOHORTCited in: Management: Surgical and Local Therapies - [160]
Kuliavas J, Marcinkeviciute K, Vaicekauskaite I et al.. “Increased Risk of Central Mesocolic Lymph Node Metastases in BRAF-Mutated Stage I-III Colon Cancer.” Journal of clinical medicine (2026). PMID: 41977067 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [161]
Kapturkiewicz B, Kazanowski M, Lesiak P et al.. “Analysis of the impact of the learning curve and other factors on the duration of TaTME procedures.” Techniques in coloproctology (2026). PMID: 41917328 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [162]
Efetov S, Perez R, Hompes R et al.. “A multinational pilot survey of clinical practice patterns in tumor-specific mesocolic excision and complete lymph node dissection for colorectal cancer.” International journal of clinical oncology (2026). PMID: 41870762 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [163]
Chen WP, Li ZK, Lin L et al.. “The clinical effect and oncological results of preserving inferior mesenteric artery during laparoscopic complete mesocolic excision for patients with descending colon cancer: a propensity score-matched analysis.” Techniques in coloproctology (2026). PMID: 41838213 ↗
L5REVIEW_NARRATIVECited in: Management: Surgical and Local Therapies - [164]
Lohsiriwat V, Kaenla E, Ovartchaiyapong P. “Enhanced Recovery After Surgery Versus Conventional Care in Simultaneous Colorectal Resection and Hepatectomy for Synchronous Colorectal Liver Metastases.” World journal of surgery (2026). PMID: 41831191 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [165]
Dahlberg S, Vedin T, Syk I et al.. “Unplanned intensive care unit admission after elective colon cancer resection: population-based registry study.” BJS open (2025). PMID: 41802244 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [166]
Chen YC, Chang TK, Su WC et al.. “Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Locally Advanced Rectal Cancer Treated with Neoadjuvant Concurrent Chemoradiotherapy and Robotic-Assisted Resection.” Oncology research (2026). PMID: 41799506 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [167]
Chew C, Panesa A, Haq MU et al.. “Feasibility and outcomes of robotic colorectal cancer surgery in patients with high body mass index.” Techniques in coloproctology (2026). PMID: 41793538 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [168]
Omura Y, Nakauchi M, Hiro J et al.. “Lateral lymph node dissection via robotic surgery: technical feasibility and patterns of lateral lymph node recurrence in rectal cancer.” Surgical oncology (2026). PMID: 41759372 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [169]
Pretta A, Giampieri R, Ziranu P et al.. “Clinical characteristics and outcomes in patients with early-onset locally advanced rectal cancer.” Therapeutic advances in medical oncology (2026). PMID: 41743382 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [170]
Slørdahl KS, Balto A, Guren MG et al.. “Patient reported outcomes after treatment for colon cancer - A nationwide study.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41722357 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [171]
Bunjo Z, Seneviratne I, Murshed I et al.. “Statewide analysis of outcomes in patients with early-stage rectal cancer undergoing standard-of-care upfront resection.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41719784 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [172]
Swilling AC, Chalise P, Al-Kasspooles M et al.. “Volume-Outcome Relationships in Total Mesorectal Excision Quality and Grading: A National Cancer Database Study.” Annals of surgical oncology (2026). PMID: 41703205 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [173]
Jo MH, Kim HS, Chung SS et al.. “Single-incision robotic complete mesocolic excision for right-sided colon neoplasms: technical and oncologic feasibility.” Surgical endoscopy (2026). PMID: 41703038 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [174]
Wang L, Li G, Lv Y et al.. “Optimization of artery-first approach in right-sided colon cancer CME: preoperative CTA assessment of MCA branching and MCV-Henle's trunk relationship.” World journal of surgical oncology (2026). PMID: 41699604 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [175]
Ahluwalia AS, Ramesh H, Asad Z et al.. “Assessing the Association of Age and Preoperative Sodium Level on Colectomy Outcomes: An NSQIP Study.” The Journal of surgical research (2026). PMID: 41687140 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [176]
Li Y, Han C, Tang J. “Neoadjuvant chemoradiotherapy with or without PD-1 inhibitors in MMR-proficient non-metastatic rectal cancer: a meta-analysis of randomized controlled trials.” Frontiers in immunology (2026). PMID: 41853263 ↗
L1aSR_MA_RCTCited in: Management: Systemic and Radiation Therapy, Landmark Trials and Key Evidence - [177]
Arjona-Sánchez A, Gutiérrez-Calvo A, Segura-Sampedro JJ et al.. “Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colorectal cancer (HIPECT4): final analysis of randomized clinical trial.” BJS open (2025). PMID: 41891861 ↗
L1bRCTCited in: Management: Systemic and Radiation Therapy - [178]
Kito Y, Yamazaki K, Shoji H et al.. “Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).” European journal of cancer (Oxford, England : 1990) (2026). PMID: 41880871 ↗
L1bRCTCited in: Management: Systemic and Radiation Therapy - [179]
Xicheng W, Yanhong D, Yanqiao Z et al.. “A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI/Cetuximab in Chinese Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: The NAUTICAL Study.” Cancer medicine (2026). PMID: 41852303 ↗
L1bRCTCited in: Management: Systemic and Radiation Therapy, Supportive Care and Complication Management - [180]
Gregorc V, Majem M, Lo Russo G et al.. “Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial.” The Lancet. Oncology (2026). PMID: 41926959 ↗
L2bTRIAL_NONRANDOMCited in: Management: Systemic and Radiation Therapy - [181]
Chibaudel B, Dourthe LM, André T et al.. “STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer.” Signal transduction and targeted therapy (2026). PMID: 41980919 ↗
L1bRCTCited in: Management: Systemic and Radiation Therapy - [182]
Ding L, Peng L, Xu Z et al.. “Interpretable machine-learning prediction of severe myelosuppression in colorectal cancer patients receiving chemotherapy using XGBoost and SHAP: a retrospective study with a web-based calculator.” Frontiers in oncology (2026). PMID: 41939468 ↗
L2bCOHORTCited in: Management: Systemic and Radiation Therapy - [183]
Qadri F, Afghan MK, Lutfi A et al.. “Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer.” Therapeutic advances in medical oncology (2026). PMID: 41883872 ↗
L4CASE_REPORTCited in: Management: Systemic and Radiation Therapy - [184]
Cashin PH, Frühling P, Grönlund P et al.. “Preoperative chemotherapy in colorectal peritoneal metastatic disease - a real-world observational cohort study.” Pleura and peritoneum (2026). PMID: 41868813 ↗
L2bCOHORTCited in: Management: Systemic and Radiation Therapy - [185]
Abbas N, Mourad M, Smaily H et al.. “EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance.” International journal of molecular sciences (2026). PMID: 41977448 ↗
L5REVIEW_NARRATIVECited in: Management: Systemic and Radiation Therapy - [186]
Yang W, Zhang J, Liang P et al.. “Irinotecan with trifluridine/tipiracil and bevacizumab for second-line metastatic colorectal cancer: a phase II multicenter study.” Signal transduction and targeted therapy (2026). PMID: 41956997 ↗
L2bTRIAL_NONRANDOMCited in: Management: Systemic and Radiation Therapy - [187]
Wang Q, Liu Z, Jin K. “Natural Polymers Based Biocompatible Nanomedicines for Targeting Colon Cancer: Prospects and Challenges.” International journal of nanomedicine (2026). PMID: 41939211 ↗
L5REVIEW_NARRATIVECited in: Management: Systemic and Radiation Therapy - [188]
Cives-Losada C, Soldani C, Polidoro MA et al.. “Understanding the Tumor Microenvironmental Mechanisms Driving Immunotherapy Resistance in Colorectal Cancer Liver Metastases.” Oncology research (2026). PMID: 41930154 ↗
L5REVIEW_NARRATIVECited in: Management: Systemic and Radiation Therapy - [189]
Cao M, Alvarez J, Mitra R et al.. “IFNγ-induced antigen loss in chimeric antigen receptor-T cell therapy.” Frontiers in immunology (2026). PMID: 41924255 ↗
L5OTHERCited in: Management: Systemic and Radiation Therapy - [190]
Funk MA, Heinemann V, Bücklein V et al.. “Gastric and Rectal Administration of Encorafenib with Targeted Chemotherapy against BRAF V600E-Mutant Rectal Cancer with Bowel Obstruction.” The oncologist (2026). PMID: 41920914 ↗
L5OTHERCited in: Management: Systemic and Radiation Therapy - [191]
Kang W, Zhang Z, Li W et al.. “Breaching the immune-cold barrier in pMMR/MSS metastatic colorectal cancer: emerging strategies beyond standard care.” Frontiers in immunology (2026). PMID: 41909713 ↗
L5REVIEW_NARRATIVECited in: Management: Systemic and Radiation Therapy - [192]
Wang F, Zhang Z, Chen J et al.. “Nanodynamic Therapy in Colorectal Cancer: Engineering Precision Immunotherapy and Multimodal Synergy.” International journal of nanomedicine (2026). PMID: 41907375 ↗
L5REVIEW_NARRATIVECited in: Management: Systemic and Radiation Therapy - [193]
Wagner AD, Raeisi M, Rakez M et al.. “Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 41903302 ↗
L5OTHERCited in: Management: Systemic and Radiation Therapy - [194]
Kawczak P, Bączek T. “Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib.” Journal of clinical medicine (2026). PMID: 41899309 ↗
L5REVIEW_NARRATIVECited in: Management: Systemic and Radiation Therapy - [195]
Yeh JH, Hsu CW, Shen CS et al.. “Save the injection needle for colorectal ESD: a multicenter feasibility study of the needleless injection technique using short-tip endoknife.” Techniques in coloproctology (2026). PMID: 41896390 ↗
L5OTHERCited in: Management: Systemic and Radiation Therapy - [196]
Gao S, Liao X, He Y et al.. “The effectiveness of multimodal prehabilitation on functional capacity and clinical outcomes in patients undergoing elective laparoscopic colorectal cancer surgery: a systematic review of meta-analysis of randomized controlled trials.” Journal of cancer survivorship : research and practice (2026). PMID: 41872610 ↗
L1aSR_MA_RCTCited in: Supportive Care and Complication Management - [197]
He Y, Yuan X, Gao S et al.. “Home-based multimodal prehabilitation before colorectal cancer surgery: a systematic review and meta-analysis.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41870618 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [198]
Lin Y, Tian D, He J et al.. “The invisible wall: experiences of social isolation in colorectal cancer patients with ostomy-a qualitative meta-synthesis.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41817765 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [199]
Xiaobing Y, Qidi L, Liyan L et al.. “The effect of thunder-fire moxibustion on cancer-related fatigue in patients with Qi stagnation and blood stasis type colorectal cancer undergoing chemotherapy: a randomized controlled trial.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41986533 ↗
L1bRCTCited in: Supportive Care and Complication Management - [200]
Reeves J, Koh C, Smith AB et al.. “Acceptability and Feasibility of a Virtual Multimodal (P)Rehabilitation Programme for Gastrointestinal Cancer Patients: The PRIORITY-CONNECT 2 Pilot Randomised Controlled Trial.” Annals of surgical oncology (2026). PMID: 41832362 ↗
L1bRCTCited in: Supportive Care and Complication Management - [201]
Kubo E, Satomi E, Mukohara T et al.. “Randomized Controlled Trial to Relieve Pain of Chemotherapy-Induced Peripheral Neuropathy by Magnetic Field: SMILE Study.” Cancers (2026). PMID: 41749832 ↗
L1bRCTCited in: Supportive Care and Complication Management - [202]
Díaz-Sánchez C, Rodríguez-Muñoz PM, Navarro-López V et al.. “Impact of Ostomy on Quality of Life in Patients with Colorectal Cancer: A Systematic Review and Meta-Analysis.” Healthcare (Basel, Switzerland) (2026). PMID: 41753958 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [203]
Ben Kridis W, Aboturkia AM, Aqoup MO et al.. “Diet and Physical Activity Interventions to Improve Outcomes in Colorectal Cancer Survivors: A Multicenter Randomized Controlled Trial in North Africa.” JCO global oncology (2026). PMID: 41886719 ↗
L1bRCTCited in: Supportive Care and Complication Management - [204]
Wang C, Nie L, Li X et al.. “Effects of combined dietary fiber and probiotic supplementation on gut microbiota, immune function, and clinical outcomes in patients with advanced colorectal cancer: a retrospective cohort study.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41823995 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [205]
Peng W, Shi H, Fan L et al.. “Efficacy of a plant-based diet on FOLFOX chemotherapy-induced gastrointestinal toxicity in patients with colorectal cancer: study protocol for a multicentre, stratified, randomised controlled trial.” Trials (2026). PMID: 41772652 ↗
L2bTRIAL_NONRANDOMCited in: Supportive Care and Complication Management - [206]
Addington C, Davies N, Howell P et al.. “Lived experiences of cancer care for people living with HIV who are treated for anal cancer: a scoping review.” BMJ open (2026). PMID: 41916622 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [207]
Noiret B, Perez RO, Conroy T et al.. “Disruptive Analysis of Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Clinical and Therapeutic Distinctions Between Low- and Mid-Rectal Cancers.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 41791024 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [208]
Wu Y, Pang J, Li J et al.. “Curcumin for the Treatment of Inflammatory Bowel Disease: From Mechanism to Clinic.” The American journal of Chinese medicine (2026). PMID: 41757464 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [209]
Sokólska W, Gudowska-Sawczuk M, Orywal K. “Cytokines and Chemokines as Emerging Biomarkers and Therapeutic Targets in Colorectal Cancer-Narrative Review.” International journal of molecular sciences (2026). PMID: 41752132 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [210]
Chen H, Wang Q, Chen Y et al.. “Risk factors and prediction model for early high-output stoma after colorectal cancer surgery: A retrospective study.” Asia-Pacific journal of oncology nursing (2026). PMID: 41858760 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [211]
Li Y, Zou D, Hu J et al.. “A multimodal neoadjuvant strategy incorporating PDT, RFA, and ICIs results in a notable pathological response and preservation of the sphincter in microsatellite stable low rectal cancer: A highly distinctive case report and literature review.” Photodiagnosis and photodynamic therapy (2026). PMID: 41833681 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [212]
Pan S, Wang G. “Perioperative Systemic Stress Phenotypes Predict Immune Recovery Failure, Molecular Residual Disease, and Long-Term Outcomes After Colorectal Cancer Surgery: A Prospective Cohort Study.” World journal of surgery (2026). PMID: 41917719 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [213]
Burlaka A, Zemskov S, Rozhkova V et al.. “Laparoscopic versus open minor liver resections of colorectal cancer liver metastases in a state at war: A prospective cohort study.” Surgery open science (2026). PMID: 41971756 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [214]
Shan S, Fu S, Ma Z et al.. “Temporally Programmed and Laser-Triggered Immunomodulatory Hydrogel Enables Synergistic Wound Healing and Prevention of Postoperative Tumor Recurrence.” ACS applied materials & interfaces (2026). PMID: 41995291 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [215]
AlAwadhi HK, Chang NH, Jogendran M et al.. “Gastroenterology/Hepatology: What You May Have Missed in 2025.” Annals of internal medicine (2026). PMID: 41974014 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [216]
Moretto R, Studiale V, Hyun SW et al.. “Circulating tumor DNA dynamics in patients with liver-limited metastatic colorectal cancer resected after first-line systemic treatment.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41973053 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [217]
Machida E, Takamizawa Y, Takayanagi D et al.. “Microbiomic and immunogenic biomarkers of adjuvant chemotherapy efficacy in stage III colorectal cancer.” JNCI cancer spectrum (2026). PMID: 41965123 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [218]
Zhu G, Liu Y, Shi Y et al.. “Dissecting tumor heterogeneity in colorectal cancer: uncovering the role of BCL2L1+ cells through single-cell analysis.” Frontiers in immunology (2026). PMID: 41958675 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [219]
Aref AT, Pathan M, Habib R et al.. “Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction using three independent cohorts.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41954643 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [220]
Liu Z, Gao D, Martin T et al.. “Impact of Rural Hospital Closures on Survival Among Medicare Beneficiaries Diagnosed With Colorectal, Lung, Breast, and Prostate Cancer.” The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association (2026). PMID: 41947577 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [221]
Wang J, Li Y, Liu X et al.. “Methylated Septin9 as an auxiliary biomarker for the diagnostic, recurrence monitoring and prognosis of colorectal cancer.” Clinica chimica acta; international journal of clinical chemistry (2026). PMID: 41941932 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [222]
Lu J, Wang R, Chong YY. “Effects of psychosocial interventions on cancer-related fatigue in patients with colorectal cancer: a systematic review and meta-analysis of randomised controlled trials.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41840094 ↗
L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence - [223]
Xun X, Wang R, Cheng Q et al.. “The Impact of Prehabilitation on Postoperative Outcomes in Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials.” Journal of the American Medical Directors Association (2026). PMID: 41698408 ↗
L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence - [224]
Blanchard-Cavagis ER, Abrahão Reis PC, Visani FLV et al.. “Adjuvant aspirin and Cyclooxygenase-2 inhibitors in resected, PIK3CA-mutated colorectal cancer: A systematic review and meta-analysis of randomized controlled trials.” Critical reviews in oncology/hematology (2026). PMID: 41621633 ↗
L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence - [225]
Li Y, Ho K, Lui TK et al.. “Comparison of Image-Enhanced Endoscopy Techniques for Colorectal Lesion Detection and Characterization: A Network Meta-Analysis of Randomized Controlled Trials.” The American journal of gastroenterology (2026). PMID: 41472621 ↗
L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence - [226]
Srinivasan A, Yi KM, Sharma D et al.. “Integrating multimodal prehabilitation into enhanced recovery after surgery programs (MPhERAS) for elderly patients: a systematic review and meta-analysis of randomized controlled trials and cohort studies.” Techniques in coloproctology (2025). PMID: 41455772 ↗
L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence - [227]
Mirza W, Iqbal H, Yasmin S et al.. “Indocyanine green fluorescence-guided perfusion vs. standard assessment to prevent clinical anastomotic leak after colorectal resection: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials with site-specific subgroup analysis.” World journal of surgical oncology (2025). PMID: 41422225 ↗
L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence - [228]
Li T, Yin L, Li Y et al.. “Folate exposures and risk of colorectal cancer: an umbrella review of meta-analyses of observational studies and randomised controlled trials.” BMJ open (2025). PMID: 41314820 ↗
L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence - [229]
Garfinkle R, Balvardi S, Carmichael H et al.. “Outcomes reported in randomized controlled trials of rectal cancer treatment: A scoping review for the CORRECT initiative.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41564846 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [230]
Zhang X, Zhou J, Geng J et al.. “Feasibility of ctDNA-guided precision neoadjuvant therapy in locally advanced rectal cancer: Insights from the ongoing CINTS-R trial.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 41435753 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [231]
Zhang T, Shi L, Jian L et al.. “Clinical Benefit and Cost-Effectiveness of FOLFOX Versus LCCRT in Neoadjuvant Treatment for Patients with Locally Advanced Rectal Cancer: An Economic Analysis of the FOWARC and PROSPECT Trial.” Annals of surgical oncology (2026). PMID: 41379261 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [232]
Huang Y, Yang X, Qin S et al.. “Effect of Perioperative Glutamine-Enhanced Parenteral Nutrition on Short-Term Outcomes in Colorectal Cancer Patients Undergoing Radical Resection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Technology in cancer research & treatment (2026). PMID: 41891764 ↗
L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence - [233]
Abideen ZU, Waseem MH, Shoaib A et al.. “Comparing various bowel preparation regimens in constipated patients undergoing colonoscopy: A systematic review and network meta-analysis of randomised controlled trials.” Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2026). PMID: 41684308 ↗
L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence - [234]
Garfinkle R, George M, Jethwa K et al.. “Development of a CORe outcome set for clinical trials of RECTal cancer treatment: protocol for the CORRECT initiative.” BMJ open (2026). PMID: 41974548 ↗
L2bTRIAL_NONRANDOMCited in: Landmark Trials and Key Evidence - [235]
Chen YD, He ZY, Zhao WJ et al.. “Qu-Shi-Jie-Du Decoction for Prevention of Recurrence and Metastasis in High-Risk Stage II/III Colon Cancer: Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Trial.” Integrative cancer therapies (2026). PMID: 41810508 ↗
L2bTRIAL_NONRANDOMCited in: Landmark Trials and Key Evidence - [236]
Shimomura M, Ishikawa S, Miguchi M et al.. “Possible preventive effect of surgical glove compression therapy on oxaliplatin-induced peripheral neuropathy: study protocol of a multicentre, phase II/III, randomised controlled trial-the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)-12 trial.” BMJ open (2026). PMID: 41698721 ↗
L2bTRIAL_NONRANDOMCited in: Landmark Trials and Key Evidence - [237]
Abdulla R, Boxtha C, Courtney EP et al.. “Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening (MATCHES): Study protocol for a hybrid 1 stepped-wedge multibehavioral randomized trial.” Contemporary clinical trials (2026). PMID: 41692274 ↗
L2bTRIAL_NONRANDOMCited in: Landmark Trials and Key Evidence - [238]
Guntupalli Y, Nimmagadda R, Potluri V et al.. “Blood-Based Circulating Tumor DNA for Early Detection of Colorectal Cancer: A Systematic Review and Meta-Analysis.” Digestive diseases (Basel, Switzerland) (2026). PMID: 41911100 ↗
L2aSR_OBSCited in: Prevention and Screening - [239]
Majsniarova Z, Minarikova D, Minarik P et al.. “Pharmacist-Led Interventions for Colorectal Cancer Prevention: A Systematic Review.” Current oncology (Toronto, Ont.) (2026). PMID: 41892205 ↗
L2aSR_OBSCited in: Prevention and Screening - [240]
Ramai D, Pan CW, Rodriguez B et al.. “Interventions for Increasing Colorectal Cancer Screening Uptake: A Systematic Review and Network Meta-Analysis.” Gastroenterology (2026). PMID: 41932450 ↗
L2aSR_OBSCited in: Prevention and Screening - [241]
Carbone F, Ciardiello D, Granieri S et al.. “Blood-based circulating tumour DNA (ctDNA) tests for colorectal cancer screening: Systematic review and meta-analysis of diagnostic accuracy.” Critical reviews in oncology/hematology (2026). PMID: 41881272 ↗
L2aSR_OBSCited in: Prevention and Screening - [242]
Greene M, Gameng L, Nowd P et al.. “Adherence to Obstetrician-/Gynecologist-Ordered Multi-target Stool DNA Test Screening and Follow-Up Colonoscopy: A National Multi-payer Study of US Women.” Advances in therapy (2026). PMID: 41984312 ↗
L5OTHERCited in: Prevention and Screening - [243]
Liao TE, Chuang C, Liu SY et al.. “Klebsiella Pneumoniae Liver Abscess as the Herald of Underlying Colorectal Neoplasm.” Open forum infectious diseases (2026). PMID: 41983149 ↗
L5OTHERCited in: Prevention and Screening - [244]
Devall MA, Taha HM, Chen M et al.. “Interrogating the mechanistic link between neighborhood deprivation and colorectal cancer risk through transcriptomic analysis of normal colorectal biopsies.” Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2026). PMID: 41979606 ↗
L5OTHERCited in: Prevention and Screening - [245]
Vickers AL, Fichera A. “The Evolution of the Management of Dysplasia in Ulcerative Colitis.” Cancers (2026). PMID: 41976387 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [246]
Xu S, Gong L, Lu Y et al.. “A simplified multitarget stool test for colorectal cancer and advanced precancerous lesion detection.” Clinical chemistry and laboratory medicine (2026). PMID: 41965119 ↗
L5OTHERCited in: Prevention and Screening - [247]
Li X, Zhao Z, Stassen L et al.. “Head-to-head comparison of the diagnostic value of fecal and serum carcinoembryonic antigen for colorectal cancer detection.” International journal of cancer (2026). PMID: 41957956 ↗
L5OTHERCited in: Prevention and Screening - [248]
Kim J, Mabiala-Maye G, Michaud T et al.. “Using a cross-sectoral partnership to improve colorectal cancer screening and follow-up among African Americans in the United States: A protocol and preliminary results.” Preventive medicine reports (2026). PMID: 41953108 ↗
L5OTHERCited in: Prevention and Screening - [249]
Pi-Chun Chuang M, Hsu WF, Su CW et al.. “Fecal Hemoglobin-Guided Precision Post-polypectomy Surveillance within the Current Framework: A Four-Million-Participant FIT-based Screening Study.” Gastroenterology (2026). PMID: 41932453 ↗
L5OTHERCited in: Prevention and Screening - [250]
Lux TJ, Saßmannshausen Z, Kafetzis I et al.. “Artificial intelligence assisted colorectal lesion detection in private practices a randomized controlled study.” NPJ digital medicine (2026). PMID: 41922731 ↗
L5OTHERCited in: Prevention and Screening - [251]
de Jong R, De Roover R, Devlin L et al.. “ESTRO technical guideline: intensity modulated radiotherapy and image guided radiotherapy for rectal cancer.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2026). PMID: 41662929 ↗
L1cGUIDELINECited in: Guidelines and Resources - [252]
Kennecke H, Delpassand E, Felder S et al.. “NANETS Guidelines for the diagnosis and management of stage I-III rectal neuroendocrine tumors.” Endocrine-related cancer (2026). PMID: 41562331 ↗
L1cGUIDELINECited in: Guidelines and Resources - [253]
Huo B, Arezzo A, Sochorova D et al.. “EAES, ESCP, and ESGAR clinical practice guideline update on taTME for rectal cancer.” Surgical endoscopy (2026). PMID: 41413298 ↗
L1cGUIDELINECited in: Guidelines and Resources - [254]
Tanakaya K, Yamaguchi T, Hirata K et al.. “Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2024 for the clinical practice of hereditary colorectal cancer.” International journal of clinical oncology (2026). PMID: 41214301 ↗
L1cGUIDELINECited in: Guidelines and Resources - [255]
Korngold EK, Kambadakone AR, Berlin J et al.. “ACR Appropriateness Criteria® Staging and Disease Monitoring of Rectal Cancer.” Journal of the American College of Radiology : JACR (2025). PMID: 41193050 ↗
L1cGUIDELINECited in: Guidelines and Resources - [256]
Korngold EK, Kambadakone AR, Berlin J et al.. “ACR Appropriateness Criteria® Staging and Disease Monitoring of Colon Cancer and Appendiceal Cancer.” Journal of the American College of Radiology : JACR (2025). PMID: 41193049 ↗
L1cGUIDELINECited in: Guidelines and Resources - [257]
Kinugasa Y, Uehara K, Yamaguchi K et al.. “Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer.” International journal of clinical oncology (2025). PMID: 41186794 ↗
L1cGUIDELINECited in: Guidelines and Resources - [258]
Poynten IM, Turner RC, Varma R et al.. “Australian guidelines for anal cancer screening using anal human papillomavirus testing with cytology triage in people living with HIV.” HIV medicine (2025). PMID: 41130598 ↗
L1cGUIDELINECited in: Guidelines and Resources - [259]
Ngamruengphong S, Othman MO, Wang AY et al.. “AGA Clinical Practice Update on Endoscopic Resection for Early Colorectal Cancer: Commentary.” Gastroenterology (2025). PMID: 41114683 ↗
L1cGUIDELINECited in: Guidelines and Resources - [260]
Gallon R, McCormick L, Saetta A et al.. “EMQN best practice guidelines for analysis and reporting of microsatellite instability in solid tumours.” European journal of human genetics : EJHG (2026). PMID: 40836023 ↗
L1cGUIDELINECited in: Guidelines and Resources - [261]
Mussetto A, Radaelli F, Galloro G et al.. “SIED-GISCOR recommendations for colonoscopy in screening programs: Part 2 - Endoscopic treatment.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2025). PMID: 40784850 ↗
L1cGUIDELINECited in: Guidelines and Resources - [262]
Gambella A, Parente P, Grillo F et al.. “Pathology of the malignant colorectal polyp: Issues in morphologic criteria and recommendations from the Italian Group of Gastrointestinal Pathologists.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2025). PMID: 40769863 ↗
L1cGUIDELINECited in: Guidelines and Resources - [263]
Wach MM, Dineen SP. “ASO Practice Guideline Series: Management of Colorectal Peritoneal Metastases.” Annals of surgical oncology (2025). PMID: 40587073 ↗
L1cGUIDELINECited in: Guidelines and Resources - [264]
Godfrey EL, Mahoney F, Bansal VV et al.. “Consensus guideline for the management of patients with appendiceal tumors, part 2: Appendiceal tumors with peritoneal involvement.” Cancer (2025). PMID: 40558065 ↗
L1cGUIDELINECited in: Guidelines and Resources - [265]
Mali J, Valadão M, Araujo RO et al.. “Brazilian Society of Surgical Oncology: Guidelines for the Lymphadenectomy in Colorectal Cancer.” Journal of surgical oncology (2025). PMID: 40521833 ↗
L1cGUIDELINECited in: Guidelines and Resources - [266]
Calderwood AH, Yoshida CM, Das KK et al.. “AGA Clinical Practice Update on Surveillance of Metaplastic and Premalignant Conditions of the Esophagus and Colorectum in Older Adults: Expert Review.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026). PMID: 42545305 ↗
L1cCited in: Epidemiology and Risk Factors - [267]
Levin TR, Ciemins E, Dominitz J et al.. “Improving follow-up of abnormal stool test results used for colorectal cancer screening.” Gastrointestinal endoscopy (2026). PMID: 42524792 ↗
L1cCited in: Epidemiology and Risk Factors - [268]
Abdelrahim M, Esmail A, Mustafa N et al.. “Comparing the Effectiveness and Safety of Different Third-Line Management Options for Patients with Metastatic Colorectal Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-Analysis.” Cancers (2026). PMID: 42512271 ↗
L1aCited in: Epidemiology and Risk Factors - [269]
Ng K, Ou FS, Zemla T et al.. “Addition of High-Dose Vitamin D3 to Standard Treatment in Patients With Metastatic Colorectal Cancer: The SOLARIS Randomized Clinical Trial (Alliance A021703).” JAMA (2026). PMID: 42545685 ↗
L2bCited in: Epidemiology and Risk Factors - [270]
Li H, Cai Y, Wang Y et al.. “Electroacupuncture for Postoperative Gastrointestinal Recovery After Laparoscopic Colorectal Cancer Resection: A Randomized Controlled Trial Electroacupuncture Fastens Recovery.” Diseases of the colon and rectum (2026). PMID: 42559736 ↗
L1bCited in: Epidemiology and Risk Factors - [271]
Zhai D, Feng M, Tong X. “Development and validation of a predictive model for colorectal polyps in patients with NAFLD based on risk factors identified from a meta-analysis.” Frontiers in medicine (2026). PMID: 42553569 ↗
L2aCited in: Epidemiology and Risk Factors - [272]
Mizuno H, Nakatani E, Oze I et al.. “High incidence of colorectal cancer in Japanese individuals with hypertension.” Hypertension research : official journal of the Japanese Society of Hypertension (2026). PMID: 42521804 ↗
L2bCited in: Epidemiology and Risk Factors - [273]
Ding Y, Lin X. “Age Inflection Points of Colorectal Adenoma Risk in Young Adults: A Joinpoint Regression Analysis of a Single-Center Retrospective Colonoscopy-Based Cohort.” Journal of clinical medicine (2026). PMID: 42513546 ↗
L2bCited in: Epidemiology and Risk Factors - [274]
Huntley C, Loong L, Mallinson C et al.. “Impact of surveillance colonoscopy on colorectal cancer incidence and mortality in Lynch syndrome: a national observational cohort study of patients in the English NHS 2010-2022.” Gut (2026). PMID: 42562418 ↗
L2bCited in: Epidemiology and Risk Factors - [275]
O'Sullivan DE, Hilsden RJ, Harsanyi H et al.. “Risk of Developing Subsequent Primary Colorectal Cancers Among Non-Colorectal Cancer Survivors: Implications for Prevention and Screening.” International journal of cancer (2026). PMID: 42572253 ↗
L3bCited in: Epidemiology and Risk Factors - [276]
Muhonen E, Seppä K, Ryynänen H et al.. “Incidence Trends of Colorectal Cancer by Social and Behavioral Factors-A Pooled Cohort Study.” International journal of cancer (2026). PMID: 42552866 ↗
L3bCited in: Epidemiology and Risk Factors - [277]
Tang D, Mao Z, Lan S et al.. “Deficient Mismatch Repair Represents a Distinct Molecular Feature of Early-Onset Colorectal Cancer in Chinese Single-Center Cohort.” International journal of cancer (2026). PMID: 42538607 ↗
L3bCited in: Epidemiology and Risk Factors - [278]
Liu YS, Chang PK. “Comparison of outcomes between robot-assisted and laparoscopic colorectal cancer surgery in patients with heart failure: a national readmission database analysis.” Surgical endoscopy (2026). PMID: 42536088 ↗
L3bCited in: Epidemiology and Risk Factors - [279]
Luo Z, Safizadeh F, Mandic M et al.. “Age- and sex-dependent associations of metabolic syndrome with colorectal cancer in the UK Biobank.” British journal of cancer (2026). PMID: 42533014 ↗
L3bCited in: Epidemiology and Risk Factors - [280]
Li X, Ji F, Cao Y et al.. “Colorectal cancer screening awareness among rural populations in Northern China.” BMC public health (2026). PMID: 42522007 ↗
L3bCited in: Epidemiology and Risk Factors - [281]
Chang WY, Wang J, Lin HH et al.. “Metabolic Optimization and Risk of Metachronous Advanced Colorectal Neoplasia in Patients With MASLD.” JAMA network open (2026). PMID: 42518234 ↗
L3bCited in: Epidemiology and Risk Factors - [282]
Yu J, Zhang J, Su Y. “Real-world propensity score-matched analysis of integrative medicine formula for chemotherapy-related gastrointestinal adverse events in colorectal cancer.” Explore (New York, N.Y.) (2026). PMID: 42520443 ↗
L2bCited in: Epidemiology and Risk Factors - [283]
Severino A, Rondinella D, Varca S et al.. “Feasibility and Compliance of Stool Collection for Future Microbiome-Based Colorectal Cancer Screening: Preliminary Findings from a Prospective Multicenter FIT-Positive Cohort.” Microorganisms (2026). PMID: 42514069 ↗
L4Cited in: Epidemiology and Risk Factors - [284]
Alatise OI, Peeri NC, Abdulkareem FB et al.. “Colorectal Cancer Risk Factors in Adults in Nigeria.” JAMA network open (2026). PMID: 42545699 ↗
L3bCited in: Epidemiology and Risk Factors - [285]
Andreu-Ballester JC, Amorós-García C, Benlloch-Pérez S et al.. “Downregulation of CD132 in Colonic Adenomas and Cancer Is Associated with γδ T-Cell Loss, Increased Apoptosis, and Microsporidia Infection.” Cancers (2026). PMID: 42512338 ↗
L3bCited in: Epidemiology and Risk Factors - [286]
Hüneburg R, van Bokhorst QNE, Pellisé M et al.. “Artificial intelligence-assisted detection and optical differentiation of colorectal lesions in Lynch syndrome surveillance (CADLY2): a multicentre, open-label, randomised controlled superiority trial.” The lancet. Gastroenterology & hepatology (2026). PMID: 42462747 ↗
L1bCited in: Etiology and Triggering Factors - [287]
Burn J, Borthwick GM, Elliott F et al.. “Aspirin for cancer prevention in individuals with Lynch syndrome: first results from the CaPP3 multicentre, randomised, double-blind, non-inferiority trial.” The lancet. Gastroenterology & hepatology (2026). PMID: 42425127 ↗
L1bCited in: Etiology and Triggering Factors - [288]
Poo SXW, Dai N, Cross AJ et al.. “Detection of adenoma, serrated lesion, and colorectal cancer in Lynch syndrome: a systematic review and meta-analysis.” Endoscopy (2026). PMID: 42442403 ↗
L2aCited in: Etiology and Triggering Factors - [289]
Yoshioka T, Yamamoto Y, Tsukada Y et al.. “Clinical utility and cost-effectiveness of universal tumor screening to identify Lynch syndrome in patients with stage II/III colorectal cancer: a prospective observational study in Japan.” International journal of clinical oncology (2026). PMID: 42552405 ↗
L4Cited in: Etiology and Triggering Factors - [290]
Zhen J, Dong M, Li Y et al.. “Human salivary microbiome as a potential non-invasive biomarker for early-onset colorectal cancer screening: a prospective study.” BMC microbiology (2026). PMID: 42469627 ↗
L2bCited in: Etiology and Triggering Factors - [291]
Chejara P, Eriksson A. “Gut microbiome biomarkers for colorectal cancer detection: a systematic review highlighting age as a key confounder.” Frontiers in oncology (2026). PMID: 42518809 ↗
L2aCited in: Etiology and Triggering Factors - [292]
Wang Y, Jin S, Xu L et al.. “The Relation Between Antibiotic Use and Gastrointestinal Cancer: A Systematic Review and Meta-Analysis.” Journal of biochemical and molecular toxicology (2026). PMID: 42402956 ↗
L2aCited in: Etiology and Triggering Factors - [293]
Serna G, Obón-Santacana M, Baraibar I et al.. “Intratumoral Fusobacterium species and survival in resectable colorectal cancer: a multicenter cohort study.” ESMO open (2026). PMID: 42526180 ↗
L3bCited in: Etiology and Triggering Factors - [294]
Ahmet RAM, Nascu AG, Camen GC et al.. “Fusobacterium in the Gut-Breast Axis: Interpreting Systemic Dysbiosis in a Romanian Breast Cancer Cohort.” Medicina (Kaunas, Lithuania) (2026). PMID: 42512808 ↗
L2bCited in: Etiology and Triggering Factors - [295]
Wang X, Wang J, Chen W et al.. “Metagenome analysis reveals multi-kingdom gut microbiota as diagnostic markers for colorectal cancer.” Frontiers in microbiology (2026). PMID: 42519695 ↗
L3bCited in: Etiology and Triggering Factors - [296]
Nardelli C, Nunziato M, Di Maggio F et al.. “CCL2: A Pro-Inflammatory Driver and Candidate Diagnostic Biomarker in Colorectal Cancer Patients.” International journal of molecular sciences (2026). PMID: 42511815 ↗
L3bCited in: Etiology and Triggering Factors - [297]
Zhili G, Jie L, Yuyue X et al.. “Fecal metagenomic profiling in patients with colorectal adenomas to characterize gut microbial composition and functional potential.” Frontiers in microbiology (2026). PMID: 42487710 ↗
L3bCited in: Etiology and Triggering Factors - [298]
Jiang Z, Li L, Long Q et al.. “Cross-sectional gut microbiota and serum metabolite differences across clinically defined groups in colorectal cancer.” Frontiers in cellular and infection microbiology (2026). PMID: 42499546 ↗
L3bCited in: Etiology and Triggering Factors - [299]
García G, Díaz A, Fernández LT et al.. “Del immune V and microbiome restructuring in colorectal cancer surgery: a randomized double blind placebo controlled trial.” Frontiers in cellular and infection microbiology (2026). PMID: 42482993 ↗
L4Cited in: Etiology and Triggering Factors - [300]
Druzhinin VG, Baranova ED, Demenkov PS et al.. “Features of the Intestinal and Respiratory Microbiome in Colorectal Cancer Patients in Western Siberia.” Microorganisms (2026). PMID: 42513897 ↗
L3bCited in: Etiology and Triggering Factors - [301]
Sankaran H, Kotliarov Y, Zhao Y et al.. “Associations of Age With Tumor Genomic Characteristics in Relapsed/Refractory Cancers Interrogated With the NCI-MATCH Trial Targeted Gene Panel Assay.” JCO precision oncology (2026). PMID: 42566732 ↗
L5Cited in: Etiology and Triggering Factors - [302]
Tang SS, Bi Y, Chan DKH. “Genomic, transcriptomic, and molecular predictors of response to neoadjuvant therapy in locally advanced rectal cancer: a narrative review.” Medical oncology (Northwood, London, England) (2026). PMID: 42565918 ↗
L5Cited in: Etiology and Triggering Factors - [303]
Wespiser M, Rochefort P, Gauduchon T et al.. “Pharmacological prevention of second primary cancers: From chemoprevention to precision cancer interception.” Cancer treatment reviews (2026). PMID: 42556070 ↗
L5Cited in: Etiology and Triggering Factors - [304]
Seraphine C, Macleod A, Thornsberry T et al.. “Macrophage Polarization as a Target for Colorectal Cancer Treatment Optimization: A Systematic Review.” Cancers (2026). PMID: 42449595 ↗
L1aCited in: Pathophysiology and Molecular Biology - [305]
Rocha Lima CMSP, Yothers G, George TJ et al.. “COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 42525921 ↗
L1bCited in: Pathophysiology and Molecular Biology - [306]
Hu H, Shen X, Li Y et al.. “Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial.” The Lancet. Oncology (2026). PMID: 42385761 ↗
L2bCited in: Pathophysiology and Molecular Biology - [307]
Kyrochristou I, Kyrochristou G, Anagnostopoulos G et al.. “Genomic and molecular landscape of early onset colorectal cancer: Emerging insights and clinical implications-A systematic review.” Surgery (2026). PMID: 42492394 ↗
L2aCited in: Pathophysiology and Molecular Biology - [308]
Balaha M, Aldosari SA, Alamer AA et al.. “Tissue-Agnostic Targeting in Solid Tumors: A PRISMA-Compliant Meta-Analysis of Efficacy, Safety, and Resistance Determinants Across Histologies.” Oncology research (2026). PMID: 42358834 ↗
L4Cited in: Pathophysiology and Molecular Biology - [309]
Reyes-de-la-Mata Y, Fenix-Caballero S, Salmeron-Navas FJ. “Systematic review and adjusted indirect comparison of first-line immune checkpoint inhibitors in metastatic colorectal cancer.” Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria (2026). PMID: 42481259 ↗
L1aCited in: Pathophysiology and Molecular Biology - [310]
Hasegawa H, Inamoto R, Sugiyama K et al.. “Trifluridine/tipiracil with or without bevacizumab in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: A retrospective observational study.” Therapeutic advances in medical oncology (2026). PMID: 42571189 ↗
L3bCited in: Pathophysiology and Molecular Biology - [311]
Bichalski BW, Bichalska-Lach M, Nycz M et al.. “Searching for Novel Molecular Prognostic Markers in Colorectal Cancer-The Tumor Suppressor Proteins p53 and PTEN.” Biomedicines (2026). PMID: 42511928 ↗
L3bCited in: Pathophysiology and Molecular Biology - [312]
Morimoto Y, Uemura M, Kagawa Y et al.. “Prevalence of MSI-H/dMMR Colorectal Cancer in Japan: Data From the Clinical Study Group of the University of Osaka-Colorectal Registry.” Annals of gastroenterological surgery (2026). PMID: 42495674 ↗
L3bCited in: Pathophysiology and Molecular Biology - [313]
LaPelusa M, Shah P, Bhamidipati D et al.. “Patterns of progression and survival in patients with mismatch repair deficient/ microsatellite instability- high metastatic colorectal cancer treated with immunotherapy.” The oncologist (2026). PMID: 42475509 ↗
L3bCited in: Pathophysiology and Molecular Biology - [314]
Lu Y, Wang H, Chen G. “Independent and sex-stratified association between microsatellite instability and peripheral hemoglobin in colorectal cancer.” Frontiers in oncology (2026). PMID: 42528664 ↗
L2bCited in: Pathophysiology and Molecular Biology - [315]
Moris D, Nguyen B, Kroemer A et al.. “Integrative Genomic and Clinical Profiling of Colorectal Cancer Liver Metastases to Guide Personalized Surgery and Liver Transplantation.” Cancer genomics & proteomics (2026). PMID: 42373221 ↗
L2bCited in: Pathophysiology and Molecular Biology - [316]
Ben Kridis W, Khanfir A. “First-Line Immunotherapy Versus Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis of Phase III Studies.” Journal of gastrointestinal cancer (2026). PMID: 42474934 ↗
L2aCited in: Pathophysiology and Molecular Biology - [317]
Jie Y, Lu Z, Wang X et al.. “xinguangA preliminary characterization of PI4K/PIPK alterations across solid tumors: an exploratory framework for prognostic and therapeutic stratification.” Cancer biology & therapy (2026). PMID: 42445966 ↗
L4Cited in: Pathophysiology and Molecular Biology - [318]
Lv K, Yang H, Xi X et al.. “Clinicopathological and molecular profiling of sporadic synchronous multiple primary colorectal cancers: focus on microsatellite instability status.” Journal of gastrointestinal oncology (2026). PMID: 42434246 ↗
L3bCited in: Pathophysiology and Molecular Biology - [319]
Li X, Yasin F, Pavlick DC et al.. “Genomic Landscape and Therapeutic Implications of ALK Fusion-Positive Colorectal Cancer.” The oncologist (2026). PMID: 42565556 ↗
L5Cited in: Pathophysiology and Molecular Biology - [320]
Shan Y, Zhang X, Liu J et al.. “Targeting molecular residual disease and immune escape in colorectal cancer recurrence: biomarker-guided immunotherapy and cell therapies.” Frontiers in medicine (2026). PMID: 42558893 ↗
L5Cited in: Pathophysiology and Molecular Biology - [321]
Glazunova E, Kurnosov A, Bogacheva A et al.. “Virulome over taxonomy: refining the driver-passenger model in colorectal carcinogenesis.” Frontiers in cellular and infection microbiology (2026). PMID: 42523711 ↗
L5Cited in: Pathophysiology and Molecular Biology - [322]
Fu Y, Wang Y, Wu S et al.. “Cell cycle dysregulation: a central hub in colitis-associated colorectal carcinogenesis.” Frontiers in immunology (2026). PMID: 42519326 ↗
L5Cited in: Pathophysiology and Molecular Biology - [323]
Vu JK, Younan E, Karunaratne S et al.. “Locally Recurrent Rectal Cancer in the Molecular Era: A Scoping Review of Biomarkers of Oncologic Outcome following Salvage Surgery.” Annals of surgical oncology (2026). PMID: 42518147 ↗
L5Cited in: Pathophysiology and Molecular Biology - [324]
Brown KGM, Stevenson ARL, Solomon MJ et al.. “Laparoscopic versus open surgery for rectal cancer: individual patient data meta-analysis of the ALaCaRT and Z6051 randomized trials.” BJS open (2026). PMID: 42565372 ↗
L1aCited in: Diagnosis and Workup - [325]
Tappenden P, Harnan S, Ren S et al.. “PillCam COLON 2 for investigation of the colon through direct visualisation: systematic review and economic evaluation.” Health technology assessment (Winchester, England) (2026). PMID: 42517739 ↗
L1aCited in: Diagnosis and Workup - [326]
Afshari K, Onerup A, Li Y et al.. “Effects of Prehabilitation by Physical Activity on Fatigue After Surgery for Colorectal Cancer. Results From Secondary Analyses in the Randomized Controlled Trial PHYSSURG-C.” Cancer medicine (2026). PMID: 42568293 ↗
L1bCited in: Diagnosis and Workup - [327]
Lu J, Chong YY. “Effects of a Psycho-Behavioural Intervention on Cancer-Related Fatigue Among Patients With Colorectal Cancer: A Pilot Randomised Controlled Trial.” Psycho-oncology (2026). PMID: 42568201 ↗
L4Cited in: Diagnosis and Workup - [328]
Serra-Aracil X, Gonzalez A, Bargalló J et al.. “Quality of life, bowel dysfunction, and long-term oncological outcomes after transanal versus laparoscopic total mesorectal excision for mid- and low- rectal cancer (Ta-LaTME study): multicentre randomized open-label trial.” BJS open (2026). PMID: 42551037 ↗
L1bCited in: Diagnosis and Workup - [329]
Mo S, Zhou C, Ma M et al.. “Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 42525894 ↗
L1bCited in: Diagnosis and Workup - [330]
Keppel GA, Ike B, Andrilla CHA et al.. “Recruiting Rural Patients for Clinical Research: Lessons From a Colorectal Cancer Screening Trial.” The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association (2026). PMID: 42517457 ↗
L1bCited in: Diagnosis and Workup - [331]
Sadien ID, Cooper G, Phillips V et al.. “Influence of KRAS mutation subtypes on response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: meta-analysis.” BJS open (2026). PMID: 42551038 ↗
L2aCited in: Diagnosis and Workup - [332]
Zhang N, He Y, Qin Z et al.. “Prognostic significance of tumoral Siglec-15 expression in solid tumors: a systematic review and meta-analysis.” Frontiers in immunology (2026). PMID: 42553325 ↗
L2aCited in: Diagnosis and Workup - [333]
Chen W, Li S, Wu Z et al.. “Diagnostic accuracy of computer-aided detection for colorectal polyps of any size, ≤ 5 mm, and 6-9 mm: a meta-analysis.” World journal of surgical oncology (2026). PMID: 42533341 ↗
L2aCited in: Diagnosis and Workup - [334]
Guo C, Liu S, Li L et al.. “A Comprehensive Meta-Analysis and Review of Intraoperative Radiotherapy in Colorectal Cancer: Examining Radiation Dosage, Long-Term Prognosis, and Treatment-Related Complications.” Cancer medicine (2026). PMID: 42522172 ↗
L2aCited in: Diagnosis and Workup - [335]
Kenzie ES, Herreid-O'Neill A, Myers E et al.. “Facilitation of Health Plan-Clinic Partnerships to Improve Colorectal Cancer Screening for Rural Medicaid Enrollees: A Qualitative Study.” The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association (2026). PMID: 42572815 ↗
L2bCited in: Diagnosis and Workup - [336]
Cwaliński T, Bigus Z, Lesiak P et al.. “Understanding Textbook outcome failure after robotic colorectal cancer surgery: a multicenter domain-specific analysis.” Journal of robotic surgery (2026). PMID: 42570129 ↗
L3bCited in: Diagnosis and Workup - [337]
Gao L, Liu Y, Lv X et al.. “HDL-C presents a suggestive negative moderating trend for the association between total cholesterol and colorectal polyps: model construction and bootstrap internal assessment of a predictive nomogram.” Frontiers in endocrinology (2026). PMID: 42558406 ↗
L3bCited in: Diagnosis and Workup - [338]
Bujanda L, Val B, Portillo Villares I et al.. “Colorectal Cancer Mortality Following an Organized Fecal Immunochemical Test-Based Screening Program.” JAMA network open (2026). PMID: 42555038 ↗
L3bCited in: Diagnosis and Workup - [339]
Xin X, Qiu H, Zang Y et al.. “Association of intratumoral CD68+CD163+ M2-like macrophages with survival in metastatic colorectal cancer treated with chemotherapy plus bevacizumab.” Frontiers in immunology (2026). PMID: 42539549 ↗
L3bCited in: Diagnosis and Workup - [340]
Lei XH, Li R, Wang DM et al.. “Tertiary Lymphoid Structures as Predictors of Recurrence in Colorectal Cancer: Development and Validation of a Machine Learning-Based Scoring Model.” Cancer medicine (2026). PMID: 42538596 ↗
L3bCited in: Diagnosis and Workup - [341]
Takaoka A, Irie N, Sugino A et al.. “Treatment outcomes of robot-assisted rectal cancer surgery with multivisceral resection of adjacent organs.” Journal of robotic surgery (2026). PMID: 42530722 ↗
L4Cited in: Diagnosis and Workup - [342]
Peery AF, Strate LL, Stollman N et al.. “ACG Clinical Guideline: Colonic Diverticulitis.” The American journal of gastroenterology (2026). PMID: 42390126 ↗
L1cCited in: Differential Diagnosis - [343]
Schultz JK, Sigurdardottir JM, Backstad LT et al.. “Accuracy and reliability of preoperative CT in perforated diverticulitis: Post hoc secondary analysis from the SCANDIV trial.” Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society (2026). PMID: 41692579 ↗
L1bCited in: Differential Diagnosis - [344]
Curia S, Taoum C, Piozzi GN et al.. “Robotic surgery in colorectal emergencies: a systematic review of current evidence.” World journal of emergency surgery : WJES (2026). PMID: 42104446 ↗
L4Cited in: Differential Diagnosis - [345]
Gao L, Guo Z, Wang Z et al.. “An algorithm-enhanced stool DNA system improves the differential diagnosis of colorectal cancer versus Crohn's disease in high-risk symptomatic patients.” Computer methods and programs in biomedicine (2026). PMID: 41950614 ↗
L2bCited in: Differential Diagnosis - [346]
Stirrat T, Bejugam D, Alukal J et al.. “Colitis cystica profunda: a systematic review.” European journal of gastroenterology & hepatology (2026). PMID: 41604561 ↗
L2aCited in: Differential Diagnosis - [347]
Kraft M, Maroli A, Pera M et al.. “Subclinical anxiety and depression and postoperative complications after major colorectal surgery: A 2-center study.” Surgery (2026). PMID: 42224963 ↗
L4Cited in: Differential Diagnosis - [348]
Ma R, Nasseri Y, Wu G et al.. “The importance of procedural indication in predicting operative time for elective robotic colon surgery.” Journal of robotic surgery (2026). PMID: 41866630 ↗
L3bCited in: Differential Diagnosis - [349]
Tang L, Liu G, Lv X et al.. “Quantitative parameters of dual-layer spectral CT for differentiating metastatic and non-metastatic lymph nodes in colorectal cancer.” Cancer imaging : the official publication of the International Cancer Imaging Society (2026). PMID: 41865009 ↗
L3bCited in: Differential Diagnosis - [350]
Wael Mahmood M, Abraham-Nordling M, Löf-Granström A et al.. “Enhanced recovery after surgery in diverticular disease: A multicenter comparison with colorectal cancer.” Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society (2026). PMID: 41853898 ↗
L3bCited in: Differential Diagnosis - [351]
Booth AL, Torlakovic EE, Chetty R et al.. “Despite simplified diagnostic criteria, intraobserver and interobserver variability remain in the interpretation of colorectal serrated polyps.” Histopathology (2026). PMID: 41622126 ↗
L3bCited in: Differential Diagnosis - [352]
Zhao Q, Shi D, Zhong H et al.. “The predictive value of MR cytometry in histological differentiation of rectal cancer: an exploratory study.” European radiology (2026). PMID: 41617831 ↗
L3bCited in: Differential Diagnosis - [353]
Mejza M, Bajer A, Biskup L et al.. “Preferences, Expectations and Management Satisfaction in IBD Patients: A Cross-Sectional Questionnaire-Based Study.” Journal of clinical medicine (2026). PMID: 42122997 ↗
L3bCited in: Differential Diagnosis - [354]
Abu Sneineh A, Haj Ali S, Quteishat B et al.. “Diagnostic yield of endoscopy in women under 50 with iron deficiency anemia: a retrospective cohort study from Jordan.” Frontiers in global women's health (2026). PMID: 42523980 ↗
L3bCited in: Differential Diagnosis - [355]
Usman M, Correa E, Chung WY et al.. “Development and internal validation of a nomogram to predict colorectal cancer risk in patients with diverticulitis.” International journal of colorectal disease (2026). PMID: 42337066 ↗
L3bCited in: Differential Diagnosis - [356]
Usman M, Correa E, Chung W et al.. “Rethinking the role of endoscopy for colorectal cancer following diverticulitis: An exploratory model for guiding endoscopic assessment.” The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland (2026). PMID: 41633884 ↗
L3bCited in: Differential Diagnosis - [357]
Wu S, Wang Z, Qiu C et al.. “Nomogram based on MRI images and clinical data for differentiating mucinous from non-mucinous rectal adenocarcinoma.” BMC medical imaging (2025). PMID: 41449349 ↗
L3bCited in: Differential Diagnosis - [358]
Tehrani FR, Asgari N, Jamalli A et al.. “Exploring the link between Mycobacterium avium subsp. Paratuberculosis and colorectal cancer development.” BMC gastroenterology (2026). PMID: 41580611 ↗
L3bCited in: Differential Diagnosis - [359]
Saleh M, Akil A, Chehade L et al.. “Tumor Characteristics and Survival Predictors in Patients With Colorectal Cancer: A Lebanese Single-Center Experience.” Clinical Medicine Insights. Oncology (2026). PMID: 42471825 ↗
L4Cited in: Differential Diagnosis - [360]
Kitaguchi D, Forgione A, Serra-Aracil X et al.. “Systematic review and Bayesian network meta-analysis comparing multiple anastomotic techniques after total mesorectal excision in rectal cancer.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 42330709 ↗
L1aCited in: Management: Surgical and Local Therapies - [361]
Gosavi R, Smith B, Mealy A et al.. “Resection quality and oncologic outcomes after robotic versus laparoscopic total mesorectal excision for mid and low rectal cancer: a systematic review and meta-analysis of randomised trials.” Journal of robotic surgery (2026). PMID: 42223567 ↗
L1aCited in: Management: Surgical and Local Therapies - [362]
Keating T, Drumm C, Kennedy N et al.. “Systemic inflammatory response after robotic versus laparoscopic abdominal surgery: a systematic review and meta-analysis with colorectal cancer subgroup analysis.” Journal of robotic surgery (2026). PMID: 42223505 ↗
L1aCited in: Management: Surgical and Local Therapies - [363]
Morarasu S, Lunca S, Clancy C et al.. “Robotic versus laparoscopic TME for rectal cancer: meta-analysis of pathological quality indicators.” Techniques in coloproctology (2026). PMID: 42213239 ↗
L1aCited in: Management: Surgical and Local Therapies - [364]
Sun Y, Xu Z, Wang X et al.. “Comparative Oncologic Outcomes of Laparoscopic versus Open Surgery for Early-Onset Low Rectal Cancer: 3-Year Results From the LASRE Trial.” World journal of surgery (2026). PMID: 42272043 ↗
L1bCited in: Management: Surgical and Local Therapies - [365]
Moolenaar LR, Ali M, Aufenacker TJ et al.. “Adjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): a multicentre, randomised, controlled, phase 3, non-inferiority trial.” The lancet. Gastroenterology & hepatology (2026). PMID: 42202843 ↗
L1bCited in: Management: Surgical and Local Therapies - [366]
Mason JD, Khan JS, Ahmed S et al.. “ACPGBI position statement on the role of standard high-quality right hemicolectomy and complete mesocolic excision in right-sided colon cancer.” Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2026). PMID: 42175521 ↗
L1cCited in: Management: Surgical and Local Therapies - [367]
Wu F, Hu X, Li B et al.. “Short-Course Radiotherapy-Based Total Neoadjuvant Therapy plus Tislelizumab for Locally Advanced Rectal Cancer (Neo-STAR): Early Outcomes of a Randomized Phase II Trial.” Cancer communications (London, England) (2026). PMID: 42495710 ↗
L2bCited in: Management: Surgical and Local Therapies - [368]
Arun Kumar G, Sharma G, Arun Kumar B. “The Multi-Dimensional Learning Curve in Robotic-Assisted vs. Laparoscopic Rectal Cancer Resection: A Systematic Review of Procedural Efficiency, Pathological Integrity, and Ergonomic Impact.” Journal of robotic surgery (2026). PMID: 42474778 ↗
L2aCited in: Management: Surgical and Local Therapies - [369]
Mao H, Ma S, Li Y et al.. “Interpretable machine learning model for predicting operative difficulty in robotic total mesorectal excision for mid-low rectal cancer.” Journal of robotic surgery (2026). PMID: 42223752 ↗
L2bCited in: Management: Surgical and Local Therapies - [370]
Zhang Y, Lin Q, Cai H et al.. “Anatomic distribution of postoperative recurrence and radiotherapy target volume optimization in rectal cancer: A large-scale real-world study.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2026). PMID: 42177995 ↗
L2bCited in: Management: Surgical and Local Therapies - [371]
Yu JG, Wang SY, Zhang TH et al.. “Reduced-port robot radical colorectal cancer surgery a prospective trial and standardized port strategy.” Journal of robotic surgery (2026). PMID: 42474928 ↗
L2bCited in: Management: Surgical and Local Therapies - [372]
K AJ, Sharma S. “Rare colorectal manifestations of pediatric gastrointestinal lymphoma: a systematic review of clinical spectrum and surgical implications.” Pediatric surgery international (2026). PMID: 42437396 ↗
L2aCited in: Management: Surgical and Local Therapies - [373]
Wong TN, Kong CY, Ishak P et al.. “Peri-Operative Systemic Inflammatory Responses Predict Post-Operative Complications in Patients Undergoing Pelvic Exenterative Surgery for Primary Locally Advanced Sigmoid and Rectal Cancer.” Journal of surgical oncology (2026). PMID: 42437514 ↗
L3bCited in: Management: Surgical and Local Therapies - [374]
Parmar KL, Ul-Haq E, Martin E et al.. “Transition to total robotic colorectal practice: feasibility and outcomes in a UK colorectal unit.” Journal of robotic surgery (2026). PMID: 42303930 ↗
L4Cited in: Management: Surgical and Local Therapies - [375]
Sato Y, Miyo M, Ishii M et al.. “Real-time indocyanine green fluorescence imaging enhances the precision of lymph node dissection in laparoscopic colon cancer surgery: a propensity score-matched cohort study.” Surgical endoscopy (2026). PMID: 42301453 ↗
L3bCited in: Management: Surgical and Local Therapies - [376]
Lal T, Liu F, Cabulong A et al.. “Age-stratified risk profiles for emergency colorectal cancer resection: A machine-learning analysis.” Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (2026). PMID: 42263377 ↗
L3bCited in: Management: Surgical and Local Therapies - [377]
Lococo J, Rodríguez C, Pedro L et al.. “Analysis and development of the learning curve in robotic colorectal surgery at a specialized center.” Journal of robotic surgery (2026). PMID: 42260235 ↗
L4Cited in: Management: Surgical and Local Therapies - [378]
Nie G, Li X, Wang Y et al.. “Integrated Evaluation of Survival, Surgical Conversion, and Toxicity for Induction Therapy in Initially Unresectable Colorectal Liver Metastases: An Individual Patient Data Network Meta-analysis.” Annals of surgical oncology (2026). PMID: 42463606 ↗
L1aCited in: Management: Systemic and Radiation Therapy - [379]
Sebag-Montefiore D, Adams R, Gollins S et al.. “Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial.” The Lancet. Oncology (2026). PMID: 42508427 ↗
L1bCited in: Management: Systemic and Radiation Therapy - [380]
Sun X, Fang Y, Yang X et al.. “Neuroprotection and prevention of oxaliplatin-induced neuropathy with Huangqi Guizhi Wuwu Decoction: a 12-center randomized, double-blind trial with mechanistic validation.” Phytomedicine : international journal of phytotherapy and phytopharmacology (2026). PMID: 42435525 ↗
L1bCited in: Management: Systemic and Radiation Therapy - [381]
Yan M, Bai R, Yan W. “The role of targeted therapy in the management of colorectal cancer liver metastases: a systematic review and meta-analysis.” Translational cancer research (2026). PMID: 42445395 ↗
L1aCited in: Management: Systemic and Radiation Therapy - [382]
Du H, Zhou C, Zhang X. “Prognostic Factors and Radiotherapy Benefit in pT3N0M0 Rectal Cancer: A Retrospective Analysis.” Technology in cancer research & treatment (2026). PMID: 42507765 ↗
L1bCited in: Management: Systemic and Radiation Therapy - [383]
Rustemov S, Kuandyk A, Bertleuova A et al.. “Resistance of Colorectal Cancer Stem Cells to Modern Therapies: A Systematic Review.” International journal of molecular sciences (2026). PMID: 42511628 ↗
L2aCited in: Management: Systemic and Radiation Therapy - [384]
Liu X, Su S, Shi X et al.. “HER2 overexpression/amplification in colorectal cancer: spatial intratumoral heterogeneity as a key determinant of detection discordance and therapy response.” Virchows Archiv : an international journal of pathology (2026). PMID: 42507169 ↗
L4Cited in: Management: Systemic and Radiation Therapy - [385]
Rémond M, Aparicio T, Martinez-Tapia C et al.. “Predicting severe toxicities and mortality in older patients with colorectal cancer: An analysis of 3 clinical trials and 3 prospective cohorts.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 42456539 ↗
L2bCited in: Management: Systemic and Radiation Therapy - [386]
Zhang Z, Xi Q, Zhuang Q et al.. “Impact of oral nutritional supplements on chemotherapy tolerance and overall survival in postoperative colorectal cancer patients undergoing chemotherapy.” Asia Pacific journal of clinical nutrition (2026). PMID: 42521230 ↗
L1bCited in: Management: Systemic and Radiation Therapy - [387]
Taheri Z, Emadi E, Esfandiary Rad AM et al.. “Prioritizing Chemotherapy in Total Neoadjuvant Therapy Improves pCR Rate in Locally Advanced Rectal Cancer in Countries with Limited Radiotherapy Access: A Randomized Controlled Trial.” Journal of gastrointestinal cancer (2026). PMID: 42501213 ↗
L1bCited in: Management: Systemic and Radiation Therapy - [388]
Belfort GR, Pompeu BF, Velucci MP et al.. “Salvage abdominoperineal resection for anal squamous cell carcinoma: A systematic review and meta-analysis of proportions.” Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2026). PMID: 42439211 ↗
L4Cited in: Management: Systemic and Radiation Therapy - [389]
Lunca S, Ong WL, Morarasu S et al.. “Total Neoadjuvant Therapy Versus Long-Course Chemoradiotherapy in Locally Advanced Rectal Cancer: Real-World Tumor Response and Clinical Outcomes.” Medical sciences (Basel, Switzerland) (2026). PMID: 42506362 ↗
L3bCited in: Management: Systemic and Radiation Therapy - [390]
Guo Z, Guo C, Lu Z et al.. “Macroscopic fractal dynamics characterize the "physical-metabolic" dual barriers and systemic immune exhaustion associated with primary resistance to immunotherapy in liver metastases.” Frontiers in immunology (2026). PMID: 42495635 ↗
L3bCited in: Management: Systemic and Radiation Therapy - [391]
Herr FL, Stock JK, Solms-Baruth VGZ et al.. “CEUS with VEGFR2-targeted microbubbles for monitoring of early immunotherapy effects in a colorectal cancer model.” Cancer imaging : the official publication of the International Cancer Imaging Society (2026). PMID: 42538573 ↗
L4Cited in: Management: Systemic and Radiation Therapy - [392]
Guardascione M, Rizzetto M, Foltran L et al.. “Prolonged response to combined BRAF and MEK inhibition in BRAF mutant colorectal cancer, a case report.” Frontiers in oncology (2026). PMID: 42534285 ↗
L2bCited in: Management: Systemic and Radiation Therapy - [393]
Finch DA, Chaudhury MP, Morris R et al.. “Outcomes reported in studies of anal high-grade squamous intraepithelial lesions treatments: systematic review.” BJS open (2026). PMID: 42400410 ↗
L1aCited in: Supportive Care and Complication Management - [394]
de Oliveira Campos E Silva V, Reeves J, Ferreira GD et al.. “A multidisciplinary virtual (p)rehabilitation model of care for colorectal cancer surgery.” World journal of surgical oncology (2026). PMID: 42432694 ↗
L1bCited in: Supportive Care and Complication Management - [395]
van Driel MHE, Swartjes H, Lemmens JMG et al.. “Patient-led, home-based follow-up for colorectal cancer: DISTANCE multicentre stepped-wedge cluster randomised trial.” The British journal of surgery (2026). PMID: 42359543 ↗
L1bCited in: Supportive Care and Complication Management - [396]
Song MY, Li M, Tu L et al.. “Effects of digital health interventions on anxiety, depression, and quality of life in colorectal cancer patients: a meta-analysis of randomized controlled trials.” Frontiers in oncology (2026). PMID: 42311272 ↗
L1aCited in: Supportive Care and Complication Management - [397]
Trevisol E, Fabbri N, Pesce A et al.. “Trimodal prehabilitation and psychological outcomes in colorectal cancer surgery: preliminary findings from a single-center randomized trial.” Frontiers in surgery (2026). PMID: 42499628 ↗
L4Cited in: Supportive Care and Complication Management - [398]
Hanlon E, Hayden L, Karl J et al.. “Body Image Following Ostomy Surgery for Cancer: A Systematic Review.” Psycho-oncology (2026). PMID: 42400471 ↗
L2aCited in: Supportive Care and Complication Management - [399]
Molla MD, Symonds EL, Winter JM et al.. “Multicomponent Lifestyle Interventions During Colorectal Cancer Surveillance: A Systematic Review.” Cancers (2026). PMID: 42352441 ↗
L2aCited in: Supportive Care and Complication Management - [400]
Pérez-Manchón D, Lozano-Hernández CM, Mata-González G et al.. “Impact of nursing shift patterns on work-related gastrointestinal disorders: a systematic review and meta-analysis.” Frontiers in public health (2026). PMID: 42326947 ↗
L2aCited in: Supportive Care and Complication Management - [401]
Loroña NC, Liu L, Kazemian E et al.. “Longitudinal Associations Between Inflammatory Biomarkers and Fatigue in Patients With Colorectal Cancer: A Multicenter Study.” Cancer medicine (2026). PMID: 42498976 ↗
L2bCited in: Supportive Care and Complication Management - [402]
He C, Xu W, Li J et al.. “Validation and cutpoints of the treatment-induced neuropathy assessment scale (TNAS) in Chinese cancer patients: a prospective cohort study.” Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (2026). PMID: 42493739 ↗
L2bCited in: Supportive Care and Complication Management - [403]
Lindsköld M, Gerdin A, Park J et al.. “Minimal long-term impact of anastomotic leakage on quality of life after anterior resection for rectal cancer: A population-based cohort study.” Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society (2026). PMID: 42473772 ↗
L2bCited in: Supportive Care and Complication Management - [404]
Lunenberg RA, van Erning FN, Sijtsma FPC et al.. “Patient-reported quality of life after chemoradiotherapy in patients with non-metastatic anal squamous cell carcinoma: A cross-sectional cohort study.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2026). PMID: 42324023 ↗
L2bCited in: Supportive Care and Complication Management - [405]
Choubey AP, Leal J, White C et al.. “Beyond Survival: Prospective Longitudinal Insights into Health-related Quality of Life After Hepatectomy for High-risk Colorectal Liver Metastases.” Annals of surgery (2026). PMID: 42572133 ↗
L3bCited in: Supportive Care and Complication Management - [406]
Huang SH, Chiang SF, Tsai KY et al.. “A quasi-bridge to surgery approach for stage IV obstructive colon cancer: extending the bridge-to-surgery concept to metastatic disease.” World journal of surgical oncology (2026). PMID: 42426861 ↗
L4Cited in: Supportive Care and Complication Management - [407]
Nåhls NS, Rautakorpi L, Nuutinen M et al.. “Association Between Timing of Specialist Palliative Care and End-Of-Life Healthcare Utilization in Patients With Colorectal Cancer and Related Intestinal Cancers: A Nationwide Register-Based Study.” Cancer control : journal of the Moffitt Cancer Center (2026). PMID: 42569855 ↗
L2bCited in: Supportive Care and Complication Management - [408]
Tashiro K, Osumi H, Kataoka K et al.. “Time-dependent recurrence patterns after curative resection for stage II/III colorectal cancer: An integrated analysis of four phase III randomized controlled trials (JCOG2310A-S4).” European journal of cancer (Oxford, England : 1990) (2026). PMID: 42520593 ↗
L1bCited in: Prognosis and Long-term Outcomes - [409]
Zeng H, Lan K, Wang X et al.. “Endoscopic obstruction and site-specific metastatic patterns after curative resection of non-metastatic colorectal cancer: A two-center retrospective cohort study.” Surgical oncology (2026). PMID: 42531781 ↗
L2bCited in: Prognosis and Long-term Outcomes - [410]
Kawata A, Miyamoto Y, Nakamura H et al.. “Age-Dependent Prognostic Significance of Preoperative Transthyretin After Curative Resection for Stage I-III Colorectal Cancer.” Annals of gastroenterological surgery (2026). PMID: 42540025 ↗
L3bCited in: Prognosis and Long-term Outcomes - [411]
Ku GY, Ryoo SB, Kim MJ et al.. “Laparoscopic surgery for colorectal cancer in patients with liver cirrhosis: a comparative study on risk of open conversion.” American journal of surgery (2026). PMID: 42537286 ↗
L4Cited in: Prognosis and Long-term Outcomes - [412]
Guccione L, Wong C, Yeung JM et al.. “Aligning with optimal care pathways for people with colon cancer: Clinical, survival and cost implications across socioeconomic and geographic populations in Australia.” Health policy (Amsterdam, Netherlands) (2026). PMID: 42531715 ↗
L3bCited in: Prognosis and Long-term Outcomes - [413]
Chen B, Liu J, Gan K et al.. “A network meta-analysis of endocrine adverse events induced by immune checkpoint inhibitors in colorectal cancer.” Frontiers in immunology (2026). PMID: 42500681 ↗
L1aCited in: Landmark Trials and Key Evidence - [414]
Fadeli L, Desouky M, Alfarone L et al.. “Traction-assisted versus conventional endoscopic submucosal dissection for colorectal lesions: an updated systematic review and meta-analysis of randomized trials.” Techniques in coloproctology (2026). PMID: 42230412 ↗
L1aCited in: Landmark Trials and Key Evidence - [415]
Do PNV, Nguyen TK, Qi Y et al.. “Effectiveness of survivorship programmes to enhance health-related quality of life of colorectal cancer survivors: a systematic review and meta-analysis of randomised controlled trials.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 42149231 ↗
L1aCited in: Landmark Trials and Key Evidence - [416]
Bananzadeh A, Bahadori M, Tadayon SMK et al.. “The role of artificial intelligence in adenoma detection during colonoscopy: a systematic review and meta-analysis of randomized controlled trials-Artificial intelligence and adenoma detection.” Techniques in coloproctology (2026). PMID: 42135566 ↗
L1aCited in: Landmark Trials and Key Evidence - [417]
Li L, Meng X, Wu Q et al.. “Comparative efficacy of neoadjuvant short-course versus long-course radiotherapy-based regimens with or without immunotherapy for locally advanced pMMR rectal cancer: a systematic review and network meta-analysis.” BMC medicine (2026). PMID: 41826948 ↗
L1aCited in: Landmark Trials and Key Evidence - [418]
Alfarone L, Spadaccini M, Rizkala T et al.. “Prophylactic clipping after colorectal endoscopic submucosal dissection in randomized controlled trials: a systematic review and meta-analysis.” Endoscopy (2026). PMID: 41760121 ↗
L1aCited in: Landmark Trials and Key Evidence - [419]
Iguchi K, Yamazaki K, Misumi T et al.. “Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 42372637 ↗
L1bCited in: Landmark Trials and Key Evidence - [420]
Backenroth D, Roels S, Dibaj S et al.. “Practical considerations when using the covariate-adjusted log-rank test for the analysis of time-to-event endpoints in oncology trials.” Biometrics (2026). PMID: 42308366 ↗
L1bCited in: Landmark Trials and Key Evidence - [421]
Kitaguchi D, Forgione A, Innocenzi C et al.. “Decompression stent, stoma, transanal tube or immediate surgery: Systematic review and Bayesian network meta-analysis for left-sided malignant colonic obstruction.” Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2026). PMID: 42244048 ↗
L1aCited in: Landmark Trials and Key Evidence - [422]
Lal N, Cheong Chung KJN, Hodges N et al.. “MRI prognostic features in rectal cancer neoadjuvant trials: A systematic review of reporting gaps across two decades.” Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2026). PMID: 42170773 ↗
L1aCited in: Landmark Trials and Key Evidence - [423]
Wang S, Gu R, Lu J et al.. “Efficacy and risk analysis of monotherapy and dual immunotherapy in dMMR/MSI-H metastatic colorectal cancer: a meta-analysis based on randomized controlled trials.” BMC cancer (2026). PMID: 42168914 ↗
L1aCited in: Landmark Trials and Key Evidence - [424]
Rafi R, Yasmin N, Ghani M et al.. “Performance of artificial intelligence software: EndoAngel, EndoAID, CAD-EYE, GI Genius, and EndoScreener in adenoma detection: an extended network meta-analysis.” European journal of gastroenterology & hepatology (2026). PMID: 42066011 ↗
L1aCited in: Landmark Trials and Key Evidence - [425]
Zhang Z, Luo T, Tang H. “Prophylactic hyperthermic intraperitoneal chemotherapy in patients with high-risk colorectal cancer with abdominal metastasis: a systematic review and meta-analysis.” BMC gastroenterology (2026). PMID: 42032590 ↗
L1aCited in: Landmark Trials and Key Evidence - [426]
Tun SNL, Singweratham N, Siewchaisakul P et al.. “The efficacy of colorectal cancer screening: a systematic review and meta-analysis.” Preventive medicine reports (2026). PMID: 42472250 ↗
L1aCited in: Prevention and Screening - [427]
Thygesen MK, Wehberg S, Dieperink KB et al.. “Improving self-efficacy through nurse navigation in patients during treatment for colorectal cancer: a randomized controlled trial.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 42557451 ↗
L1bCited in: Prevention and Screening - [428]
Schwartz PH, Imperiale TF, Perkins SM et al.. “Effect of Personalized Risk Messages on Patient Intent and Decision Making in Colorectal Cancer Screening: A Randomized Controlled Trial.” Medical decision making : an international journal of the Society for Medical Decision Making (2026). PMID: 42517432 ↗
L1bCited in: Prevention and Screening - [429]
Kaneko M, Sakuraba A. “Colorectal cancer screening uptake and lesion detection in people living with HIV: A systematic review and meta-analysis.” HIV medicine (2026). PMID: 42495884 ↗
L2aCited in: Prevention and Screening - [430]
Li Y, Li S, Wang H et al.. “Prospective evaluation of a multi-gene cfDNA methylation assay for CRC screening in a high-risk cohort.” Clinical chemistry and laboratory medicine (2026). PMID: 42517221 ↗
L2bCited in: Prevention and Screening - [431]
Chao YJ, Hsieh YH, Tang CP et al.. “Real-world evidence of water exchange colonoscopy improving adenoma detection rates: A propensity score-matched analysis.” Therapeutic advances in gastroenterology (2026). PMID: 42523998 ↗
L3bCited in: Prevention and Screening - [432]
Kim SY, Lee SW, Kim SY et al.. “Association between colonoscopy and colorectal cancer risk in adults aged 75 to 85 years: a nationwide population-based cohort study.” Gastrointestinal endoscopy (2026). PMID: 42497981 ↗
L4Cited in: Prevention and Screening - [433]
Jung KU, Lee SR, Park J et al.. “Preoperative 18F-FDG PET/CT as a surgical triage tool for synchronous neoplasm detection in acute left-sided obstructive colorectal cancer: a two-institution retrospective cohort study.” Frontiers in surgery (2026). PMID: 42548845 ↗
L4Cited in: Prevention and Screening - [434]
Wolf AMD, Hoffman RM, Walter LC et al.. “Colorectal cancer screening: An update to the American Cancer Society guideline, 2026.” CA: a cancer journal for clinicians (2026). PMID: 42200680 ↗
L1cCited in: Guidelines and Resources - [435]
Godfrey EL, Mahoney F, Bansal VV et al.. “Consensus Guideline for the Management of Patients with Appendiceal Tumors, Part 2: Appendiceal Tumors with Peritoneal Involvement.” Annals of surgical oncology (2025). PMID: 40560501 ↗
L1cCited in: Guidelines and Resources - [436]
Horvat N, Liu PS, Fowler KJ et al.. “ACR Appropriateness Criteria® Staging and Follow-up of Anal Cancer.” Journal of the American College of Radiology : JACR (2025). PMID: 40409890 ↗
L1cCited in: Guidelines and Resources - [437]
Kuznetsova O, Battaiotto E, Malvezzi G et al.. “Anti-EGFR rechallenge compared with standard of care for patients with ctDNA RAS/BRAF wild-type chemorefractory metastatic colorectal cancer: A systematic review and meta-analysis.” Critical reviews in oncology/hematology (2026). PMID: 41651313 ↗
L1aCited in: Guidelines and Resources - [438]
Li Y, Han C, Tang J. “Efficacy and safety of neoadjuvant therapy combined with immunotherapy in MMR‑proficient/microsatellite stable non‑metastatic rectal cancer: a systematic review and meta‑analysis.” Journal of cancer research and clinical oncology (2025). PMID: 41396282 ↗
L1aCited in: Guidelines and Resources - [439]
Liu L, Yao G, Yang J et al.. “Optimal choice of different neoadjuvant chemoradiotherapies for locally advanced rectal cancer: systematic review and network meta-analysis.” Cancer metastasis reviews (2025). PMID: 40699387 ↗
L1aCited in: Guidelines and Resources - [440]
Mankaney G, Idos GE, Stoffel EM et al.. “ACG Clinical Guideline: Diagnosis and Management of Adenomatous Colorectal Polyposis Syndromes.” The American journal of gastroenterology (2026). PMID: 42683623 ↗
L1cCited in: Etiology and Triggering Factors - [441]
Jorgensen KA, Agusti N, Coffin T et al.. “A Multilevel Intervention to Identify Individuals for Genetic Testing and Treatment: The IGNITE-TX Pilot Randomized Clinical Trial.” JAMA network open (2026). PMID: 42658496 ↗
L4Cited in: Etiology and Triggering Factors - [442]
Gao G, Zhao X, Lu X et al.. “IBD-related inflammatory memory and colorectal cancer: epigenetic mechanisms and microbiome interventions.” Frontiers in immunology (2026). PMID: 42688076 ↗
L2aCited in: Etiology and Triggering Factors - [443]
Negro S, Lessio S, Passeri D et al.. “Universal Tumor Screening in Colorectal Cancer: Role of MMR Immunohistochemistry for Lynch Syndrome and Early-Onset CRC.” Cancers (2026). PMID: 42649864 ↗
L3bCited in: Etiology and Triggering Factors - [444]
Liu W, Liu J, Chen Y et al.. “Colorectal laterally spreading tumors exhibit a distinct carcinogenic eco-metabolic shift defined by multi-omics profiling.” Frontiers in microbiology (2026). PMID: 42638748 ↗
L3bCited in: Etiology and Triggering Factors - [445]
Araujo-Blesa M, Pabón-Carrasco M, García-Muñoz C et al.. “Quality of life and perceived care in Lynch syndrome: Associated factors and interpretable machine-learning classification.” European journal of oncology nursing : the official journal of European Oncology Nursing Society (2026). PMID: 42731507 ↗
L3bCited in: Etiology and Triggering Factors - [446]
Ashour AM, Alhayyan A, Alhayyan R. “A PRISMA-guided systematic review of pharmacogenetic anticancer clinical trials registered on clinicaltrials.gov.” Medicine (2026). PMID: 42601762 ↗
L2aCited in: Etiology and Triggering Factors - [447]
Vembar P, Dow E. “Uptake of germline testing for Lynch Syndrome in patients with deficient mismatch repair/ microsatellite-high colorectal cancer in the public hospital system in South Australia.” Familial cancer (2026). PMID: 42720705 ↗
L4Cited in: Etiology and Triggering Factors - [448]
Wen Y, Luo Z, Li Z et al.. “Oral and gut microbiota profiles in patients with locally advanced rectal cancer with varying responses to neoadjuvant chemoradiotherapy.” Functional & integrative genomics (2026). PMID: 42690486 ↗
L3bCited in: Etiology and Triggering Factors - [449]
Rametta A, Barella M, Scardino A et al.. “Lynch syndrome-associated urothelial carcinoma: clinical and molecular findings from a single-institution cohort.” Familial cancer (2026). PMID: 42684488 ↗
L4Cited in: Etiology and Triggering Factors - [450]
Atarere J, Bilalaga MM, Vasireddy R et al.. “Adenomas and Beyond: Colonoscopy Surveillance, Racial and Socioeconomic Disparities in Lynch Syndrome.” Gastro hep advances (2026). PMID: 42602763 ↗
L3bCited in: Etiology and Triggering Factors - [451]
Crespo-Cruz M, Rodriguez-Justo M, Humphries A et al.. “Colonic Polyp Regression After Nous-209 Cancer Immunotherapy: A Clinical Trial Case Report.” Journal of immunotherapy and precision oncology (2026). PMID: 42662364 ↗
L4Cited in: Etiology and Triggering Factors - [452]
Liu B, Li J, Wang G et al.. “Current status of knowledge, diagnosis and management of hereditary colorectal cancer among physicians in China: a national questionnaire survey of 81 doctors from different hospitals.” Familial cancer (2026). PMID: 42720829 ↗
L3bCited in: Etiology and Triggering Factors - [453]
Semenov D, Achkasov S, Bodunova N et al.. “Prevalence and clinicopathological correlates of MSI/dMMR in colorectal cancer: a prospective multicenter registry study from Russia.” Frontiers in oncology (2026). PMID: 42682457 ↗
L3bCited in: Etiology and Triggering Factors - [454]
Helliwell JA, Chilton CH, Bestall J et al.. “Tranexamic acid to prevent anastomotic leak after rectal cancer surgery: protocol for a feasibility trial with embedded mechanistic analysis of the microbiome.” BMJ open (2026). PMID: 42731830 ↗
L5Cited in: Etiology and Triggering Factors - [455]
Soriano I, Sherwood K, Ward JC et al.. “Heterozygous germline mutations in MSH3, and probably MLH3, act as classical tumour suppressors, leading to excess somatic deletion mutations, signature ID4 and increased colorectal cancer risk.” Gut (2026). PMID: 42728028 ↗
L5Cited in: Etiology and Triggering Factors - [456]
Tang W, Xu P, Wang S et al.. “Multi-omics characterization of a GPRC5A+ epithelial subpopulation associated with malignant features in colorectal cancer.” Journal of translational medicine (2026). PMID: 42723078 ↗
L5Cited in: Etiology and Triggering Factors - [457]
Amzaleg Y, McDonnell KJ, Idos GE et al.. “Bayesian Integration of Tumor Mutational Signatures and Somatic Features Refines Pathogenicity Assessment of Germline Mismatch Repair Variants.” Human mutation (2026). PMID: 42719515 ↗
L5Cited in: Etiology and Triggering Factors - [458]
Burn J, Bishop DT. “Is Less More? An Update on Aspirin for Cancer Prevention in Lynch Syndrome From the Cancer Prevention Programme-CaPP.” International journal of cancer (2026). PMID: 42717387 ↗
L5Cited in: Etiology and Triggering Factors - [459]
Zhang Y, Cai D, Zhao J et al.. “Integrative multi-omics profiling of insomnia-related molecular features reveals microbiome, immune, and therapy-relevant heterogeneity in colorectal cancer.” Microbiology spectrum (2026). PMID: 42714160 ↗
L5Cited in: Etiology and Triggering Factors - [460]
Aiolfi A, Cammarata F, Rausa E et al.. “Prognostic impact of low versus high inferior mesenteric artery ligation in rectosigmoid cancer: individual patient data meta-analysis of randomized trials.” BJS open (2026). PMID: 42725584 ↗
L1aCited in: Diagnosis and Workup - [461]
Ba L, Qi Y, Lv X et al.. “Comparative Efficacy of Different AI Systems for Polyp Detection by Size During Colonoscopy: Systematic Review and Network Meta-Analysis.” Journal of medical Internet research (2026). PMID: 42714031 ↗
L1aCited in: Diagnosis and Workup - [462]
Kato T, Tsukamoto S, Oishi Y et al.. “Surgical rectus sheath block versus laparoscopic bilateral dual transversus abdominis plane block after minimally invasive colorectal cancer surgery: randomized clinical trial of impact on recovery.” The British journal of surgery (2026). PMID: 42685302 ↗
L1bCited in: Diagnosis and Workup - [463]
Cen Z, Sun Z, Ma T et al.. “KangDuo surgical robot KD-SR-01 versus da Vinci Xi in robot-assisted colorectal cancer resection: oncologic outcomes at three years in a multicenter randomized trial.” Journal of robotic surgery (2026). PMID: 42678457 ↗
L1bCited in: Diagnosis and Workup - [464]
Khajeh E, Sosková A, Fellhofer-Hofer J et al.. “Early versus late closure of protective ileostomy after rectal cancer surgery.” International journal of colorectal disease (2026). PMID: 42722914 ↗
L1aCited in: Diagnosis and Workup - [465]
Liew AN, Tan RYM, Lim WM et al.. “Is there a preferred management option for malignant large bowel obstruction secondary to colorectal cancer: A systematic review and meta-analysis between colonic stents as a bridge to surgery versus emergency surgery?” Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2026). PMID: 42717759 ↗
L1aCited in: Diagnosis and Workup - [466]
He L, Sun Z, Guo Q et al.. “Effects of Esketamine on Postoperative Hospital Anxiety and Depression Scale Scores in Patients Undergoing Laparoscopic Radical Resection for Colorectal Cancer.” Journal of investigative surgery : the official journal of the Academy of Surgical Research (2026). PMID: 42723442 ↗
L1bCited in: Diagnosis and Workup - [467]
Han Y, Sha L. “Laparoscopic versus robotic surgery for colorectal cancer: an updated meta-analysis with comparison against published systematic reviews.” Journal of robotic surgery (2026). PMID: 42714744 ↗
L2aCited in: Diagnosis and Workup - [468]
Abdul-Hafez HA, Awashra A, Elgendy MS et al.. “Cardiac metastases from colorectal cancer: a comprehensive systematic review of clinical presentation, cardiac involvement, and outcomes.” Clinical & experimental metastasis (2026). PMID: 42700272 ↗
L4Cited in: Diagnosis and Workup - [469]
Gunasekaran GH, Ibrahim B, Saleem F et al.. “Exploring disparities in adherence to colorectal cancer clinical practice guidelines and associated survival outcomes: a systematic review and meta-analysis.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 42684532 ↗
L2aCited in: Diagnosis and Workup - [470]
Takabayashi K, Murata S, Sasaki M et al.. “Diagnostic Performance and Reproducibility of Chromoendoscopic Classification (FOCUS Classification: Flat-Type Dysplasia Optical Assessment by Chromoendoscopy in Ulcerative ColitiS) for Flat-Type Dysplasia in Ulcerative Colitis-Associated Neoplasia.” Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society (2026). PMID: 42711733 ↗
L2bCited in: Diagnosis and Workup - [471]
Saqib M, Mirza W, Zaidi ST et al.. “Comparative efficacy and safety of pharmacokinetically guided and body surface area-based 5-fluorouracil dosing in colorectal cancer: a systematic review and meta-analysis.” European journal of clinical pharmacology (2026). PMID: 42687040 ↗
L2aCited in: Diagnosis and Workup - [472]
Zhuo Y, Zheng Y, Xu J et al.. “Development and validation of a hypoglycemia risk prediction model for hospitalized type 2 diabetes patients following laparoscopic colorectal cancer resection: a retrospective cohort study.” Frontiers in endocrinology (2026). PMID: 42729291 ↗
L4Cited in: Diagnosis and Workup - [473]
Lu T, Yuan L, Zhang C et al.. “CT-derived extracellular volume fraction and AI-assisted body composition for predicting neoadjuvant therapy response and prognosis in colorectal cancer.” Abdominal radiology (New York) (2026). PMID: 42726133 ↗
L3bCited in: Diagnosis and Workup - [474]
Giordano A, Marano L, Lamacchia G et al.. “Staying minimally invasive: robotic versus laparoscopic colorectal cancer surgery in a propensity-weighted Italian multicentre cohort.” Journal of robotic surgery (2026). PMID: 42704554 ↗
L3bCited in: Diagnosis and Workup - [475]
Yi A, He L, Liu X et al.. “Real-world efficacy and safety of fruquintinib plus PD-1 inhibitors with or without radiotherapy in refractory metastatic colorectal cancer: a single-center retrospective cohort study.” Journal of gastrointestinal oncology (2026). PMID: 42703438 ↗
L4Cited in: Diagnosis and Workup - [476]
Zivanovic V, Ignjatovic D, Luzon JA et al.. “Preoperative CT-based 3D analysis of middle colic vein anatomy for complete mesocolic excision in right-sided colon cancer: a retrospective cohort study from a prospective clinical trial.” Surgical and radiologic anatomy : SRA (2026). PMID: 42684439 ↗
L2bCited in: Diagnosis and Workup - [477]
Zhang L, Liu G, Huo J et al.. “Development and validation of a model for predicting central lymph node metastasis in colorectal cancer based on CT textural features and clinical indicators.” Translational cancer research (2026). PMID: 42724860 ↗
L3bCited in: Diagnosis and Workup - [478]
Martins M, Nunes MV, Macedo G et al.. “Efficacy, safety, and outcomes of endoscopic submucosal dissection for inflammatory bowel disease-associated colorectal neoplasia: a systematic review and meta-analysis comparing Asian and Western outcomes.” Journal of Crohn's & colitis (2026). PMID: 42609137 ↗
L2aCited in: Differential Diagnosis - [479]
Gao X, Ma X, Zhang Z et al.. “Differentiating sub-centimeter lung metastases in colorectal cancer by deep learning: a multicenter retrospective study.” BMC medical imaging (2026). PMID: 42316047 ↗
L3bCited in: Differential Diagnosis - [480]
Ueda T, Kanesaka T, Ando Y et al.. “Submucosal Lidocaine Injection in Colonic Endoscopic Submucosal Dissection: A Single-Center, Double-Blind, Randomized Controlled Trial.” Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society (2026). PMID: 42666074 ↗
L1bCited in: Management: Systemic and Radiation Therapy - [481]
Wang DS, Chen WC, Ren C et al.. “Circulating tumour DNA to guide rechallenge with cetuximab plus irinotecan in RAS/BRAF wild-type metastatic colorectal cancer: A nonrandomised clinical trial.” Clinical and translational medicine (2026). PMID: 42723578 ↗
L2bCited in: Management: Systemic and Radiation Therapy - [482]
Bach SP, Sebag-Montefiore D, Homer V et al.. “Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial.” The Lancet. Oncology (2026). PMID: 42633754 ↗
L2bCited in: Management: Systemic and Radiation Therapy - [483]
Güç ZG, Demir L, Döngelli H et al.. “Neurotrophic-Inflammatory Imbalance and Cognitive Decline After Adjuvant Chemotherapy in Colon Cancer: A Prospective Cohort Study.” Psycho-oncology (2026). PMID: 42640690 ↗
L2bCited in: Management: Systemic and Radiation Therapy - [484]
Luo Z, Xiang R, Shen R et al.. “Watch-and-wait after immunotherapy-containing neoadjuvant treatment in pMMR/MSS locally advanced rectal cancer: a multicenter real-world study.” Frontiers in immunology (2026). PMID: 42638754 ↗
L4Cited in: Management: Systemic and Radiation Therapy - [485]
Signorelli C, Basso M, Anghelone A et al.. “On-Treatment Grade 3-4 Neutropenia and Clinical Outcomes with Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: ReTrITA Real-World Evidence.” Oncology research (2026). PMID: 42630503 ↗
L2bCited in: Management: Systemic and Radiation Therapy - [486]
Wang C, Huang M, Li W et al.. “A Phase II Clinical Trial of Chemotherapy Rechallenge with or without Targeted Therapy in Refractory Metastatic Colorectal Cancer.” Oncology research (2026). PMID: 42630712 ↗
L2bCited in: Management: Systemic and Radiation Therapy - [487]
Perpar A, Georg P, Ermenc AS. “The role of particle therapy in the treatment of locally recurrent rectal cancer: a systematic review.” Radiology and oncology (2026). PMID: 42704036 ↗
L2aCited in: Management: Systemic and Radiation Therapy - [488]
Cao C, Liu S, Shan S et al.. “Network temperature and stability of symptom clusters in colorectal cancer patients undergoing adjuvant chemotherapy: a prospective longitudinal study.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 42717059 ↗
L3bCited in: Management: Systemic and Radiation Therapy - [489]
Kaneko S, Sawada K, Hatanaka K et al.. “A multicenter retrospective study on the clinical features of patients with human epidermal growth factor receptor 2-positive colorectal cancer (HGCSG2304).” International journal of clinical oncology (2026). PMID: 42701140 ↗
L4Cited in: Management: Systemic and Radiation Therapy - [490]
Vetere G, Osterlund E, Yousef MMG et al.. “Overall survival of immunotherapy versus standard of care in chemorefractory microsatellite stable metastatic colorectal cancer: a propensity score matched analysis of 708 patients.” Journal for immunotherapy of cancer (2026). PMID: 42686374 ↗
L3bCited in: Management: Systemic and Radiation Therapy - [491]
Chiang SW, Chen MC, Lin CL et al.. “Differential Tumor Response and Conversion Outcomes Associated with First-Line Biologic Strategies in Liver-Limited RAS Wild-Type Metastatic Colorectal Cancer.” Oncology research (2026). PMID: 42630475 ↗
L3bCited in: Management: Systemic and Radiation Therapy - [492]
Liu X, Wu C, Song S et al.. “Selenium Nanoparticles Selectively Target KRAS G13D to Inhibit Colorectal Cancer.” Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026). PMID: 42610521 ↗
L3bCited in: Management: Systemic and Radiation Therapy - [493]
Kou F, Wang X, Li J et al.. “Second-line raltitrexed plus irinotecan (SALIRI) with bevacizumab, cetuximab, or alone for metastatic colorectal cancer: a prospective multicenter cohort-based secondary analysis of the SALLY trial.” Journal of gastrointestinal oncology (2026). PMID: 42703466 ↗
L2bCited in: Management: Systemic and Radiation Therapy - [494]
Song Z, Zhu L, Liu Y et al.. “Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial.” The Lancet. Oncology (2026). PMID: 42636835 ↗
L4Cited in: Management: Systemic and Radiation Therapy - [495]
Pinar SA, Wong TN, Mitchell T et al.. “Evidence Gap in Managing Lateral Pelvic Lymph Nodes in Rectal Cancer: a Systematic Review of Radiation Boost Strategies.” Journal of gastrointestinal cancer (2026). PMID: 42704578 ↗
L2aCited in: Management: Systemic and Radiation Therapy - [496]
Howaidi J, Alnajjar F, Abu Alnasr R et al.. “Impact of Leucovorin Shortage: A Comparison of Standard-Dose Versus Reduced-Dose Leucovorin in Metastatic Colorectal Cancer.” JCO global oncology (2026). PMID: 42715502 ↗
L3bCited in: Management: Systemic and Radiation Therapy - [497]
Pilko G, Petric R. “Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a single-institution experience.” Radiology and oncology (2026). PMID: 42704034 ↗
L3bCited in: Management: Systemic and Radiation Therapy - [498]
Wang N, Xu T, Kang Y et al.. “Real-world clinical impact of implementing and updating a deep learning-based automatic contouring system in rectal cancer radiotherapy.” Journal of applied clinical medical physics (2026). PMID: 42665916 ↗
L3bCited in: Management: Systemic and Radiation Therapy - [499]
Feng X, Wang J, Shi H et al.. “Effect of Digital Health Interventions on the Nutritional Status and Quality of Life of Patients With Colorectal Cancer: Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Journal of medical Internet research (2026). PMID: 42613928 ↗
L1aCited in: Supportive Care and Complication Management - [500]
Wenzelberg CL, Rönnow CF, Petersson U et al.. “Impact of incisional hernia on quality of life after colorectal cancer surgery - results of the Rein4CeTo1 randomized clinical trial.” Journal of abdominal wall surgery : JAWS (2026). PMID: 42643482 ↗
L1bCited in: Supportive Care and Complication Management - [501]
Jalili F, Mah CL, Lebenbaum M et al.. “The associations between household food insecurity and cancer: A comprehensive systematic review and meta-analysis of observational studies among adults.” Social science & medicine (1982) (2026). PMID: 42685390 ↗
L4Cited in: Supportive Care and Complication Management - [502]
Idrees ABB, Iqbal K, Ullah S et al.. “Impact of BMI on robotic rectal cancer surgery versus three-dimensional laparoscopic rectal cancer surgery: a retrospective study.” Surgical endoscopy (2026). PMID: 42711588 ↗
L3bCited in: Supportive Care and Complication Management - [503]
Pham HV, Tran TM, Pham PNN. “Linear versus circular stapler for colorectal anastomosis in laparoscopic sigmoidectomy: a retrospective comparative study.” Annals of coloproctology (2026). PMID: 42687601 ↗
L2bCited in: Supportive Care and Complication Management - [504]
Li T, Liu W, Jiang B et al.. “SEMS bridge to elective laparoscopic surgery versus emergency surgery for obstructive colorectal cancer: a propensity score-matched retrospective cohort study.” Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy (2026). PMID: 42610777 ↗
L2bCited in: Supportive Care and Complication Management - [505]
Al Hayek M, Sawaf B, Capogreco A et al.. “Additional Surgery versus Surveillance After Non-curative ESD for Early Colorectal Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-analysis.” Gastrointestinal endoscopy (2026). PMID: 42716253 ↗
L2aCited in: Prognosis and Long-term Outcomes - [506]
Zhu L, Liu Y, Mou W et al.. “The impact of using dexmedetomidine during surgery on the postoperative survival of cancer patients: a meta-analysis and systematic review of real-world studies.” Frontiers in pharmacology (2026). PMID: 42682618 ↗
L2aCited in: Prognosis and Long-term Outcomes - [507]
Manganaro L, Russo T, Novello L et al.. “Prognostic models and predictors of recurrence in resectable colorectal liver metastases: A systematic review and meta-analysis.” Critical reviews in oncology/hematology (2026). PMID: 42669322 ↗
L2aCited in: Prognosis and Long-term Outcomes - [508]
Pan S, Wang G. “Perioperative immunocircadian recovery and its association with circulating tumor DNA-based minimal residual disease and long-term survival after colorectal cancer surgery.” Surgery (2026). PMID: 42697086 ↗
L2bCited in: Prognosis and Long-term Outcomes - [509]
Nahime RH, Stevanato Filho PR, Bezerra TS et al.. “Impact of robotic platform transition on short term outcomes in colorectal cancer surgeries.” Journal of robotic surgery (2026). PMID: 42667338 ↗
L2bCited in: Prognosis and Long-term Outcomes - [510]
Valladares-Ayerbes M, García Alfonso P, Heinemann V et al.. “Association of ctDNA RAS mutational status and clinical benefits in first-line metastatic colorectal cancer therapy with chemotherapy plus anti-EGFR (overall response rate and progression-free survival): a brief report of systematic review and meta-analysis.” Journal of gastrointestinal oncology (2026). PMID: 42703453 ↗
L2aCited in: Prognosis and Long-term Outcomes - [511]
El Khoury S, Fanaeian MM, Yousef M et al.. “Risk of Relapse and Efficacy of Adjuvant Chemotherapy in Localized Appendiceal Adenocarcinoma.” JAMA surgery (2026). PMID: 42714885 ↗
L3bCited in: Prognosis and Long-term Outcomes - [512]
Kasashima H, Fukuoka T, Naito N et al.. “Comparison of surgical outcomes between robot-assisted and laparoscopic right colectomy for colon cancer: a single-center cohort study.” Journal of robotic surgery (2026). PMID: 42671704 ↗
L4Cited in: Prognosis and Long-term Outcomes - [513]
Zhou B, Chen J, Chen C et al.. “The preoperative hemoglobin, albumin, lymphocyte, and platelet score as a prognostic Indicator for survival in gastric and colorectal cancer patients.” Frontiers in nutrition (2026). PMID: 42694194 ↗
L2bCited in: Prognosis and Long-term Outcomes - [514]
Cuccia F, Mortellaro G, Campione M et al.. “Single-fraction stereotactic radiotherapy for lung malignancies: preliminary results of a mono-institutional experience.” Frontiers in oncology (2026). PMID: 42688051 ↗
L4Cited in: Prognosis and Long-term Outcomes - [515]
Chauhan D, Dello Russo C, Thompson J et al.. “UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).” British journal of clinical pharmacology (2026). PMID: 42389808 ↗
L1cCited in: Guidelines and Resources